
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_rcar_renovacareinc.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001016708 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001016708</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0095" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0107" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0108" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0157" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0158" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0182" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0203" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0205" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0208" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0210" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0213" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0214" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0225" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0227" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0230" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0232" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0235" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0236" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0274" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0283" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0286" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0289" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0304" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0450" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0525" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0613" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0621" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0693" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0778" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0779" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="rcar-20211231.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-18_us-gaap_SubsequentEventMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">rcar:ConvertibleNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_StockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-012013-07-31_custom_AssetPurchaseAgreementMember_custom_DrGerlachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">rcar:AssetPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:DrGerlachMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2013-07-01</xbrli:startdate>
        <xbrli:enddate>2013-07-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-07-31_custom_AssetPurchaseAgreementMember_custom_DrGerlachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">rcar:AssetPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:DrGerlachMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandThirteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">rcar:TwoThousandThirteenPlanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_Plan2013Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">rcar:Plan2013Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-26_custom_ConsultingAgreementMember_custom_JustinFrereMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">rcar:ConsultingAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:JustinFrereMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-26_custom_ConsultingAgreementMember_custom_JustinFrereMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">rcar:ConsultingAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:JustinFrereMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-07-01</xbrli:startdate>
        <xbrli:enddate>2021-07-26</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesEMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesEMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesEMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesFMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesFMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesFMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesFMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesFMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesFMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesGMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesGMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesGMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesHMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesHMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesHMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesIMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesIMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rcar:SeriesIMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CharitableGiftAgreementMember_custom_UniversityOfPittsburghMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">rcar:CharitableGiftAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">rcar:UniversityOfPittsburghMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StemCellSystemsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:StemCellSystemsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StemCellSystemsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:StemCellSystemsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StephenYanKlessonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:StephenYanKlessonMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-02_custom_KalenCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:KalenCapitalCorpMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-31_custom_KalenCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:KalenCapitalCorpMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2020-10-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-22_custom_VectorAssetManagementIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">rcar:VectorAssetManagementIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2018-06-01</xbrli:startdate>
        <xbrli:enddate>2018-06-22</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VectorAssetManagementIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">rcar:VectorAssetManagementIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_VectorAssetManagementIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">rcar:VectorAssetManagementIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-15_us-gaap_SubsequentEventMember_custom_SpearsAndImesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:SpearsAndImesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-02-01</xbrli:startdate>
        <xbrli:enddate>2022-02-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-18_us-gaap_SubsequentEventMember_custom_KalenCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:KalenCapitalCorpMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012022-03-18_us-gaap_SubsequentEventMember_custom_KalenCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcar:KalenCapitalCorpMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-03-01</xbrli:startdate>
        <xbrli:enddate>2022-03-18</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-18_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001016708</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20210101__20211231_zBxurC2Y8Bm5"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentType" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 2%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--DocumentAnnualReport_c20210101__20211231_zVT8wCMfYlI7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="true" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></b></span></td>
    <td style="width: 98%; font-size: 10pt"><span style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended&nbsp;<b><span style="text-decoration: underline"><span id="xdx_90F_edei--DocumentPeriodEndDate_c20210101__20211231_zyaJnXv1X9l1"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span id="xdx_902_edei--CurrentFiscalYearEndDate_c20210101__20211231_zbZUWc2FzHK6"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span></span>,
2021</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentTransitionReport_c20210101__20211231_zognrxQ9KQj"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="true" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from ___________ to _________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number&nbsp;<b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityFileNumber_c20210101__20211231_zDj3xiSxzg26"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">000-30156</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityRegistrantName_c20210101__20211231_zlnVRdiP48Xa"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName" inside-table="false" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">RENOVACARE, INC.</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 49%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zSXMz59OXnN1"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nevada</ix:nonnumeric></span></span></b></span></td>
    <td style="width: 3%; font-size: 10pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 48%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20210101__20211231_znyrZ5JarJT4"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98-0384030</ix:nonnumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of incorporation)</span></td>
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  <tr>
    <td colspan="3" style="font-size: 10pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityAddressAddressLine1_c20210101__20211231_zctvelN79yV4"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9375 E Shea Blvd.</ix:nonnumeric></span></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20210101__20211231_zitji0ecRB0g"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2" inside-table="true" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Suite 107-A</ix:nonnumeric></span></span></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityAddressCityOrTown_c20210101__20211231_zBxetXiL79Af"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Scottsdale</ix:nonnumeric></span></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20210101__20211231_zrIRyeaJ26we"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">AZ</ix:nonnumeric></span></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20210101__20211231_ziJAodVLJci1"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85260</ix:nonnumeric></span></span></span></b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--CityAreaCode_c20210101__20211231_z0RYiYhKcYhh"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">(888)</ix:nonnumeric></span></span> <span id="xdx_908_edei--LocalPhoneNumber_c20210101__20211231_zgL8qXg2THz7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">398-0202</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrants telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:&nbsp;<b><span style="text-decoration: underline">None</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(g)
of the Act:&nbsp;<b><span style="text-decoration: underline">None</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif"></span>
<span id="xdx_902_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_zLpAXQi6QSrh"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif"></span>
<span id="xdx_908_edei--EntityVoluntaryFilers_c20210101__20211231_zCvhWuYyBlXl"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <span id="xdx_90B_edei--EntityCurrentReportingStatus_c20210101__20211231_zbLZWD9hUwAd"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> <span style="font-family: Times New Roman, Times, Serif"></span> No <span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Date file required to be submitted and posted
pursuant to Rule 405 of Regulations S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). <span id="xdx_902_edei--EntityInteractiveDataCurrent_c20210101__20211231_zRjy1wNKGyCl"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> <span style="font-family: Times New Roman, Times, Serif"></span>
No <span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if disclosure of delinquent
filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrants knowledge,
in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
<span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of large accelerated filer, accelerated filer, smaller reporting company
and emerging growth company in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr>
    <td style="width: 44%"><span style="font-size: 10pt">Large accelerated filer</span></td>
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="width: 40%"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr>
    <td><span style="font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20210101__20211231_zT3UQxCkQC19"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td><span style="font-size: 10pt">Smaller reporting company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntitySmallBusiness_c20210101__20211231_zhgcBw0ak5cc"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></span></td></tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Emerging Growth Company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20210101__20211231_zcfdyeOzqVB6"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes <span style="font-family: Times New Roman, Times, Serif"></span>
<span id="xdx_900_edei--EntityShellCompany_c20210101__20211231_zACEp3qJjGh3"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has filed a report on
and attestation to its managements assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
<span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting and non-voting
common equity held by non-affiliates of the registrant as of the last business day of the registrants most recently completed second
fiscal quarter, based upon the closing sale price of the registrants common stock on June 30, 2021, as reported on the Pink Open
Market was $<span id="xdx_90E_edei--EntityPublicFloat_iI_c20210630_zQmIUefLjZN"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,964,279</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 28, 2022,&nbsp;the&nbsp;most&nbsp;recent&nbsp;practicable&nbsp;date,
the number of Common Shares outstanding was <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_c20220328_zCLr5yep62z5"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2022-03-28" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,352,364</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Documents incorporated by reference: <span id="xdx_905_edei--DocumentsIncorporatedByReferenceTextBlock_c20210101__20211231_zrDDMQ9942g1"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">None.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="width: 13%">&nbsp;</td>
    <td style="width: 80%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 6%; text-align: center"><span style="font-size: 10pt"><b>Page&nbsp;</b>&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="4" style="text-align: center"><a href="#a_001" tabindex="18"><span style="font-size: 10pt"><b><span style="text-decoration: underline">PART I</span></b></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="4" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_026" tabindex="18"><span style="font-size: 10pt">Item 1.</span></a></td>
    <td><a href="#a_026" tabindex="18"><span style="font-size: 10pt">Business</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_026" tabindex="18"><span style="font-size: 10pt">3</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_002" tabindex="18"><span style="font-size: 10pt">Item 1A.</span></a></td>
    <td><a href="#a_002" tabindex="18"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_002" tabindex="18"><span style="font-size: 10pt">11</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_003" tabindex="18"><span style="font-size: 10pt">Item 1B.</span></a></td>
    <td><a href="#a_003" tabindex="18"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_003" tabindex="18"><span style="font-size: 10pt">34</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_004" tabindex="18"><span style="font-size: 10pt">Item 2.</span></a></td>
    <td><a href="#a_004" tabindex="18"><span style="font-size: 10pt">Properties</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_004" tabindex="18"><span style="font-size: 10pt">34</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_005" tabindex="18"><span style="font-size: 10pt">Item 3.</span></a></td>
    <td><a href="#a_005" tabindex="18"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_005" tabindex="18"><span style="font-size: 10pt">34</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_006" tabindex="18"><span style="font-size: 10pt">Item 4.</span></a></td>
    <td><a href="#a_006" tabindex="18"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_006" tabindex="18"><span style="font-size: 10pt">36</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="4" style="text-align: center"><a href="#a_007" tabindex="18"><span style="font-size: 10pt"><b><span style="text-decoration: underline">PART II</span></b></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="4" style="text-align: center">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#a_008" tabindex="18"><span style="font-size: 10pt">Item 5.</span></a></td>
    <td style="vertical-align: bottom"><a href="#a_008" tabindex="18"><span style="font-size: 10pt">Market for Registrants Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center"><a href="#a_008" tabindex="18"><span style="font-size: 10pt">36</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_009" tabindex="18"><span style="font-size: 10pt">Item 6.</span></a></td>
    <td><a href="#a_009" tabindex="18"><span style="font-size: 10pt">Selected Financial Data</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_009" tabindex="18"><span style="font-size: 10pt">38</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_010" tabindex="18"><span style="font-size: 10pt">Item 7.</span></a></td>
    <td><a href="#a_010" tabindex="18"><span style="font-size: 10pt">Managements Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_010" tabindex="18"><span style="font-size: 10pt">38</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_011" tabindex="18"><span style="font-size: 10pt">Item 7A.</span></a></td>
    <td><a href="#a_011" tabindex="18"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_011" tabindex="18"><span style="font-size: 10pt">42</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_012" tabindex="18"><span style="font-size: 10pt">Item 8.</span></a></td>
    <td><a href="#a_012" tabindex="18"><span style="font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_012" tabindex="18"><span style="font-size: 10pt">43</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_013" tabindex="18"><span style="font-size: 10pt">Item 9.</span></a></td>
    <td><a href="#a_013" tabindex="18"><span style="font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_013" tabindex="18"><span style="font-size: 10pt">65</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_014" tabindex="18"><span style="font-size: 10pt">Item 9A.</span></a></td>
    <td><a href="#a_014" tabindex="18"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_014" tabindex="18"><span style="font-size: 10pt">65</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_015" tabindex="18"><span style="font-size: 10pt">Item 9B.</span></a></td>
    <td><a href="#a_015" tabindex="18"><span style="font-size: 10pt">Other Information</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_015" tabindex="18"><span style="font-size: 10pt">66</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="4" style="text-align: center"><a href="#a_016" tabindex="18"><span style="font-size: 10pt"><b><span style="text-decoration: underline">PART III</span></b></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="4" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_017" tabindex="18"><span style="font-size: 10pt">Item 10.</span></a></td>
    <td><a href="#a_017" tabindex="18"><span style="font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_017" tabindex="18"><span style="font-size: 10pt">66</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_018" tabindex="18"><span style="font-size: 10pt">Item 11.</span></a></td>
    <td><a href="#a_018" tabindex="18"><span style="font-size: 10pt">Executive Compensation</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_018" tabindex="18"><span style="font-size: 10pt">70</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_019" tabindex="18"><span style="font-size: 10pt">Item 12.</span></a></td>
    <td style="vertical-align: bottom"><a href="#a_019" tabindex="18"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center"><a href="#a_019" tabindex="18"><span style="font-size: 10pt">74</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_020" tabindex="18"><span style="font-size: 10pt">Item 13.</span></a></td>
    <td><a href="#a_020" tabindex="18"><span style="font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_020" tabindex="18"><span style="font-size: 10pt">75</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_021" tabindex="18"><span style="font-size: 10pt">Item 14.</span></a></td>
    <td><a href="#a_021" tabindex="18"><span style="font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_021" tabindex="18"><span style="font-size: 10pt">76</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="4" style="text-align: center"><a href="#a_022" tabindex="18"><span style="font-size: 10pt"><b><span style="text-decoration: underline">PART IV</span></b></span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="4" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><a href="#a_023" tabindex="18"><span style="font-size: 10pt">Item 15.</span></a></td>
    <td><a href="#a_023" tabindex="18"><span style="font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_023" tabindex="18"><span style="font-size: 10pt">77</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#a_024" tabindex="18"><span style="font-size: 10pt">Item 16.</span></a></td>
    <td><a href="#a_024" tabindex="18"><span style="font-size: 10pt">Form 10K Summary</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_024" tabindex="18"><span style="font-size: 10pt">77</span></a></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td><a href="#a_025" tabindex="18"><span style="font-size: 10pt">Signatures</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><a href="#a_025" tabindex="18"><span style="font-size: 10pt">78</span></a></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K (including the section regarding Managements Discussion and Analysis of Financial Condition and Results of Operations) contains
certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, as well as information relating to RenovaCare, Inc. and its wholly-owned subsidiary
that is based on managements exercise of business judgment and assumptions made by and information currently available to management.
Although forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, such statements
can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks
and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the
forward-looking statements. When used in this document and other documents, releases and reports released by us, the words anticipate,
believe, estimate, expect, intend, the facts suggest and words of
similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking
statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could
differ materially from those anticipated in these forward-looking statements. Actual events, transactions and results may materially differ
from the anticipated events, transactions or results described in such statements. Although we believe that our expectations are based
on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to
differ materially from our forward-looking statements and unknown, unidentified or unpredictable factors could materially and adversely
impact our future results. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions
to our forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated
events. Several of these factors include, without limitation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 3%"><span style="font-size: 10pt"><b></b></span></td>
    <td style="width: 92%; text-align: justify"><span style="font-size: 10pt">our ability to meet requisite regulations or receive regulatory approvals in the United States, and our ability to retain any regulatory approvals that we may obtain; and the absence of adverse regulatory developments in the United States and abroad;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in general economic, business or demographic conditions or trends in the U.S. or throughout the world or changes in the political environment, including changes in GDP, interest rates and inflation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">new entrance of competitive products or further penetration of existing products in our markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain additional financing, if at all, at times and on terms acceptable to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disruptions or other extraordinary or force majeure events, such as the COVID-19 pandemic, and the ability to insure against losses resulting from such events or disruptions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the effect on us from adverse publicity related to our products or the company itself; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any adverse claims relating to our intellectual property.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The safe harbor provisions
of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to
forward-looking statements made by the Company. The reader is cautioned that no statements contained in this Form 10-K should be construed
as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking
statements as a result of various factors, including, without limitation, the risks described in this report and matters described in
this report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained
in this filing will in fact occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file reports with the Securities
and Exchange Commission (SEC). We make available on our website free of charge our annual report on Form 10-K, quarterly
reports on Form 10-Q, current reports on Form 8-K and amendments to those reports as soon as reasonably practicable after we electronically
file such materials with or furnish them to the SEC. Information appearing at our website is not a part of this Annual Report on Form
10-K. You can also read and copy any materials we file with the SEC on its website at www.sec.gov).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span id="a_001"></span><b>Part
i</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b><span id="a_026"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RenovaCare, Inc. (together
with its wholly owned subsidiary RenovaCare Sciences Corp., <b>RenovaCare,</b> the <b>Company,</b> <b>we,</b>
<b>us,</b> and <b>our,</b>) was incorporated on July 14, 1983 in the State of Utah under the name Far West
Gold, Inc., and changed its domicile to Nevada in 1997. On January 7, 2014, the Company changed its name at the time from Janus
Resources, Inc. to RenovaCare, Inc. so as to more fully reflect its current operations and business and changed its
trading symbol from JANI to RCAR effective as of January 9, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RenovaCare has an authorized
capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of December 31, 2021,
and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development-stage
biotech and medical device company focusing on the research, development and commercialization of autologous (using a patient's own cells)
cellular therapies that can be used for medical and aesthetic applications. We do not have any commercialized products. Our activities
have consisted principally of performing research and development activities, business development efforts, and raising capital to support
such activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Treatment of large deep thermal
burn wounds has evolved significantly in recent years. While traditional skin grafting was used for decades since the 19th century, over
the past 20 years sheets of skin cells grown <i>in vitro </i>and cytokine-treated skin cells applied with mesh matrices have been developed.
The newest therapies involve the use of autologous skin cells. We believe RenovaCares technology represents a new generation of
autologous skin cell therapy that, while still in development may become, if approved, the standard of care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through RenovaCare Sciences
Corp. we own the CellMist System, which is comprised of (a) a treatment methodology for cell isolation for the regeneration of
human skin cells and other tissues (the CellMist Solution) and (b) a solution sprayer device (the SkinGun)
for delivering cells to the treatment area.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we announced
that the US Food and Drug Administration (FDA) fully approved the Companys Investigational Device Exemption (IDE) application to
conduct a clinical trial, designated CELLMIST 1, designed to evaluate the safety and feasibility of autologous skin and pluripotent stem
cells rendered by its manual CellMist System from donor skin and applied topically with the electronic SkinGun spray device
for treatment of acute burn wounds. The clinical trial protocol is an open-label single-arm clinical study designed enroll 14 adult human
burn subjects with partial-thickness, second-degree thermal burn wounds covering between 10% and 30% total body surface area. The Company
may engage up to four (4) U.S. burn centers to conduct the clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to year end, the Board decided to suspend
enrollment of adult burn patients into the CELLMIST 1 clinical trial and take other measures to reduce the Companys overhead in
an effort to conserve financial resources as it continues to defend against a civil action filed by the U.S. Securities and Exchange Commission
(the <b>SEC</b>) and several class actions the and derivative actions (collectively, the <b>Lawsuits</b>),
premised in part on the allegations made by the SEC in its filing, that were subsequently filed. See <i>Item 1A.Risk Factors
</i>and <i>Item 3.Legal Proceedings.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The clinical study suspension
was not due to any safety concerns or adverse events. The Company hopes to resume the clinical trial at a future date, as, if, and when,
in the opinion of the Companys management, circumstances, including the consummation of additional financing transactions, permit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development of our new
closed, automated cell isolation device prototype for the CellMist<sup>TM</sup>&nbsp;System which is in early-stage development continues,
and we anticipate that we will be required to expend significant time and resources to further develop and validate this technology and
determine whether a commercially viable product can be developed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has enlisted the
assistance of several Contract Manufacturing Organizations (CMO) to manufacture clinical supplies including components of the CellMist
System and the electronic SkinGun spray devices in compliance with FDAs guidance for current Good Manufacturing Practices
(cGMP) and Contract Research Organizations (CRO) to test clinical samples and conduct clinical trials to evaluate the safety and feasibility
of an autologous skin cell therapy using the Companys products to facilitate burn wound healing. The activities of the CMOs and
CRO are being scaled back to accommodate the Companys financial constraints and the clinical trial suspension. These development
activities are subject to significant risks and uncertainties, including possible failure of preclinical and clinical testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research, development and
commercialization of new technologies generally requires significant financial resources, involves a high degree of risk, and there is
no assurance that development activities will result in a commercially viable product. The Company has not generated any revenue and has
sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues
development of its products and technologies and defend itself against the Lawsuits. See <i>Item 3. Legal Proceedings.</i>
The Company will need to raise additional capital through the sale of equity securities, debt, or strategic alliances in order to accomplish
its business plan. Failing to secure such additional funding poses a significant risk. The Company's ability to meet its financial obligations,
including to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities.
There can be no assurance as to the availability or terms upon which such financing and capital might be available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Mission and Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ultimate goal is to leverage
the potential of our CellMist<sup>TM</sup>&nbsp;System with the SkinGun<sup>TM</sup>&nbsp;spray device, as next generation cell therapies
for burns and other acute and chronic wounds and skin disorders. Before we can do so, however, there are multiple steps we must first
take, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">resuming our clinical trial to determine the safety, feasibility, and efficacy of the CellMist<sup>TM</sup>&nbsp;System&nbsp;with the SkinGun<sup>TM</sup>&nbsp;spray device for treating partial-thickness second-degree thermal burns;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">completing development in validation of our closed, automated cell isolation device;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">creating a network of clinical research partners;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">achieving FDA and/or other regulatory approval and clearance; and</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expanding the range of possible clinical applications for unmet health needs.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To achieve our goal, we have
established the following four strategic priorities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successfully defend against the Lawsuits. See
    Item 1A.-Risk Factors and Item 3.-Legal Proceedings.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Obtain marketing approval and prepare to commercialize our CellMist<sup>TM</sup>&nbsp;System with the SkinGun<sup>TM</sup>&nbsp;spray device.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Selectively pursue strategic partnerships, joint ventures, and licensing opportunities to complement and expand our existing operations.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Secure additional financing.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.05pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.05pt 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we
will need to pursue financing opportunities, traditional and non-dilutive, in order to raise sufficient capital to fund our ongoing and
planned research and development operations. Such financing may or may not be available at acceptable terms or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we have an
experienced leadership and scientific team which has come together to achieve our mission of improving the lives of burn patients by creating
potentially more effective, safer, efficient, and cost-saving treatments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Strategic Collaboration with StemCell
Systems</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, we announced
the official launch of our new RenovaCare R&amp;D Innovation Center located in Berlin, Germany, where our patented technologies for isolating
and spraying self-donated stem cells to regenerate tissues and organs have been under development alongside new product initiatives. Important
programs at the Center include preclinical support to our regulatory submissions for our flagship SkinGun, which delivers a proprietary
gentle CellMist spray of a patients own skin cells on to burns and wounds. The Innovation Center is the result of a multi-year
collaboration agreement with StemCell Systems, with whom we have maintained an R&amp;D relationship since 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Innovation Center houses
dedicated RenovaCare cell biology laboratories, additional engineering, fabrication, prototyping and performance testing facilities, product
design studios, and pilot-scale manufacturing for medical devices and biomedical products. Experienced contract bioengineers, cell biologists,
and support staff work under the direction of a team of MD-PhDs who are experts in regenerative medicine, new product development, and
clinical translation. Thomas Bold, an inventor of several of our technologies and a long-serving advisor to the Company, leads the Innovation
Center and interfaces regularly with our management team. This collaboration has been significant to the development of the CellMist
System and the SkinGun spray device, and will be an important contributor to our future new product development initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Market Opportunity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Burns</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Burns are one of the most
common and devastating forms of trauma. Most burn injuries involve layers of the upper skin, the epidermis. Severe major trauma involves
a complete loss of the entire thickness of the skin and often requires major surgery involving split-skin mesh-grafting. Skin grafting
is a procedure where healthy skin is removed from one area of the body and transplanted to a wound site.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patients with serious thermal
injury require immediate specialized definitive care to minimize morbidity and mortality. Data from the National Center for Injury Prevention
and Control in the U.S. show that approximately 2 million fires are reported each year which result in 1.5 million people suffering burn
injuries (<i>see</i>&nbsp;American Burn Association&nbsp;<i>Burn Incidence and Treatment in the US: 2014 Fact Sheet</i>, available at:
http://www.ameriburn.org). Moderate to severe burn injuries requiring hospitalization account for approximately 50,000 of these cases,
and about 5,000 patients die each year in the U.S. from burn-related complications (see Burns injuries on CDC website https://www.cdc.gov/masstrauma/factsheets/public/burns.pdf(2020).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prevalence of patients
with severe burns is even higher in emerging economies. For example, according to the World Health Organization over 1,000,000 people
in India are moderately to severely burnt every year and approximately 180,000 people worldwide die from burn related injuries (see World
Health Organization <i>Burns: Fact Sheet No. 365</i>, reviewed March 6, 2018, available at: http://www.who.int/mediacentre/factsheets/fs365/en/).
According to Critical Care, an international clinical medical journal, burns are also among the most expensive traumatic injuries due
to long and costly hospitalization, rehabilitation and wound and scar treatment (see Brusselaers, N., Monstrey, et al, <i>Severe
Burn Injury in Europe: A systematic Review of the Incidence, Etiology, Morbidity, and Mortality</i> available at: http://ccforum.com/content/14/5/R188).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Burn injuries account for
a significant cost to the health care system in North America and worldwide. In the U.S. there are currently 132 centers specializing
in burn care. Recent estimates in the U.S. show that 150,000 patients are admitted annually for definitive care treatment of burn injuries,
and over 60% of the estimated U.S. acute hospitalizations related to burn injury were admitted to burn centers. Such centers now average
over 200 annual admissions each for burn injury and skin disorders requiring similar treatment. The other 4,500 U.S. acute care hospitals
average less than 3 burn admissions each per year (see American Burn Association&nbsp;<i>Burn Incidence and Treatment in the US: 2013
Fact Sheet</i>, available at: http://www.ameriburn.org).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Agency for
Healthcare Research and Quality, the annual costs for the treatment of burns is $1.5 billion, with another $5 billion in costs associated
with lost work (see https://www.hcup-us.ahrq.gov/reports/statbriefs/sb217-Burn-Hospital-Stays-ED-Visits-2013.pdf). Initial hospitalization
costs and physicians' fees for specialized care of a patient with a major burn injury are currently estimated to be $200,000. Overall,
costs escalate for major burn cases because of repeated admissions for reconstruction and rehabilitation therapy. In the U.S., current
annual estimates show that more than $18 billion is spent on specialized care of patients with major burn injuries (see Church D, Elsayed
S, Reid O, Winston B, Lindsay R <i>Burn wound infections</i> Clinical Microbiology Reviews 2006;19(2):40334, available
at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1471990).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Wounds</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to The Wall Street
Journal, 6.5 million people are affected by chronic wounds, and $25 billion is spent annually on treating chronic wounds on patients in
the U.S. alone (see Jrbrink, Krister et al. Prevalence and incidence of chronic wounds and related complications: a protocol
for a systematic review.&nbsp;<i>Systematic reviews</i>&nbsp;vol. 5,1 152. 8 Sep. 2016 doi:10.1186/s13643-016-0329-y).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Wound Care Market Global
Forecast to 2024 report issued by Markets &amp; Markets states that in 2019, advanced wound care products accounted for the largest share
of the total market and is expected to have the highest growth, with a projected compound annual growth rate of 4.6% to 2024. Major factors
driving the growth of this market of hard-to-heal wounds are an increase in an aging population and greater prevalence of chronic disease,
including diabetes and obesity. The development of regenerative medicine and healing capabilities allow for more effective treatment,
quicker healing and improved health economic outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare facilities
(hospitals and clinics) segment accounted for the largest market share in 2019 as these systems are used for critical cases, improve quality
of care for patients, and have the infrastructure and resources to support treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Technology</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CellMist System is comprised
of the CellMist<sup>TM&nbsp;</sup>cell suspension derived by enzymatic digestion of a patients own skin tissue applied topically
with our proprietary electronic SkinGun<sup>TM</sup>&nbsp;spray device to deliver a fine single-cell mist onto the patients burn
wound.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duration of the entire
cell isolation and cell spraying procedure is approximately 1.52 hours. Published studies show that within days following the wound
treatment procedure, complete wound closure occurs, and the skin cells generate a protective skin layer (re-epithelialization), and within
weeks the skin regains its function, color and texture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cell isolation and cell
spraying procedure occur on the same day, in an on-site hospital setting. Because the skin cells sprayed using the SkinGun<sup>TM</sup>&nbsp;spray
device are actually the patient's own cells, the skin that is regenerated looks more natural than other skin replacement technologies.
During recovery, the skin cells grow into fully functional skin layers, and the regenerated skin leaves minimal scarring in observational
case studies. Additionally, our methods require substantially smaller donor areas than skin grafting, reducing donor area burden such
as pain and the risk of complications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
August 2019, the Company was awarded a continuation of a patent allowing the SkinGun<b><sup>TM</sup></b>&nbsp;to be used to spray all
varieties of tissues and cells, thus allowing for its potential application in the regeneration of tissues and organs, beyond skin; and,
in November 2020 and October 2021, the Company was issued a total of three new patents&nbsp;encompassing improvements to the SkinGun,
expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to
include drugs, hormones, and other useful agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The CellMist<sup>TM</sup></b>&nbsp;System
for which patient applications were submitted on the closed, automated cell isolation device to the USPTO in December 2020, remains an
experimental, unproven methodology and we continue to evaluate its safety and efficacy. There is no guarantee that we will be able to
develop a commercially viable product based upon the CellMist<b><sup>TM</sup></b>&nbsp;System and its underlying technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology, medical
device, and wound care industries are characterized by intense competition, rapid product development and technological change. Our CellMist<sup>TM</sup>&nbsp;System
competes with a variety of companies in the wound care markets, many of which offer substantially different treatments for similar problems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of our competitors are
larger, established companies with considerably greater financial, marketing, sales and technical resources than those available to us.
Additionally, many of our present and potential competitors have research and development capabilities that may allow them to develop
new or improved products that may compete with our product lines. Our potential products could be rendered obsolete or made uneconomical
by the development of new products to treat the conditions addressed by our products, technological advances affecting the cost of production,
or marketing or pricing actions by one or more of our competitors. Our closest direct competitor with its own skin cell therapy for burn
wounds, received FDA approval in September 2018 and launched its product in 2019; however, we believe, our next generation skin cell therapy
for burn wounds has multiple notable advantages including more cell types from both epidermal and dermal layers of the skin; greater cell
yield and viability; smaller ratio of donor tissue to burn wound area; greater burn wound coverage; and single cells applied with the
SkinGun spray device that rapidly adhere to the burn wound.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and its direct
competitor have autologous skin cell therapies that facilitate the healing of deep partial-thickness second-degree thermal burn wounds.
However, there are notable differences between these our competitors therapy products compared to our CellMist<sup>TM</sup>&nbsp;System,
including product configuration, processes for cell isolation from donor skin, topical administration of isolated skin cells, burn wound
coverage, and duration of patented intellectual property (IP), as enumerated below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">RenovaCares CellMist System in development utilizes a closed, automated cell isolation process, whereas existing cell therapy products utilize a manual process. We believe our closed, automated process will be easier to use and reproducible for the burn care center end-user.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The RenovaCare cell isolation process in development employs a sequential animal-free multi-enzyme process to isolate skin cells and pluripotent stem cells from both epidermal and dermal layers of donor skin tissues. Existing therapy isolates skin cells with a single animal-origin enzyme on the epidermal layer only. Significantly more cells and key cell types are afforded by our multi-enzyme process.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">RenovaCare uses the electronic SkinGun spray device to administer the skin cell suspension topically as a single-cell, fine mist on to burn wounds in an evenly, distributed comprehensive pattern, in contrast, existing therapy uses a corrugated plastic nozzle affixed onto a syringe to spray or drip cells and cell clumps onto the burn wound, which must be positioned to allow the cell suspension to roll onto the wound.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The CellMist System and SkinGun deliver single skin cells as compared to cell clumps, which enhance reepithelization and wound closure. This gentle fine mist maintains cell viability that affords rapid cell adherence without dripping and rapid cell proliferation to cover the wound, a distinct advantage over existing therapy.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The donor skin tissue to burn wound ratio of the RenovaCare product is &gt; 1:100 providing coverage of burn wounds at 10%-30% total body surface area (TBSA), whereas our competitors ratio is 1:80 with coverage &lt;20% TBSA. A practical result is that a single kit from RenovaCare may cover 30% TBSA burn wounds, as compared to multiple kits needed for 20% TBSA burn wounds by our competitor.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">RenovaCare IP which extends through 2037 has a considerably longer life than that of our competitors.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the course of conducting
our business, we from time to time create inventions. Obtaining, maintaining, and protecting our inventions, including seeking patent
protection, might be important depending on the nature of the invention. To that end, we seek to implement patent and other intellectual
property strategies to appropriately protect our intellectual property. While we file and prosecute patent applications to protect our
inventions, our pending patent applications might not result in the issuance of patents or issued patents might not provide competitive
advantages. Also, our patent protection might not prevent others from developing competitive products using related or other technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The scope, enforceability
and effective term of issued patents can be highly uncertain and often involve complex legal and factual questions. Moreover, the issuance
of a patent in one country does not assure the issuance of a patent with similar claim scope in another country, and claim interpretation
and infringement laws vary among countries, so we are unable to predict the extent of patent protection in any country. The patents we
obtain and the unpatented proprietary technology we hold might not afford us significant commercial protection or advantage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary CellMist
System and its component technologies are the subject of fourteen (14) trademarks and applications and forty-four (44) U.S. and foreign
granted or pending patents in eight patent families. Our patent filings include five (5) granted patents in the United States, and seventeen
(17) issued or allowed foreign patents, while all pending patent filings include the U.S. and multiple foreign jurisdictions, and an international
patent application. Our issued patents are scheduled to expire between 2026 and 2038 and may or may not be the basis for filing continuations.
We continually assess opportunities to seek patent protection for those aspects of our technology, designs, and methodologies and processes
that we believe may provide us with significant competitive advantages or additional commercial opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify; text-indent: 0.5in">In addition to issued
patents describe above, we may file additional patent applications that, if issued, would provide further protection for The CellMist<sup>TM</sup>&nbsp;System.
Although we believe the bases for these patents and patent applications are sound, they are untested; and there is no assurance that they
will not be successfully challenged. There can be no assurance that any patent previously issued will be of commercial value, that any
patent applications will result in issued patents of commercial value, or that our technology will not be held to infringe patents held
by others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Domestic Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Governmental authorities
in the U.S., at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development,
testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products
or devices such as those we are attempting to develop. Our device candidates, to the extent they are developed, will likely be subject
to pre-market approval by the FDA prior to their marketing for commercial use in the U.S., and to any approvals required by foreign governmental
entities prior to their marketing outside the U.S. In addition, any changes or modifications to a device that has received regulatory
clearance or approval that could significantly affect its safety or effectiveness, or would constitute a major change in its intended
use, and may require the submission of a new application or amendment to an existing premarket approval (PMA) or 510(k)
waiver application in the U.S. for pre-market approval, or for foreign regulatory approvals outside the U.S. The process of obtaining
foreign approvals, can be expensive, time consuming and uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Premarket Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be required to file
a premarket authorization (<b>PMA</b>) application for any other device that we commercialize if it is deemed a Class III
medical device. PMA is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical
devices, which are novel devices that support or sustain human life, are of substantial importance in preventing impairment of human health,
or which present a potential, unreasonable risk of illness or injury. Due to the level of risk associated with Class III devices, the
FDA has determined that general and special controls alone are insufficient to assure their safety and effectiveness. Therefore, these
devices require a PMA application under section 515 of the Federal Food, Drug and Cosmetic Act in order to obtain marketing clearance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PMA is the most stringent
type of device marketing application required by the FDA. The applicant must receive FDA approval of its PMA application prior to marketing
the device. PMA approval is based on a determination by FDA that the PMA contains sufficient valid scientific evidence to assure that
the device is safe and effective for its intended use(s). An approved PMA is, in effect, a license granting the applicant (or owner) permission
to market the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain a 510(k) clearance
for a device, a pre-market notification to the FDA must be submitted demonstrating that the device is substantially equivalent to a legally
marketed Class I or Class II predicate device. For a new device to be found substantially equivalent to one or other legally
marketed predicate devices, the new device must have: 1) the same intended use as a predicate, and 2) either a) the same technological
characteristics as the predicate device or b) different technological characteristics, but the information submitted must not raise new
questions of safety and effectiveness and must demonstrate substantial equivalence. We believe that we may be eligible to obtain 510(k)
clearance for each of our Electronic SkinGun, Disposable SkinGun and Cell Isolation Devices for certain uses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"><b>Investigational Device Exemption
(IDE)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 6, 2021, the FDA gave
full-approval of the Companys Investigational Device Exemption application to proceed with initial clinical testing of the manual
CellMist&nbsp;System and electronic SkinGun&nbsp;spray device in adult burn patients. Designated CELLMIST 1, the clinical
trial is designed to evaluate the safety and feasibility of autologous skin and pluripotent stem cells rendered by its manual CellMist
System from donor skin and applied topically with the electronic SkinGun spray device for treatment of acute burn wounds. The clinical
trial protocol is an open-label single-arm clinical study designed enroll 14 adult human burn subjects with partial-thickness, second-degree
thermal burn wounds covering between 10% and 30% total body surface area. The Company may engage up to four (4) U.S. burn centers to conduct
the clinical study. Despite the suspension of patient enrollment in the CELLMIST1 clinical trial, the Company is keeping the IDE open
to continue follow-up visits of treated patients and expedite resumption of the study at a later time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to year end, the
Board decided to suspend enrollment of new patients into the clinical trial and take other measures to reduce the Companys overhead
in an effort to conserve financial resources as it continues to defend against the Lawsuits. See <i>Item 1A.Risk Factors
</i>and <i>Item 3.Legal Proceedings.</i> The Company will continue medical and safety monitoring of the treated patients
at clinical sites in the clinical study during scheduled follow-up visits until the trial ends later in 2022. The Company hopes to restart
enrollment in the clinical trial at a future date upon the occurrence of a favorable outcome against the Lawsuits and receipt of additional
financing, as to which there is no assurance.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>HIPAA Requirements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other federal legislation
may affect our ability to obtain certain health information in conjunction with any research activities we conduct. The Health Insurance
Portability and Accountability Act of 1996 (<b>HIPAA</b>), mandates, among other things, the adoption of standards designed
to safeguard the privacy and security of individually identifiable health information. In relevant part, the U.S. Department of Health
and Human Services (<b>HHS</b>), has released two rules to date mandating the use of new standards with respect to such
health information. The first rule imposes new standards relating to the privacy of individually identifiable health information. These
standards restrict the manner and circumstances under which covered entities may use and disclose protected health information to protect
the privacy of that information. The second rule released by HHS establishes minimum standards for the security of electronic health information.
While we do not believe we are directly regulated as a covered entity under HIPAA, the HIPAA standards impose requirements on covered
entities conducting research activities regarding the use and disclosure of individually identifiable health information collected in
the course of conducting the research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other U.S. Regulatory Requirements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., the research,
manufacturing, distribution, sale, and promotion of drug and biological products are potentially subject to regulation by various federal,
state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services (formerly the Health Care
Financing Administration), other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General),
the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.
For example, sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social
Security Act, the False Claims Act, and similar state laws, each as amended. Pricing and rebate programs must comply with the Medicaid
rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended. If products
are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. These activities are also potentially subject to federal and state consumer protection, unfair competition, and other laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>International Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulation of any potential
product candidates outside of the U.S. will be subject to the applicable laws and requirements of the specific country or countries in
which we are introducing our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some countries regulate
human tissue products as a biological product, which would require us to make extensive filings and obtain regulatory approvals before
selling our product candidates. Other countries may classify our product candidates as human tissue for transplantation but may restrict
its import or sale; other countries may have no application regulations regarding the import or sale of products similar to potential
product candidates, creating uncertainty as to what standards we may be required to meet. The validation testing and manufacturing of
our medical devices are subject to ISO9000 and other industry regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, the Company
primarily has favored, when possible, to utilize the services of consultants on a contract basis rather than hiring full or part-time
employees, generally having found it to be more economical and efficient (collectively, <b>RCAR Personnel</b>). As of the
date of this report, the Company had one (1) full-time employee, and two (2) part-time consultants located in the United States. We also
have one consultant, based in Spain, who provides services in the area of product development on a full-time basis. Our full-time employee
is Dr. Robin Robinson. Mr. Harmel S. Rayat, who is the Companys majority stockholder and Chairman, effective as of March 24, 2022,
also serves as our Interim President and Chief Executive Officer, as our Interim Chief Financial Officer and Secretary. Mr. Rayat, receives
token compensation of $1 per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time-to-time, the Company
grants stock options to directors, employees and consultants on a discretionary basis. The awards relate to the recipients efforts
and contribution to the Companys effectuation of its business plan. None of the RCAR Personnel are covered by a collective bargaining
agreement.&nbsp;&nbsp;We believe our relations with RCAR Personnel are good.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our website address is&nbsp;<i>www.renovacareinc.com.&nbsp;</i>We
make available, through our website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
amendments to those reports filed or furnished pursuant to the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the SEC. The information accessible through our website is not a part
of this annual report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The public may also read and
copy any materials we file with the SEC on the SECs website at www.sec.gov which site contains reports, proxy and information statements,
and other information regarding issuers, such as us, that file electronically with the SEC. All statements made in any of our filings,
including all forward-looking statements, are made as of the date of the document(s) in which the statement is included, and we do not
assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive office is located
at 9375 E Shea Blvd., Suite 107-A, Scottsdale AZ 85260. Our telephone number is (888) 398-0202. Information contained on our web site
(or any other website) does not constitute part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stockholder Communications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders who wish to
communicate with the Board may do so by addressing their correspondence to the Board at RenovaCare, Inc., Attention: President and Chief
Executive Officer, 9375 E Shea Blvd., Suite 107-A, Scottsdale, AZ 85260. The Board will review and respond to all correspondence received,
as appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify; text-indent: 35.65pt">&nbsp;</p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">&nbsp;<span style="text-transform: uppercase"><b><span id="a_002"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>An investment in our
securities involves a high degree of risk. You should carefully consider the risks described below before investing in our common stock.
If any of the following risks actually occurs, our business, financial condition, or results of operations could be materially adversely
affected, the trading price of our common stock could decline, and you may lose all or part of your investment. The risks and uncertainties
described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe
to be immaterial may also adversely affect our business. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Risks Associated with Litigation Matters</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of lawsuits have
been commenced against the Company and its current and former directors. Collectively these lawsuits, and the SEC Complaint as defined
below, which are more fully described in Item 1A. in this Report, are at times referred to in this Report as the <b>Lawsuits</b>.
See <i>Item 3.Legal Proceedings.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Lawsuits have and will
continue to require substantial financial resources and management attention; in addition, the Lawsuits may result in, awards, injunctions,
fines, and penalties assessed against us which could materially adversely affect our operations and our ability to continue as a going
concern. The risks discussed below are those that the Company believes to be the most significant and potentially material to the operations
of the Company. The following risk factors do not purport to encompass all possible risk factors related to the Lawsuits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Risks Associated with
the SEC Action.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.5in">On May 28, 2021,
following four plus years of investigation, the SEC filed a civil complaint (the <b>SEC Complaint</b>) naming the Company
and Harmel S. Rayat, our current Interim President and Chief Executive Officer, Interim Chief Financial Officer and Chairman as defendants
(the <b>Defendants</b>). The SEC Complaint alleges that Mr. Rayat and the Company of violating the antifraud provisions
of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also alleges that Mr. Rayat aided and abetted the
Company's violation of those provisions. The SEC Complaint also alleges that the Company with violated the reporting provisions of Exchange
Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC is seeking, among other things, permanent injunctions and civil penalties
against the Defendants, and officer-and-director and penny stock bars against Mr. Rayat. On August 31, 2021 the Defendants filed a response
to the Complaint. On September 21, 2021, the SEC filed a motion to strike Defendants equitable affirmative defenses which motion was granted
by the court on October 18, 2021. The Company (and Mr. Rayat) have denied the operative allegations made by the SEC in the SEC Complaint
and continue to pursue the defense of the SEC Action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.5in">The SEC Action
has adversely affected the Company, and, as a consequence all of its stockholders. As a consequence of the SEC investigation and the filing
of the SEC Complaint:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol"></span></td><td style="text-align: justify; padding-right: 0.35pt">the Company has effectively depleted the funds available to it under its D&amp;O
Insurance Policy thus requiring the Company to begin to utilize a portion of its working capital to defray the defense costs, which are
expected to continue at least throughout fiscal 2022;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol"></span></td><td style="text-align: justify; padding-right: 0.35pt">the Company has been obliged to undertake significant cost saving measures resulting
in the recent suspension of enrollment in its clinical study, staff cuts, and research and development curtailments;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol"></span></td><td style="text-align: justify; padding-right: 0.35pt">the Company has incurred reputational harm and precluding it from effecting a financing;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol"></span></td><td style="text-align: justify; padding-right: 0.35pt">the Companys management has been required to expend more of its time addressing
and responding to numerous and continuing SEC requests for information;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol"></span></td><td style="text-align: justify; padding-right: 0.35pt">because of the reputational harm suffered by the Company it has been hampered in
retaining and recruiting experienced management personnel;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol"></span></td><td style="text-align: justify; padding-right: 0.35pt">class action and derivative lawsuits have been filed based, in part, on the allegations
set forth in the SEC Complaint; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol"></span></td><td style="text-align: justify; padding-right: 0.35pt">there has been a reduction in the market liquidity and decline in the price of
the Companys common stock has declined since the commencement of the filing of the SEC Complaint, which will affect the Companys
ability to obtain financing.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects
that the SEC Complaint, until resolved in court, will continue to materially and adversely affect the Company in all aspects of its operations
and finances, including the continued operation of the RenovaCare R&amp;D Innovation Center in Berlin and its ability to pursue other
potential research and development initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Risks Associated
with the Class Actions and the Derivative Actions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify; text-indent: 0.5in">On July 16 and July
21, 2021,&nbsp;two&nbsp;purported stockholders of the Company filed separate class actions claiming, among other things, that in connection
with the facts and circumstances underlying the allegations in the SEC Complaint, the Company engaged in fraudulent conduct and made false
and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. Plaintiffs&nbsp;seek
to declare the action to be a class action and monetary damages, including costs and expenses, and award of reasonable attorneys
fees, expert fees, and other costs, and such other relief as the Court may deem just and proper. See <i>Item 3. Legal Proceedings.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 20, 2021, January
6, 2022 and January 28, 2022,&nbsp;three&nbsp;purported stockholders of the Company filed separate derivative actions. The derivative
actions which were brought both individually and on behalf of the Company, are claiming that in connection with the facts and circumstances
underlying the allegations in the SEC Complaint, the Company executives should have known that certain representations contained
in its quarterly filings were false and misleading and that the defendants were in breach of their fiduciary duties to the Company and
its stockholders. The derivative actions generally seek, an award of the plaintiffs the costs and disbursements of the action, including
reasonable attorneys and other related fees, specific findings (including findings that the defendants breached their fiduciary
duties, wasted corporate assets, and were unjustly enriched, and violated the federal securities laws), an order requiring the Company
to take a variety of Board level actions related to among other things, corporate governance matters, monetary damages, including restitution
and return of all compensation, as well as the disgorgement of any profits that the individual defendants may have made. See <i>Item 3.
Legal Proceedings.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commencement of the Lawsuits
(see <i>Item 3. Legal Proceedings)</i> have added to the Companys financial burdens, reduced the amount of time its management
has to devote to day-to-day operations, and further exacerbated the decline in the market price and liquidity of the Companys stock
and the harm caused to the Companys reputation by the SEC Complaint. The Lawsuits have further impeded the Companys ability
to obtain financing and to retain or recruit qualified management personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company disputes
the claims asserted in the Lawsuits and believes the claims set forth in the Lawsuits are without merit and intends to defend itself vigorously.
To that end, the Company has retained counsel to defend it, and the named individual defendants, against the allegations and claims set
forth in the Lawsuits. Based on the early stages of the Lawsuits (including the SEC Complaint), and the inherent uncertainty as to their
outcome, at this time, the Company is not able to reasonably estimate a possible range of loss, if any, should the plaintiffs in these
actions be successful. However, an adverse decision in the SEC Complaint or any of the other Lawsuits, or the Companys inability
to fund its defense against the Lawsuits, will in all likelihood adversely affect the Companys operations, finances and ability
to effectuate its business plan; and, will further adversely affect the price and trading liquidity of the Companys common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not generated
any revenue and has sustained recurring losses and negative cash flows from operations since inception. Furthermore, the Company expects
to incur losses as it continues development of its products and technologies and defend itself against the Lawsuits. See <i>Item
3. Legal Proceedings.</i> The Company will need to raise additional capital through the sale of equity securities, debt, or strategic
alliances in order to accomplish its business plan and continue its legal defense of the Lawsuits. Failing to secure such additional funding
poses a significant risk. The Company's ability to meet its financial obligations, including to fund the development of its cellular therapies
and defense of the Lawsuits depends on the amount and timing of cash receipts from future financing activities. There can be no assurance
as to the availability or terms upon which such funds will be available as, if and when needed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Risks Associated with Our Business Activities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The development of
our CellMist</i><sup>TM</sup><i>&nbsp;System is subject to the risks of failure inherent in the development of any novel technology</i></b><i>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ultimately, the development
and commercialization of our CellMist<sup>TM</sup>&nbsp;System is subject to a number of risks that are particular to the development
and commercialization of any novel technology. These risks include, but are not limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may fail to develop, acquire, or license various enabling technologies that may be integral to the commercialization of the CellMist<sup>TM</sup>&nbsp;System (or any derivatives);</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the CellMist<sup>TM</sup>&nbsp;System may ultimately prove to be ineffective, unsafe or otherwise fail to receive necessary regulatory approvals;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the CellMist<sup>TM</sup>&nbsp;System (or any derivatives), even if safe and effective, may be difficult to manufacture on a large scale or uneconomical to market;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our marketing license or proprietary rights to products derived from the CellMist<sup>TM</sup>&nbsp;System may not be sufficient to protect our products from competitors;</span></td></tr>
  </tbody></table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the proprietary rights of third parties may preclude us or our collaborators from making, using or marketing products utilizing the CellMist<sup>TM</sup>&nbsp;System; or,</span></td></tr>
  </tbody></table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">third parties may market superior, more effective, or less expensive technologies or products having comparable or better results to the CellMist<sup>TM</sup>&nbsp;System (or any derivatives).</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The success of our research
and development activities is uncertain. If such efforts are not successful, or if we are unable to raise additional capital, or if we
will be unable to generate revenues from our operations and we may have to cease doing business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commercialization of our CellMist<sup>TM</sup>&nbsp;System
will require significant further research, development and testing as we must ascertain whether the CellMist<sup>TM</sup>&nbsp;System
can form the basis for a commercially viable technology or product. If our research and development activities fail to prove commercial
viability of the CellMist<sup>TM</sup>&nbsp;System, we may need to abandon our business model and/or cease doing business, in which case
our shares may have no value and you may lose your investment. While we anticipate we will remain engaged in research and development,
through at least December 31, 2022, it is uncertain at this time whether the Company will be able to bear the anticipated costs of its
defense against the SEC Action, the Class Actions and the Derivative Actions. Accordingly, the Company expects that the SEC Action, the
Class Actions and the Derivative Actions, until resolved in court, will continue to materially and adversely affect the Company in all
aspects of its operations and finances. If the Company is unable to raise additional capital, for which there is no assurance, or generate
revenues from operations, the Company may cease doing business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The Company does not
have any commercialized products and the failure to commercialize, or delays in commercializing our CellMist<sup>TM</sup>&nbsp;System,
would adversely impact our ability to attain profitability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not have
any commercialized products.&nbsp; To date, the Company's activities have consisted principally of performing research and development
activities and raising capital to support such activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has enlisted the
assistance of several Contract Manufacturing Organizations (CMO) to manufacture clinical supplies including components of the CellMist
System and the electronic SkinGun spray devices in compliance with FDAs guidance for current Good Manufacturing Practices
(cGMP) and Contract Research Organizations (CRO) to conduct clinical trials to evaluate the safety and feasibility of an autologous skin
cell therapy using the Companys products to facilitate burn wound healing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These development activities
are subject to significant risks and uncertainties, including possible failure of preclinical and clinical testing. The Company has not
generated any revenue and has sustained recurring losses and negative cash flows from operations since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should the Company fail to
commercialize its CellMist<sup>TM</sup>&nbsp;System, or if it were to incur significant delays in doing so, the Companys business
would be adversely affected, and it may not be able to achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we fail to manage
our growth effectively, our business could be disrupted.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future financial performance
and ability to successfully commercialize our products, of which there is no guarantee, and to compete effectively will depend, in part,
on our ability to manage any future growth effectively. We expect to make significant investments to enable our future growth through,
among other things, new product development, clinical trials for new indications and expansion of our marketing and sales infrastructure.
Any failure to manage future growth effectively could have a material adverse effect on our business and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our commercial success
will depend on our ability to compete effectively in product development and commercialization areas.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success will
depend on our ability to compete effectively in product development and commercialization areas such as, but not limited to device manufacturing,
product safety and efficacy, ease of use, customer acceptance, cost of goods, wholesale and retail pricing, marketing and distribution.
Our competitors may succeed in developing products that are more effective than any products derived from our research and development
efforts or that would render such products obsolete and non-competitive. The skin care and wound care industry is characterized by intense
competition, rapid product development and technological change. Most of the competition that we encounter is expected to come from companies,
research institutions and universities who are researching and developing technologies and products similar to or competitive with any
we may develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These companies enjoy numerous
competitive advantages, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">significantly greater name recognition;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">established relations with customers;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">established distribution networks;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">more advanced technologies and product development;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">additional lines of products, and the ability to offer rebates, higher discounts or incentives to gain a competitive advantage;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">successful technical transfer and manufacturing of products at commercial scale;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">greater experience in conducting research and development, manufacturing, obtaining regulatory approval for products, and marketing approved products;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">greater financial and human resources for product development, sales, and marketing, and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability to endure potentially prolonged patent litigation.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we may not
be able to compete effectively against these companies or their products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our success depends
in large part on our ability to develop and commercialize products based upon or derived from our CellMist</i><sup>TM</sup><i>&nbsp;System
and underlying technology. If we are unable to successfully market and sell products incorporating our CellMist</i><sup>TM</sup><i>&nbsp;System
and underlying technology, our business prospects will be significantly harmed, and we may be unable to achieve profitability. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future financial success
will depend substantially on our ability to effectively and profitably market and sell our products that incorporate, are based upon,
or derived from our CellMist<sup>TM</sup>&nbsp;System and underlying technology. The commercial success of our products and any of our
planned or future products will depend on a number of factors, many of which of which are beyond our control, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical indication(s) of the CellMist<sup>TM</sup> System and SkinGun<sup>TM</sup> devices approved by regulatory authorities on product label(s) in the Pre-Marketing Authorization and 510(k) clearances;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">customer acceptance of our products;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the actual and perceived effectiveness and reliability of our products, especially relative to alternative products;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the results of clinical trials relating to the use of our products;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">achieving and maintaining compliance with all regulatory requirements applicable to our products;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the level of education and awareness among physicians and hospitals concerning our products;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our reputation among physicians and hospitals;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining third-party coverage or reimbursement for our products;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">performance and reliability of our products as compared with other alternative products;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the ability to offer our products for sale at an attractive value and the willingness of physicians to administer our products and their acceptance as part of the medical department routine;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the prevalence and severity of any side effects;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the efficacy, potential advantages and timing of introduction to the market of alternative treatments; and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our failure to develop and maintain successful relationships with health care professionals, manufacturers, distributors, and other resellers, as well as strategic partners.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to achieve market
acceptance for any of our products, if and when they are approved for commercial sale, will have a material adverse effect on our business,
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may be unsuccessful
in commercializing our products due to unfavorable pricing regulations, third-party coverage and reimbursement policies or healthcare
reform initiatives.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict the pricing
and reimbursement of any products we may develop and commercialize. The regulations that govern marketing approvals, pricing and reimbursement
for new products vary widely from country to country. In some foreign jurisdictions, including the European Union, the pricing of medical
devices and treatments is subject to governmental control. In these jurisdictions, pricing negotiations with governmental authorities
can take considerable time after the receipt of marketing approval for a product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we might obtain
regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of
the product and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations
may hinder our ability to recoup our investment in any products we may develop and commercialize, even after obtaining regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we cannot
be sure that reimbursement will be available for any products we may develop and commercialize, or if reimbursement is available, what
the level of reimbursement will be. Reimbursement may affect the demand for, or the price of, any product for which we obtain marketing
approval. Obtaining reimbursement for any products we may develop and commercialize may be particularly difficult because of the higher
prices often associated with products administered under the supervision of a physician. If reimbursement is not available or is available
only at limited levels, we may not be able to successfully commercialize any products that we successfully develop. Eligibility for reimbursement
does not imply that any product will be paid for in all cases or at a rate that covers our costs. Interim payments for new products, if
applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of
the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed
and may be incorporated into existing payments for other services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The commercial success
of our products will depend upon attaining market acceptance of these products among physicians, healthcare payors and the medical community.
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success will depend on
the acceptance of our products as safe, useful and, with respect to providers, cost effective. We cannot predict how quickly, if at all,
physicians will accept our products or, if accepted, how frequently they will be used. Our products and planned or future products we
may develop or market may never gain broad market acceptance among physicians and the medical community for some or all of our targeted
indications. Healthcare providers must believe that our products offer benefits over alternative treatment methods. The degree of market
acceptance of any of our products will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether physicians and others in the medical community consider our products to be safe and cost-effective treatment methods;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the potential and perceived advantages of our products over alternative treatment methods;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the prevalence and severity of any side effects associated with using our products;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">limitations or warnings contained in the labeling cleared or approved by the FDA or other authorities;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of treatment in relation to alternative treatments methods;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the convenience and ease of use of our products relative to alternative treatment methods;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the availability of coverage and adequate reimbursement for procedures using our products from third-party payors, including government authorities;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors, including government authorities;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to provide incremental clinical and economic data that show the safety, clinical efficacy and cost effectiveness of, and patient benefits from, our products; and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the effectiveness of our sales and marketing efforts for our products.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, even if our
products achieve market acceptance, they may not maintain that market acceptance over time if competing products or technologies, which
are more cost effective or received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share
would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Development and commercialization
of any products requires successful completion of the regulatory approval process, and may suffer delays or fail.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., as well as
other jurisdictions, we will be required to apply for and receive marketing authorization before we can market our products. This process
can be time consuming and complicated and may result in unanticipated delays. To secure marketing authorization, an applicant generally
is required to submit an application that includes the data supporting preclinical and clinical safety and efficacy as well as detailed
information on the manufacturing and quality control of the product, proposed labeling and other additional information. Before marketing
authorization is granted, regulatory authorities generally require the inspection of the manufacturing facility or facilities and quality
systems (including those of third parties) at which the product candidate is manufactured and tested, as well as potential audits of the
non-clinical and clinical trial sites that generated the data cited in the marketing authorization application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict how long
the applicable regulatory authority or agency will take to grant marketing authorization or whether any such authorizations will ultimately
be granted. Regulatory agencies, including the Food and Drug Administration (the <b>FDA</b>), have substantial discretion
in the approval process, and the approval process and the requirements governing clinical trials vary from country to country. The policies
of the FDA or other regulatory authorities may change or may not be explicit, and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of any products we may develop and commercialize. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S., Europe
or elsewhere. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or
if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, any regulatory
approval that we receive may also contain requirements for potentially costly post-marketing testing and surveillance to monitor the safety
and efficacy of the product candidate. Once a product is approved, the manufacturing processes, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion, import, export and recordkeeping for the product will be subject to extensive and ongoing
regulatory requirements. These requirements include submission of safety and other post-marketing information and reports, registration
and continued compliance with good manufacturing practices for any clinical trials that we conduct post-approval.&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We utilize our technical
staff with third party Contract Research Organization and Contract Manufacturing Organizations to conduct research and development for
our CellMist</i><sup>TM</sup><i>&nbsp;System.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, we announced
the official launch of our new RenovaCare R&amp;D Innovation Center located in Berlin, Germany, where our patented technologies for isolating
and spraying self-donated stem cells to regenerate tissues and organs have been under development alongside new product initiatives. Important
programs at the Center include design, validation, and pilot-scale manufacturing of our cell isolation and SkinGun<b><sup>TM </sup></b>spray
devices; preclinical study support to our clinical studies and regulatory submissions for our flagship SkinGun spray device, which
delivers a proprietary gentle CellMist spray of a patients own skin cells on to burns and wounds. The Innovation Center
is the result of a multi-year collaboration agreement with StemCell Systems GmbH (<b>StemCell Systems</b> or <b>SCS</b>),
with whom we have maintained an R&amp;D relationship since 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on the
services of StemCell Systems to conduct our pre-clinical research and development activities for our CellMist<sup>TM</sup>&nbsp;System
and manufacture the SkinGun<b><sup>TM </sup></b>spray device at pilot scale. In the event they are unable to provide us with these services,
we may need to expend considerable resources, time, and money to locate, if possible, another research lab which could have a material
and adverse effect on our research and development activities, as well as our operating results and financial condition even, if we were
to eventually design and engage such alternative research laboratories. Additionally, because of the reputational the Company has suffered
as a result of the Lawsuits, there can be no assurance that other entities will be willing to discuss or enter into business relationships
with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may expend our
limited resources to pursue a particular product or indication and fail to capitalize on products or indications that may be more profitable
or for which there is a greater likelihood of success. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have limited
financial and managerial resources, we focus on specific products, indications, and discovery programs. As a result, we may forgo or delay
pursuit of other opportunities with others that could have had greater commercial potential. Our resource allocation decisions may cause
us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research
and development programs for specific indications may not yield any commercially viable products. If we do not accurately evaluate the
commercial potential or target market for a particular potential product, we may relinquish valuable rights to that potential product
through future collaborations, licenses, and other similar arrangements in cases in which it would have been more advantageous for us
to retain sole development and commercialization rights to such potential product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If any of our products
cause or contribute to a death or serious adverse events or malfunction in certain ways, we will be required to report under applicable
medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under FDA medical device
reporting regulations (MDR regulations), medical device manufacturers are required to report to the FDA information that
a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute
to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If we fail to report events required
to be reported to the FDA within the required timeframes, or at all, the FDA could take enforcement action and impose sanctions against
us. Any such adverse event involving our products also could result in future voluntary corrective actions, such as recalls or customer
notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as
well as defending ourselves in a lawsuit, would require our time and capital, distract management from operating our business and may
harm our reputation and have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our employees, independent
contractors, consultants, commercial partners, distributors, and vendors may engage in misconduct or other improper activities, including
noncompliance with regulatory standards and requirements. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the risk
that our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in fraudulent or illegal
activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities
to us that violates: (i)&nbsp;the laws of the FDA and other similar foreign regulatory bodies, including those laws requiring the reporting
of true, complete and accurate information to such regulators; (ii)&nbsp;manufacturing standards; (iii)&nbsp;healthcare fraud and abuse
laws in the United States and similar foreign fraudulent misconduct laws; or (iv)&nbsp;laws that require the true, complete and accurate
reporting of financial information or data. These laws may impact, among other things, future sales, marketing and education programs.
In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare
industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and
regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commissions, certain
customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use
of information obtained in the course of patient recruitment for clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a code of
business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees and other third parties,
and the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such
laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights,
those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and
administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, additional integrity reporting and oversight
obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational
harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate
our business and our results of operations. Whether or not we are successful in defending against any such actions or investigations,
we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these
claims or investigations, which could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Legislative or regulatory
reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of our planned or future products and
to manufacture, market and distribute our products after clearance or approval is obtained. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is enacted that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated
products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways
that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations
may impose additional costs or lengthen review times of planned or future products. It is impossible to predict whether legislative changes
will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, the policies that
may be adopted by the Biden Administration and their impact on the regulation of our products in the United States remain uncertain.&nbsp;The
outcome of the 2020 election resulting in one party control of the House of Representatives and the Senate could result in significant
legislative and regulatory reforms impacting the FDAs regulation of our products.&nbsp;Any change in the laws or regulations that
govern the clearance and approval processes relating to our current, planned, and future products could make it more difficult and costly
to obtain clearance or approval for new products or to produce, market and distribute existing products. Significant delays in receiving
clearance or approval or the failure to receive clearance or approval for our new products would have an adverse effect on our ability
to expand our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our products or processes
may infringe the intellectual property rights of others, which may cause us to pay unexpected litigation costs or damages or prevent us
from selling our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
our products do not and will not infringe issued patents or other intellectual property rights of third parties. We may be subject to
legal proceedings and claims in the ordinary course of our business, including claims of alleged infringement of the intellectual property
rights of third parties. Any such claims, whether or not meritorious, could result in litigation and divert the efforts of our personnel.
If we are found liable for infringement, we may be required to enter into licensing agreements (which may not be available on acceptable
terms or at all) or to pay damages and to cease making or selling certain products. We may need to redesign some of our products or processes
to avoid future infringement liability. Any of the foregoing could be detrimental to our business and ultimate profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may become exposed
to costly and damaging liability claims and any product liability insurance we have may not cover all damages from such claims.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are exposed to potential product liability risks that are inherent in the research, development, manufacturing, marketing and use of medical
device products. The future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may
expose us to liability claims. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found
to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations
of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or
a breach of warranties. Claims could also be asserted under state consumer protection acts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
outcome of litigation, particularly any class-action lawsuits, is difficult to quantify. Plaintiffs often seek recovery of very large
or indeterminate amounts, including punitive damages. The magnitude of the potential losses relating to these lawsuits may remain unknown
for substantial periods of time and the cost to defend against any such litigation may be significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory
approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials
or after approval thereof, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that
identify known potential adverse effects and patients who should not use our product candidates. If we cannot successfully defend ourselves
against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products.
Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome,
liability claims may result in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delay or termination of clinical trials;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decreased demand for any product candidates or products that we may develop;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">injury to our reputation and significant negative media attention;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">withdrawal of clinical trial participants;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">costs to defend the related litigation;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a diversion of managements time and our resources;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">substantial monetary awards to trial participants or patients;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">significant negative financial impact; and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the inability to commercialize our product candidates.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
we have procured product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur.
We may need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product
candidate. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost
or in an amount adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought
against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our
business operations could be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Our
internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Despite
the implementation of security measures, our internal computer systems, and those of our CROs and other third-party vendors on which we
rely or will rely, are vulnerable to damage from computer viruses and unauthorized access, malware, natural disasters, fire, terrorism,
war and telecommunication, electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside
our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly
through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased
as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">While
we have not experienced any such material system failure or security breach to our knowledge to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations.
For example, the loss of preclinical data or data from future clinical trials could result in delays in our regulatory approval efforts
and significantly increase our costs to recover or reproduce the data. Likewise, we plan to rely on third parties for the manufacture
of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material
adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data
or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development
and commercialization of our future product candidates could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
face competition from the existing standard of care and potential changes in medical practice and technology and the possibility that
our competitors may develop products, treatments or procedures that are similar, more advanced, safer or more effective than ours.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
medical, biotechnology and pharmaceutical industries are intensely competitive and subject to significant technological and practice changes.
We may face competition from many difference sources with respect to any products we may develop and commercialize. Possible competitors
may be medical practitioners, pharmaceutical, biotechnology, medical device, and wound care companies, academic and medical institutions,
governmental agencies and public and private research institutions, among others. Should any competitors product candidates receive
regulatory or marketing approval prior to ours, they may establish a strong market position and be difficult to displace, or will diminish
the need for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products, treatments or procedures
that are safer, more effective, have fewer or less severe adverse effects, are more convenient or are less expensive than any product
that we may develop. Many of our current or future competitors may have significantly greater financial resources and expertise in research
and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved
products than we may have. Mergers and acquisitions in the pharmaceutical, medical device, and biotechnology industries or wound care
markets may result in even more resources being concentrated among a smaller number of our competitors. Other early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
companies compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites
and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
may compete for the time and efforts of our officers and directors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Certain
of our officers and directors are also officers, directors, and employees of other companies and we may have to compete with the other
companies for their time, attention and efforts. One of our officers provide us their services on a part-time basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
maintain at-will employment or executive services consulting agreements with our officers that may be terminated by us or the respective
officer at any time and for any reason.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
maintain at-will employment agreements or executive services consulting agreements with our officers that may be terminated by us or the
respective officer at any time and for any reason. If any of our officers terminate their consulting agreement it may have a material
adverse effect on our business, financial condition or ability to operate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Our
growth and success depend on our ability to attract and retain additional highly qualified and skilled sales and marketing, research and
development, operational, managerial and finance personnel.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our growth and success
depend on our ability to attract and retain additional highly qualified and skilled sales and marketing, research and development, operational,
managerial and finance personnel. Competition for skilled personnel is intense and the unexpected loss of an employee with a particular
skill could materially adversely affect our operations until a replacement can be found and trained. If we cannot attract and retain skilled
scientific and operational personnel, as required, for our research and development and manufacturing operations on acceptable terms,
we may not be able to develop and commercialize any products. Further, any failure to effectively integrate new personnel could prevent
us from successfully growing our Company. See <i>Item 1 A. Risk Factors- <span style="text-decoration: underline">Risks Associated with Litigation Matters.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&nbsp;</i></b></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Risks Associated with a Failure to Comply
with Regulatory Requirements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Development
and commercialization of any products requires successful completion of the regulatory approval process, and may suffer delays or fail.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
medical devices and business activities are subject to rigorous regulation by the FDA and other federal, state and international governmental
authorities. These authorities and members of Congress have been increasing their scrutiny over the medical device industry. In recent
years, the U.S. Congress, Department of Justice, the Office of Inspector General of the Department of Health and Human Services, and the
Department of Defense have issued subpoenas and other requests for information to medical device manufacturers, primarily related to financial
arrangements with health care providers, regulatory compliance and marketing and product promotional practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
certain state governments have enacted legislation to increase transparency of interactions with health care providers, pursuant to which
we are required by law to disclose payments and other transfers for value to health care providers licensed by certain states. We anticipate
that the government will continue to scrutinize our industry closely, and any new regulations or statutory provisions could result in
delays or increased costs during the periods of product development, clinical trials and regulatory review and approval, as well as increased
costs to assure compliance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the U.S., as well as other jurisdictions, we will be required to apply for and receive marketing authorization before we can market our
products. This process can be time consuming and complicated and may result in unanticipated delays. To secure marketing authorization,
an applicant generally is required to submit an application that includes the data supporting preclinical and clinical safety and efficacy
as well as detailed information on the manufacturing and control of the product, proposed labeling and other additional information. Before
marketing authorization is granted, regulatory authorities generally require the inspection of the manufacturing facility or facilities
and quality systems (including those of third parties) at which the product candidate is manufactured and tested, as well as potential
audits of the non-clinical and clinical trial sites that generated the data cited in the marketing authorization application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
cannot predict how long the applicable regulatory authority or agency will take to grant marketing authorization or whether any such authorizations
will ultimately be granted. Regulatory agencies, including the Food and Drug Administration (the <b>FDA</b>), have substantial
discretion in the approval process, and the approval process and the requirements governing clinical trials vary from country to country.
The policies of the FDA or other regulatory authorities may change or may not be explicit, and additional government regulations may be
enacted that could prevent, limit or delay regulatory approval of any products we may develop and commercialize. We cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S.,
Europe or elsewhere. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
any regulatory approval that we receive may also contain requirements for potentially costly post-marketing testing and surveillance to
monitor the safety and efficacy of the product candidate. Once a product is approved, the manufacturing processes, labeling, packaging,
distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for the product will be subject
to extensive and ongoing regulatory requirements. These requirements include submission of safety and other post-marketing information
and reports, registration and continued compliance with good manufacturing practices for any clinical trials that we conduct post-approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
may encounter substantial delays in the commencement, completion, termination or suspension of our clinical trials, which could result
in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Before
obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials
to demonstrate the safety and efficacy of the product candidate for its intended indications. Clinical medical device development is a
lengthy and expensive process, with an uncertain outcome; accordingly, we cannot guarantee that any clinical trials will be conducted
as planned or completed on schedule, if at all. We may experience numerous unforeseen events during or as a result of clinical trials
that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including but not limited
to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes to a clinical trial protocol;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical trial sites deviating from a trial protocol or dropping out of a trial;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">subjects failing to enroll or remain in clinical trials at the rate we expect, or failing to return for post-treatment&nbsp;follow-up;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">subjects experiencing severe adverse effects;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical trials of our product candidates may produce unfavorable or inconclusive results;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may decide to abandon product development programs;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may need to add new or additional clinical trial sites;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any changes to manufacturing process that may be necessary or desired;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of preclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate or greater than our available financial resources; or</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or we may not be able to obtain sufficient quantities of combination therapies for use in clinical trials.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
we are required to conduct additional clinical trials or other testing of our product candidates beyond the clinical trials and testing
that we contemplate, if we are unable to successfully complete clinical trials or other testing of our product candidates, if the results
of these clinical trials or tests are unfavorable or are only modestly favorable or if there are safety concerns associated with any of
product candidates, we may, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">incur additional unplanned costs;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be delayed in obtaining marketing approval, if at all;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be subject to additional post-marketing testing or other requirements;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be required to perform additional clinical trials to support approval;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be subject to the addition of labeling statements, such as warnings or contraindications;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">be subject to lawsuits; or</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">experience damage to our reputation.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar or other events
could delay or prevent our ability to complete necessary clinical trials for our pipeline products, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulators may not authorize us to conduct a clinical trial within a country or at a prospective trial site or may change the design of a study;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays may occur in reaching agreement on acceptable clinical trial terms with regulatory authorities or prospective sites, or obtaining institutional review board approval;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our preclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional trials or to abandon strategic projects;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the number of patients required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower or more difficult than we expect, or patients may not participate in necessary follow-up visits to obtain required data, any of which would result in significant delays in our clinical testing process;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our third-party contractors, such as a research institution, may fail to comply with regulatory requirements or meet their contractual obligations to us;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be forced to suspend or terminate our clinical trials if the participants are being exposed, or are thought to be exposed, to unacceptable health risks or if any participant experiences an unexpected serious adverse event;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">undetected or concealed fraudulent activity by a clinical researcher, if discovered, could preclude the submission of clinical data prepared by that researcher, lead to the suspension or substantive scientific review of one or more of our marketing applications by regulatory agencies, and result in the recall of any approved product distributed pursuant to data determined to be fraudulent;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of our clinical trials may be significantly greater than we anticipate;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an audit of preclinical or clinical studies by regulatory authorities may reveal noncompliance with applicable protocols or regulations, which could lead to disqualification of the results and the need to perform additional studies; and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 45px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays may occur in obtaining our clinical materials.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
we do not know whether preclinical tests or clinical trials will begin or be completed as planned or will need to be restructured. Significant
delays could also shorten the patent protection period during which we may have the exclusive right to commercialize our products or could
allow our competitors to bring products to the market before we do, impairing our ability to commercialize our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Obtaining
and maintaining regulatory approval for a product candidate in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval for that product candidate in other jurisdictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Obtaining
and maintaining regulatory approval for a product candidate in one jurisdiction does not guarantee that we will be able to obtain or maintain
regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have
a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval for a product candidate,
comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product
candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods
different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials as clinical trials conducted
in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a drug
candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we
intend to charge for our products is also subject to approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
may fail to obtain regulatory approval for our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
potential product candidates could fail to receive regulatory approval for many reasons, including one or more of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials or the validation of our caregiver and patient reported outcome instruments;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for any of its proposed indications;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be unable to demonstrate that a product candidates clinical and other benefits outweigh its safety risks;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the data collected from clinical trials of our CellMist<sup>TM</sup>&nbsp;System and its underlying technology may not be sufficient to satisfy the FDA or comparable foreign regulatory authorities to support our submission or to obtain regulatory approval in the U.S. or elsewhere;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
are subject to extensive environmental, health and safety, and other laws and regulations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
our business involves the controlled use of biological materials, the risk of accidental contamination or injury from these materials
cannot be eliminated. If an accident, spill or release of any such chemicals or substances occurs, we could be held liable for resulting
damages, including for investigation, remediation and monitoring of the contamination, including natural resource damages, the costs of
which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including
those governing laboratory procedures. Additional or more stringent laws and regulations affecting our operations may be adopted in the
future. We may incur substantial capital costs and operating expenses and may be required to obtain consents to comply with any of these
or certain other laws or regulations and the terms and conditions of any permits required pursuant to such laws and regulations, including
costs to install new or updated pollution control equipment, modify our operations or perform other corrective actions at our respective
facilities. In addition, fines and penalties may be imposed for noncompliance with environmental, health and safety and other laws and
regulations or for the failure to have, or comply with the terms and conditions of, required environmental or other permits or consents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Risks Associated with our Intellectual
Property</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>If
we are unable to&nbsp;protect effectively our intellectual property, we may not be able to operate our business and third parties may
use our technology, both of which would impair our ability to compete in our markets.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
success will depend in significant part on our ability to obtain and maintain meaningful patent protection for certain of our technologies
and products throughout the world. Patent law relating to the scope of claims in the technology fields in which we will operate is still
evolving. The degree of future protection for our proprietary rights is uncertain. We will rely on patents to protect a significant part
of our intellectual property and to enhance our competitive position. However, our presently pending or future patent applications may
not issue as patents, and any patent previously issued to us or our subsidiaries may be challenged, invalidated, held unenforceable or
circumvented. Furthermore, the claims in patents that have been issued to us or our subsidiaries or that may be issued to us in the future
may not be sufficiently broad to prevent third parties from producing competing products similar to our products. In addition, the laws
of various foreign countries in which we plan to compete may not protect our intellectual property to the same extent as do the laws of
the United States. If we fail to obtain adequate patent protection for our proprietary technology, our ability to be commercially competitive
will be materially impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>If
third parties make or file claims of intellectual property infringement against us, or otherwise seek to establish their intellectual
property rights, we may have to spend time and money in response and cease some of our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.05pt; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Third
parties may claim that we are employing their proprietary technology without authorization or that we are infringing on their patents.
We could incur substantial costs and diversion of management and technical personnel in defending against any of these claims. Furthermore,
parties making claims against us may be able to obtain injunctive or other equitable relief which could effectively block our ability
to further develop, commercialize and sell products. In the event of a successful claim of infringement, courts may order us to pay damages
and obtain one or more licenses from third parties. We may not be able to obtain these licenses at a reasonable cost, if at all. Defense
of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing available products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>In addition to patented
technology, we rely on our unpatented proprietary technology, trade secrets, processes and know-how.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on proprietary information
(such as trade secrets, know-how and confidential information) to protect intellectual property that may not be patentable, or that we
believe is best protected by means that do not require public disclosure. We generally seek to protect this proprietary information by
entering into confidentiality agreements, or consulting, services or employment agreements that contain non-disclosure and non-use provisions
with our employees, consultants, contractors, scientific advisors and third parties. However, we may fail to enter into the necessary
agreements, and even if entered into, these agreements may be breached or otherwise fail to prevent disclosure, third-party infringement
or misappropriation of our proprietary information, may be limited as to their term and may not provide an adequate remedy in the event
of unauthorized disclosure or use of proprietary information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have limited control over the protection of trade secrets used by our suppliers and service providers and could lose future trade secret
protection if any unauthorized disclosure of such information occurs. In addition, our proprietary information may otherwise become known
or be independently developed by our competitors or other third parties. To the extent that our employees, consultants, contractors, scientific
advisors and other third parties use intellectual property owned by others in their work for us, disputes may arise as to the rights in
related or resulting know-how and inventions. Costly and time-consuming litigation could be necessary to enforce and determine the scope
of our and relevant third parties proprietary rights, failure to obtain or maintain protection for our proprietary information
could adversely affect our competitive business position and if third parties are able to establish that we are using their proprietary
information without their permission, we may be required to obtain a license to that information, or if such a license is not available,
re-design our products to avoid any such unauthorized use or temporarily delay or permanently stop manufacturing or sales of the affected
products. Furthermore, laws regarding trade secret rights in certain markets where we may operate may afford little or no protection to
our trade secrets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Our
proprietary rights may not adequately protect our technologies and products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
commercial success will depend on our ability to obtain patents and/or regulatory exclusivity and maintain adequate protection for our
technologies and products in the United States and other countries. We will be able to protect our proprietary rights from unauthorized
use by third parties only to the extent that our proprietary technologies and products are covered by valid and enforceable patents or
are effectively maintained as trade secrets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
intend to apply for additional patents covering both our technologies and products, as we deem appropriate. We may, however, fail to apply
for patents on important technologies or products in a timely fashion, if at all. Our existing patents and any future patents we obtain
may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products and technologies.
In addition, the patent positions of life science industry companies are highly uncertain and involve complex legal and factual questions
for which important legal principles remain unresolved. As a result, the validity and enforceability of our patents cannot be predicted
with certainty. In addition, we cannot guarantee that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we were the first to make the inventions covered by each of our issued patents and pending patent applications;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we were the first to file patent applications for these inventions;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">any of our pending patent applications will result in issued patents;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">any of our patents will be valid or enforceable;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">any patents issued to us will provide us with any competitive advantages, or will not be challenged by third parties; and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we will develop additional proprietary technologies that are patentable, or the patents of others will not have an adverse effect on our business.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The actual protection afforded
by a patent varies on a product-by-product basis, from country to country and depends on many factors, including the type of patent, the
scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country and
the validity and enforceability of the patents. Our ability to maintain and solidify our proprietary position for our products will depend
on our success in obtaining effective claims and enforcing those claims once granted. Our issued patents and those that may be issued
in the future, or those licensed to us, may be challenged, invalidated, unenforceable or circumvented, and the rights granted under any
issued patents may not provide us with proprietary protection or competitive advantages against competitors with similar products. We
also rely on trade secrets to protect some of our technology, especially where it is believed that patent protection is inappropriate
or unobtainable. However, trade secrets are difficult to maintain. While we use reasonable efforts to protect our trade secrets, our employees,
consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors.
Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain.
In addition, non-U.S. courts are sometimes less willing than U.S. courts to protect trade secrets. If our competitors independently develop
equivalent knowledge, methods and know-how, we would not be able to assert our trade secrets against them and our business could be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may not be able to
protect our intellectual property rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting and defending
patents on all of our products in every jurisdiction would be prohibitively expensive. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products. These products may compete with our products, and may not
be covered by any patent claims or other intellectual property rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The laws of some non-U.S.
countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered
significant problems in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating
to biotechnology, which could make it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights
in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>If we fail to protect
our intellectual property rights, our competitors may take advantage of our ideas and compete directly against us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success will depend to
a significant degree on our ability to secure and protect intellectual property rights and enforce patent and trademark protections relating
to our technology. While we believe that the protection of patents and trademarks is important to our business, we also rely on a combination
of copyright, trade secret, nondisclosure and confidentiality agreements, know-how and continuing technological innovation to maintain
our competitive position. From time to time, litigation may be advisable to protect our intellectual property position. However, these
legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage.
Any litigation in this regard could be costly, and it is possible that we will not have sufficient resources to fully pursue litigation
or to protect our intellectual property rights. This could result in the rejection or invalidation of our existing and future patents.
Any adverse outcome in litigation relating to the validity of our patents, or any failure to pursue litigation or otherwise to protect
our patent position, could materially harm our business and financial condition. In addition, confidentiality agreements with our employees,
consultants, customers, and key vendors may not prevent the unauthorized disclosure or use of our technology. It is possible that these
agreements will be breached or that they will not be enforceable in every instance, and that we will not have adequate remedies for any
such breach. Enforcement of these agreements may be costly and time consuming. Furthermore, the laws of foreign countries may not protect
our intellectual property rights to the same extent as the laws of the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may incur substantial
costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to
protect our rights to, or use of, our technology.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we choose to go to court
to stop someone else from using the inventions claimed in our patents or our licensed patents, that individual or company has the right
to ask the court to rule that these patents are invalid and/or should not be enforced against that third party. These lawsuits are expensive
and would consume time and other resources even if we were successful in stopping the infringement of these patents. In addition, there
is a risk that the court will decide that these patents are invalid or unenforceable and that we do not have the right to stop the other
party from using the inventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, on or about April
11, 2017, we received from Avita Medical Limited a Petition for <i>Inter Partes</i> Review purporting to challenge the validity of the
claims in U.S. Patent No. 9,610,430 before the PTAB of the U.S. Patent &amp; Trademark Office. Upon consideration of the arguments and
evidence set forth by us and Avita, on December 18, 2017, the PTAB rendered a Final Written Decision dismissing the Petition in its entirety
and, accordingly, confirming all such claims. Avitas right to file an appeal expired on February 21, 2018. Although we were thoroughly
successful in our defense of the matter, we encountered substantial legal fees as well as the diversion of management time and focus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is also the risk that,
even if the validity or enforceability of these patents is upheld, the court will refuse to stop the other party on the grounds that such
other partys activities do not infringe our rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we wish to use the technology
claimed in issued and unexpired patents owned by others, we will need to obtain a license from the owner, enter into litigation to challenge
the validity or enforceability of the patents or incur the risk of litigation in the event that the owner asserts that we infringed its
patents. The failure to obtain a license to technology or the failure to challenge an issued patent that we may require to discover, develop
or commercialize our products may have a material adverse effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a third party asserts that
we infringed its patents or other proprietary rights, we could face a number of risks that could seriously harm our results of operations,
financial condition and competitive position, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">patent infringement and other intellectual property claims, which would be costly and time consuming to defend, whether or not the claims have merit, and which could delay a product and divert managements attention from our business;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 39.75pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">substantial damages for past infringement, which we may have to pay if a court determines that our product or technologies infringe a competitors patent or other proprietary rights;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 39.75pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a court prohibiting us from selling or licensing our technologies unless the third party licenses its patents or other proprietary rights to us on commercially reasonable terms, which it is not required to do; and</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 39.75pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">if a license is available from a third party, we may have to pay substantial royalties or lump-sum payments or grant cross licenses to our patents or other proprietary rights to obtain that license.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology industry
has produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various
types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not
always uniform. If we are sued for patent infringement, we would need to demonstrate that our products or methods of use either do not
infringe the patent claims of the relevant patent, and/or that the patent claims are invalid, and/or that the patent is unenforceable
and we may not be able to do this. Proving invalidity, in particular, is difficult since it requires a showing of clear and convincing
evidence to overcome the presumption of validity enjoyed by issued patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. patent laws as well as
the laws of some foreign jurisdictions provide for provisional rights in published patent applications beginning on the date of publication,
including the right to obtain reasonable royalties, if a patent subsequently issues and certain other conditions are met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because some patent applications
in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many
foreign jurisdictions are typically not published until 18 months after filing, and because publications in the scientific literature
often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our
issued patents or our pending applications, or that we were the first to invent the technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent applications filed
by third parties that cover technology similar to ours may have priority over our patent applications and could further require us to
obtain rights to issued patents covering such technologies. If another party files a U.S. patent application on an invention similar to
ours, we may elect to participate in or be drawn into an interference proceeding declared by the U.S. Patent and Trademark Office to determine
priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts
would be unsuccessful, resulting in a loss of our U.S. patent position with respect to such inventions. Some of our competitors may be
able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.
In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on
our ability to raise the funds necessary to continue our operations. We cannot predict whether third parties will assert these claims
against us, or whether those claims will harm our business. If we are forced to defend against these claims, whether they are with or
without any merit and whether they are resolved in favor of or against us, we may face costly litigation and diversion of managements
attention and resources. As a result of these disputes, we may have to develop costly non-infringing technology, or enter into licensing
agreements. These agreements, if necessary, may be unavailable on terms acceptable to us, if at all, which could seriously harm our business
or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Risks Related to Our Financial Condition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have experienced
significant losses, have not generated any revenues, expect losses to continue for the foreseeable future and may never achieve or maintain
profitability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development-stage
company. We do not have any commercialized products and have not generated any revenue since inception and do not expect to generate any
revenue for the foreseeable future. We had a loss from operations of $5,409,000 and $9,677,000 for our fiscal years ended December 31,
2021 and 2020, respectively. We have incurred a cumulative deficit of $34,239,904 through December 31, 2021. We anticipate incurring losses
for the next several years. We may not be able to successfully achieve or sustain profitability. Successful transition to profitable operations
is dependent upon achieving a level of revenues adequate to support our cost structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
will require additional financing to expand, accelerate or sustain our current level of operations beyond our current fiscal year, and
failure to obtain such financing would have a material adverse effect on our business, operating results, financial condition and prospects.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of December 31, 2021, we had cash and cash equivalents of $2,849,192 and approximately $1,070,000 remaining under our directors
and officers insurance policy. We anticipate that we will remain engaged in research and product development activities through
at least December 31, 2022. Due to the ongoing costs of the Companys defense against the Lawsuits, we have modified our operations
to conserve cash, including suspending enrollment into our clinical trial. Based upon our recently modified level of operations and expenditures,
we believe that absent any further modifications or expansion of our existing research, development and administrative activities, cash
on hand should be sufficient to enable us to continue operations through at least one year from the filing of this Form 10-K. The Company
expects to incur losses as it continues development of its products and technologies and expects that it will need to raise additional
capital through the sale of its securities to accomplish its business plan and failing to secure such additional funding before achieving
sustainable revenue and profit from operations poses a significant risk. The Companys ability to fund the development of its cellular
therapies will depend on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the
availability or terms upon which such financing and capital might be available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
adequate funds, including proceeds, if any, from the exercise of the Warrants are not available on reasonable terms or at all, it would
result in a material adverse effect on our business, operating results, financial condition and prospects. In particular, we may be required
to delay, reduce the scope of or terminate one or more of our research programs, sell rights to our CellMist<sup>TM</sup>&nbsp;System
or other technologies or products based upon such technologies, or license the rights to such technologies or products on terms that are
less favorable to us than might otherwise be available. If we raise additional funds by issuing equity or debt securities, further dilution
to stockholders may result and new investors could have rights superior to existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
there is significant uncertainty relating to the full impact of the COVID-19 pandemic on the Companys operations and capital requirements.
Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the
Companys ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company,
if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from the operation of clinical
study sites and testing laboratories; (v) delay, limit or preclude the Company from achieving technology or product development goals,
milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one
or more of such events may affect the Companys ability to continue on its pathway to commercialization of its technology or products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
will need additional capital and if we raise such additional capital through the issuance of equity or convertible debt securities, your
ownership will be diluted, and equity securities issued may have rights, preferences and privileges superior to the shares of common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect to achieve
profitability sufficient to permit us to fund our operations and other planned actions for the foreseeable future. As a result, we will
be required to raise additional capital. There can be no assurance that such capital would be available on favorable terms, or at all.
If we raise additional capital through the issuance of equity or convertible debt securities, the percentage ownership held by existing
stockholders may be reduced, and the market price of our common stock could fall due to an increased number of shares available for sale
in the market. Further, our board has the authority to establish the designation of additional shares of preferred stock that may be convertible
into common stock without any action by our stockholders, and to fix the rights, preferences, privileges and restrictions, including voting
rights, of such shares. Any such additional shares of preferred stock may have rights, preferences and privileges senior to those of outstanding
common stock, and the issuance and conversion of any such preferred stock would further dilute the percentage ownership of our stockholders.
Debt financing, if available, may involve restrictive covenants, which may limit our operating flexibility with respect to certain business
matters. If we are unable to secure additional capital as circumstances require, we may not be able to fund our planned activities or
continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Even if financing
is available to us, because we cannot currently estimate the amount of funds or time required to commercialize our CellMist<sup>TM</sup>&nbsp;System
or to continue our defense against the Lawsuits, we may secure less funding than is actually required to effectuate our business plan.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot accurately predict
the amount of funding or the time required to successfully commercialize our CellMist<sup>TM</sup>&nbsp;System, or any products based
on our technology platform, or to fund our defense of the Lawsuits. The actual cost and time required to commercialize this technology
may vary significantly depending on, among other things, the results of our research and development efforts, the cost of developing,
acquiring, or licensing various enabling technologies, changes in the focus and direction of our research and development programs, competitive
and technological advances, the cost of filing, prosecuting, defending and enforcing claims with respect to patents, the regulatory approval
process and manufacturing, marketing and other costs associated with commercialization of these technologies. Because of this uncertainty,
even if financing is available to us, we may secure insufficient funding to effectuate our business plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Risks Related to Ownership of Our Common
Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are not a fully
reporting company under the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act; therefore, we are subject
only to the reporting requirements of Section 15(d) of the Exchange Act.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not a fully reporting
company under the Securities Exchange Act of 1934, as amended (the <b>Exchange Act</b>); therefore, we are subject only
to the reporting requirements of Section 15(d) of the Exchange Act. Until our Common Stock is registered under the Exchange Act, we will
be subject only to the reporting obligations imposed by Section 15(d) of the Exchange Act, which we refer to as Section 15(d). Section15(d)
requires that issuers file periodic and current reports with the U.S. Securities and Exchange Commission (the <b>Commission</b>
or the <b>SEC</b>) when they have issued any class of securities for which a registration statement was filed and became
effective pursuant to the Securities Act. The purpose of Section 15(d) is to ensure that investors who buy securities in registered offering
are provided with the same information on an ongoing basis that they would receive if the securities they purchased were listed on a securities
exchange or the issuer were otherwise subject to periodic reporting obligations. However, companies that are required to report only under
Section 15(d) are not subject to some of the Exchange Act reporting requirements. For example, companies that are required to report only
under Section 15(d) are not subject to the short-swing profit reporting requirements contained in Section 16 of the Exchange Act, the
beneficial ownership reporting requirements contained in Section 13 of the Exchange Act, the institutional investor reporting rules or
the third-party tender offer rules, or the Exchange Acts proxy rules contained in Section 14 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The reporting obligations
under Section15(d) of the Exchange Act are automatically suspended when: (i) any class of securities of the issuer reporting under Section
15(d) is registered under Section 12 of the Exchange Act; or (ii) at the beginning of the issuers fiscal year, other than the year
in which the applicable registration statement became effective, if the class of securities covered by the registration statement is held
of record by fewer than 300 persons. In the latter case, the Company would no longer be subject to periodic reporting obligations so long
as the number of holders remained below 300 unless we filed a registration statement with the Securities and Exchange Commission under
Section 12 of the Exchange Act. If our obligation to file reports under Section 15(d) is suspended (other than due to our having registered
our common stock under Section 12 of the Exchange Act), then investors will have reduced visibility with respect to the Company, its financial
condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since February 26, 2018, our
Common Stock has traded on the OTC Markets Group, Inc.s Pink Current Information platform, (OTC Pink-Current). Until
our Common Stock is listed on an exchange, we expect to remain eligible for quotation on the OTC Pink-Current. In addition, if we fail
to meet the criteria set forth in SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities
to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from recommending
or selling our common stock, which may further affect the liquidity of your shares. This would also make it more difficult for us to raise
additional capital or attract qualified employees or partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Our
common stock is currently quoted on the OTC Pink-Current which may make it more difficult for you to purchase or sell shares of the Companys
Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
OTC Pink-Current is viewed by most investors as a less desirable, and less liquid, marketplace. As a result, an investor may find it more
difficult to purchase, dispose of or obtain accurate quotations as to the value of, our common stock. We may reapply for listing on the
OTCQB, which application may or may not be approved. If not approved, we expect that our stock will continue to trade on the OTC Pink-Current</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
be eligible for OTCQB, companies will be required to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">meet a minimum bid price test of $0.01. Securities that do not meet the minimum bid price test 	will be downgraded to OTC Pink-Current;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">submit an application to OTCQB and pay an application and annual fee; and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">submit an OTCQB annual certification confirming the Company Profile displayed on www.otcmarkets.com is current and complete and providing additional information on officers, directors, and controlling stockholders.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the event we do not submit an application for listing on the OTCQB or other stock exchange or if we do and the application is not approved,
we expect that our stock will continue to trade on the OTC Pink-Current, which could adversely affect the market liquidity of our common
stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Our
common stock is not registered for trading on any national stock exchange and thus, should the price of our stock on the OTC Pink-Current
fall below five dollars per share and our net tangible assets fall below two million dollars our stock may be deemed a penny stock
and is not traded on a national securities exchange you may find it difficult to, deposit, transfer, sell or purchase the shares of our
common stock in open market transactions. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Penny
stocks are, generally speaking, those securities that are not listed on a national securities exchange and are priced under $5.
There are exclusions for securities of issuers that have net tangible assets greater than $2 million if they have been in operation at
least three years or greater than $5 million if in operation less than three years. Securities of issuers with average revenue of at least
$6 million for the last three years are also not considered penny stocks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Currently
our common stock is considered penny stock exempt by the OTC Pink-Current. This means that our stock is exempt from the
definition of a Penny Stock under SEC under&nbsp;Rule 240.3a51-1&nbsp;because it meets one of the following tests: 1) A price of over
$5 per share, 2) the issuer has Average Revenue of at least $6 million for the last 3 years, or 3) the issuer has Net Tangible Assets
in excess of $2 million if the issuer has been in continuous operations for at least 3 years or $5 million if less than 3 years. The value
of our net tangible assets for the fiscal years ended December 31, 2021 and 2020 was, approximately $2.2 million and $6.9 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
long as we continue to satisfy at least one of the foregoing exemptions, our common stock should continue to be deemed penny stock
exempt. However, because our stock is not registered for trading on a national stock exchange should we no longer satisfy at least
one of the exemption criteria described above, our common stock would be considered a penny stock. We expect that absent
a financing, our net tangible assets, will fall below $2,000,000 during the third or fourth quarter of fiscal 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
penny stock rules are designed to prevent deceptive or manipulative practices. It provides that a broker cannot sell a penny stock to
any person unless it has approved that person's account for penny stock transactions and the broker/dealer has received in writing from
customer agreement to the transaction; approving an account includes, among other things, reviewing the customer's financial data and
determining the customer's suitability, including the capability to evaluate the risks of trading in penny stocks. Some types of transactions
in penny stocks are exempt from these rules. Exempt transactions include those with an established customer (a customer of more than one
year or one who has made at least three separate penny stock purchases) and transactions in which the customer is an institutional investor.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, the penny stock regulations require that prior to any non-exempt buy/sell transaction in a penny stock, a disclosure schedule
proscribed by the SEC relating to the penny stock market must be delivered by a broker-dealer to the purchaser of such penny stock. This
disclosure must include the commissions payable to both the broker-dealer and the registered representative and current price quotations
for our common stock. The regulations also require that monthly statements be sent to holders of penny stock that disclose recent price
information for the penny stock and information of the limited market for penny stocks. These requirements adversely affect the market
liquidity of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Accordingly,
should our common stock be deemed a penny stock, you may find it difficult to, deposit, transfer, sell or purchase the shares
of our common stock in open market transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>The trading price of
our common stock historically has been volatile and may continue to be so in the future; such volatility may not only negatively impact
stock price but may also adversely affect our ability to raise additional capital.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of our
common stock has, from time to time, fluctuated widely and in the future may be subject to similar fluctuations. The trading price may
be affected by a number of factors including the risk factors set forth herein, as well as our operating results, financial condition,
general economic beyond our control. In recent years, broad stock market indices in general, and smaller capitalization companies, in
particular have experienced substantial price fluctuations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our common stock is
thinly traded its trading price is likely to be highly volatile and could be subject to extreme fluctuations in response to various factors,
many of which are beyond our control, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the trading volume of our common stock;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the number of securities analysts, market-makers and brokers following our common stock;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">new products or services introduced or announced by us or our competitors;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">actual or anticipated variations in quarterly operating results;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">conditions or trends in our business industries;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">announcements by us of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">additions or departures of key personnel;</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">sales of our common stock and</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">general stock market price and volume fluctuations of publicly-traded, and particularly microcap, companies.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a volatile market, we
may experience wide fluctuations in the market price of our common stock. These fluctuations may have a negative effect on the market
price of our common stock. In addition, the sale of our common stock into the public market upon the effectiveness of this registration
statement could put downward pressure on the trading price of our common stock. Such fluctuations and their potential negative impact
on our stock price may also adversely affect our ability to raise capital on favorable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Financial
Industry Regulatory Authority (FINRA) sales practice requirements may also limit a stockholders ability to buy and
sell our common stock, which could depress the price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to the penny stock rules described above, FINRA has adopted rules that require a broker-dealer to have reasonable
grounds for believing that the investment is suitable for that customer before recommending an investment to a customer. Prior to recommending
speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information
about the customers financial status, tax status, investment objectives, and other information. Under interpretations of these
rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers.
Thus, the FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may
limit your ability to buy and sell our shares of common stock, have an adverse effect on the market for our shares of common stock, and
thereby depress our price per share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Sales
of a substantial number of shares of our common stock into the public market by the Selling Stockholders may result in significant downward
pressure on the price of our common stock and may affect the ability of our stockholders to realize any trading price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sales
of a substantial number of shares of our common stock into the public market by the Selling Stockholders may result in significant downward
pressure on the price of our common stock and may affect the ability of our stockholders to realize any trading price of our common stock
when and if a trading market develops for our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
significant downward pressure on the price of our common stock as the Selling Stockholders sell their shares of our common stock could
encourage other stockholders to sell as well as short sales by the Selling Stockholders or others. Any such short sales could place further
downward pressure on the price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>The
sale by our stockholders of restricted shares, either pursuant to a resale prospectus or Rule 144, may adversely affect our ability to
raise the funds we will require to effectuate our business plan.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of March 28, 2022 we had 87,352,364 shares issued and outstanding, of which 61,248,711 are deemed control or restricted
securities within the meaning of Rule 144. The possibility that substantial amounts of our common stock may be sold into the public market,
either under Rule 144, or pursuant to a resale registration statement, may adversely affect prevailing market prices for the common stock
and could impair our ability to raise capital in the future through the sale of equity securities because of the perception that future
re-sales could decrease our stock price and because of the availability of resale shares to those interested in investing in our common
stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Mr.
Harmel S. Rayat, directly and through wholly owned entities owns a majority of our issued and outstanding stock. This ownership interest
will permit Mr. Rayat to influence or control significant corporate decisions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of March 28, 2022, Mr. Harmel S. Rayat, a director and Interim President, Interim Chief Executive Officer, Interim Chief Financial Officer
and Chairman, beneficially owned approximately 71.88% of our common shares (including shares issuable upon exercise of outstanding warrants).
See the beneficial ownership table in the section of this Form 10-K titled SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a result, Mr. Rayat may be able to exercise significant influence or control over matters requiring stockholder approval, including the
election of directors and approval of significant corporate transactions, and will have significant control over our management and policies.
Mr. Rayats interests may be different from yours. For example, he may support proposals and actions with which you may disagree
or which are not in your interest. This concentration of ownership could delay or prevent a change in control of our company or otherwise
discourage a potential acquirer from attempting to obtain control of our company, which in turn could reduce the price of our common stock.
In addition, Mr. Rayat could use his voting influence to maintain our existing management and directors in office, or support or reject
other management and board proposals that are subject to stockholder approval, such as the adoption of employee stock plans and significant
unregistered financing transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>There
are options to purchase shares of our common stock currently outstanding.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of the date of this Form 10-K we have granted options to purchase shares of our common stock to various persons and entities, under which
we could be obligated to issue up to 3,139,999 shares of our common stock. The exercise prices of these options range from $1.05 to $4.20
per share. If issued, the shares underlying these options would increase the number of shares of our common stock currently outstanding
and dilute the holdings and voting rights of our then-existing stockholders. The sale of the shares issued upon the exercise of such options
may also place downward pressure on our stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>There
are warrants to purchase shares of our common stock currently outstanding.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of the date of this Form 10-K we have issued warrants to purchase shares of our common stock to various persons and entities, under which
we could be obligated to issue up to <span style="background-color: white">11,712,496</span> shares of common stock. Each of the warrants
may be exercised on a cashless basis using the formula set forth therein at prices ranging from <span style="background-color: white">$2.00
to $3.45</span> per share. If exercised the shares issuable may be resold immediately pursuant to Rule 144, to the extent available. Such
sales could exert downward pressure on the market price of our common stock and may cause other stockholders and others to sell their
stock or to enter into short sales transactions which will further exacerbate the downward pressure on the stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
may sell additional equity securities in the future and your ownership interest in the Company may be diluted as a result of such sales.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
intend to sell additional equity securities in order to fully implement our business plan. Such sales will be made at prices determined
by our board of directors based on factors deemed appropriate at the time; accordingly, such sales by us could be made at prevailing market
prices at the time, in which case, investors could experience dilution of their investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
may issue preferred stock which may have greater rights than our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
Articles of Incorporation allow our Board of Directors to issue up to 10,000,000 shares of preferred stock. Currently, no shares of preferred
stock are issued and outstanding. However, we can issue shares of our preferred stock in one or more series and can set the terms of the
preferred stock without seeking any further approval from the holders of our common stock. Any preferred stock that we issue may rank
ahead of our common stock in terms of dividend priority or liquidation premiums and may have greater voting rights than our common stock.
In addition, such preferred stock may contain provisions allowing it to be converted into shares of common stock, which could dilute the
value of our common stock to then current stockholders and could adversely affect the market price, if any, of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Our
compliance with changing laws and rules regarding corporate governance and public disclosure may result in additional expenses to us which,
in turn, may adversely affect our ability to continue our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Keeping
abreast of, and in compliance with, changing laws, regulations and standards relating to corporate governance and public disclosure, including
the Sarbanes-Oxley Act of 2002, new SEC regulations and, in the event that we are ever approved for listing on a registered national exchange,
such exchanges rules, will require an increased amount of management attention and external resources. We intend to continue to
invest all reasonably necessary resources to comply with evolving standards, which may result in increased general and administrative
expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. Our failure to
adequately comply with any of these laws, regulations, standards or rules may result in substantial fines or other penalties and could
have an adverse impact on our ongoing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Because
we do not intend to pay dividends for the foreseeable future you should not purchase our shares if you are seeking dividend income.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
currently intend to retain future earnings, if any, to support the development and expansion of our business and do not anticipate paying
cash dividends in the foreseeable future. Our payment of any future dividends will be at the discretion of our Board after considering
various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any
credit agreements that we may be a party to at the time. Accordingly, investors must rely on sales of their common stock after price appreciation,
which may never occur, as the only way to realize their investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Our
articles of incorporation provide for indemnification of officers and directors at our expense and limit their liability, which may result
in a major cost to us and hurt the interests of our stockholders because corporate resources may be expended for the benefit of officers
and/or directors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
articles of incorporation and applicable Nevada law provide for the indemnification of our directors, officers, employees, and agents,
under certain circumstances, against attorneys fees and other expenses incurred by them in any litigation to which they become
a party arising from their association with or activities on our behalf. We will also bear the expenses of such litigation for any of
our directors, officers, employees, or agents, upon such persons promise to repay us if it is ultimately determined that any such
person shall not have been entitled to indemnification. This indemnification policy could result in substantial expenditures by us, which
we will be unable to recoup.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive officers, or persons controlling
us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<span style="text-transform: uppercase"><b><span id="a_003"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b><span id="a_004"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt">Our corporate
office is located at 9375 E. Shea Blvd., Suite 107-B, Scottsdale, AZ 85260. The office is provided free from rent by our Chairman.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b><span id="a_005"></span>ITEM 3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><b><i>SEC Civil Complaint </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.5in">On May 28, 2021
the SEC filed the SEC Complaint in the United States District Court for the Southern District of New York, naming the Company and Harmel
S. Rayat, the Companys current President, Chief Executive Officer, Chief Financial Officer and Sole Director as defendants as defendants
(the <b>SEC Defendants</b>). The SEC Complaint alleges among other things that Mr. Rayat and the Company with violated the
antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also alleges that Mr. Rayat
with aided and abetted the Company's violations of those provisions. The SEC Complaint also alleges that the Company with violated the
reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks, among other relief, permanent
injunctions and civil penalties against the Defendants, and officer-and-director and penny stock bars against Mr. Rayat. On August 31,
2021 the Defendants filed an answer to the Complaint. On September 21, 2021, the SEC filed a motion to strike Defendants equitable affirmative
defenses which motion was granted by the court on October 18, 2021. The Company disputes the claims asserted in the SEC Complaints and
believes the claims set forth in the SEC Complaint are without merit and intends to defend itself vigorously. To that end, the Company
has retained counsel to defend the SEC Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Class Action Complaints</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2021, Gabrielle
A. Boller filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the <b>Boller Lawsuit</b>),
against the Company and certain past and current officers and members of the Companys board of directors (collectively, the <b>Boller
Defendants</b>). The Boller Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying
the allegations in the SEC Complaint, the Boller Defendants engaged in fraudulent conduct and made false and misleading statements of
material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination
that the Boller Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs
and expenses incurred in the Boller Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company disputes the plaintiffs
claims in the Boller Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the
Boller Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for,
among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of
loss that may result from these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 21, 2021, Michael
Solakian, filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the <b>Solakian Lawsuit</b>),
against the Company and certain past and current officers and members of the Companys board of directors (collectively, the <b>Solakian
Defendants</b>). The Solakian Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying
the allegations in the SEC Complaint, the Solakian Defendants engaged in fraudulent conduct and made false and misleading statements of
material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination
that the Solakian Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable
costs and expenses incurred in the Solakian Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem
proper.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company disputes the plaintiffs
claims in the Solakian Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend
the Solakian Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met
for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range
of loss that may result from these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><b><i>Shareholder Derivative Complaints</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 20, 2021Melvin
Emberland (Emberland), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the <b>Emberland
Lawsuit</b>) in the United States District Court for the District of New Jersey against the Company and certain of its current
and former executive officers (the <b>Emberland Defendants</b>). In the complaint, Emberlands allegations, relating
to the facts and circumstances underlying the allegations in the SEC Complaint include, but are not limited to (i) breach of fiduciary
duties by the individual Emberland Defendants, (ii) unjust enrichment and (iii) violation of Section 10(b) and 21D of the Securities Exchange
Act of 1934. Emberland did not quantify any alleged damages in his complaint but, in addition to attorneys fees and costs, Emberland
seeks (i) a declaration that the Emberland Defendants have breached and/or aided and abetted the breach of their fiduciary duties to the
Company, (ii) a determination awarding to the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement
of all profits, benefits and other compensation obtained by the Emberland Defendants, (iii) a directive to the Company and the Emberland
Defendants to take all necessary actions to reform and improve the Companys corporate governance and internal procedures to comply
with applicable laws, and (iv) Plaintiff is seeking, among other things, restitution from the individual Emberland Defendants and disgorgement
of profits, benefits and other compensation obtained by such Emberland Defendants, costs and disbursements of the action including reasonable
attorneys fees, accountants and expert fees and expenses, an order directing the taking of certain corporate actions relating
to its board of directors and corporate governance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company disputes Emberlands
claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Emberland Defendants.
Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things,
class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result
from these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 6, 2022, Zoser
Vargas (<b>Vargas</b>), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the <b>Vargas
Lawsuit</b>) in the United States District Court for the District of New Jersey against the Company and certain of its current
and former executive officers (the <b>Vargas Defendants</b>). In the complaint Vargas allegations relating to the
facts and circumstances underlying the allegations in the SEC Complaint include but are not limited to, (i) breach of fiduciary duties,
(ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his
complaint but, in addition to attorneys fees and costs, Meyer seeks, in addition to other things, (i) against the Vargas Defendants
and in favor of the Company the amount of damages sustained by the Company as a result of the Vargas Defendants breaches of fiduciary
duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate
governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution from the Vargas Defendants,
and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Vargas Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company disputes Vargas
claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Vargas Defendants. Given
the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class
certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from
these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 28, 2022, Aviva
Meyer (<b>Meyer</b>), derivatively and on behalf of nominal defendant RenovaCare, Inc. filed a lawsuit (the <b>Meyer
Lawsuit</b>) in the United States District Court for the District of New Jersey against the Company and certain of its current
and former executive officers (the <b>Meyer Defendants</b>). In the complaint Meyers allegations relating to the
facts and circumstances underlying the allegations in the SEC Complaint include but are not limited to, (i) breach of fiduciary duties,
(ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his
complaint but, in addition to attorneys fees and costs, Meyer seeks, in addition to other things, (i) against the <b>Vargas</b>
Defendants and in favor of the Company the amount of damages sustained by the Company as a result of the <b>Vargas</b> Defendants
breaches of fiduciary duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions
to improve its corporate governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution
from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the
Meyer Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company disputes Meyers
claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Meyer Defendants Given
the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class
certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from
these actions. See Note&nbsp;8 <span style="background-color: white"><i>Commitments and ContingenciesLegal Proceedings.</i></span>
of the Notes to Consolidated Financial Statements included in Item 8 of this Report. See also Item 1A. Risk Factors- <i>Risks Associated
with Litigation Matters.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b><span id="a_006"></span>ITEM 4. MINE SAFETY
DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_007"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt"><span style="text-transform: uppercase"><b><span id="a_008"></span>ITEM 5. MARKET FOR
REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Market Information and Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt">Our common stock
is listed on the OTC Pink-Current under the symbol RCAR. As of March 22, 2022, there were approximately 362 stockholders
of record (this number does not include stockholders who hold their stock through brokers, banks and other nominees).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent of our
common stock is Worldwide Stock Transfer, LLC, having an office at One University Plaza, Suite 505, Hackensack, NJ, USA 07601; their phone
number is (201) 820-2008.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Penny Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt">Our stock is
currently exempt from the penny stock rules. However, should our stock price remain under $5.00 per share and our net tangible
assets drop below $2,000,000, our stock will then be deemed a penny stock. The Securities and Exchange Commission has adopted
rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities
with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system,
provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system.
The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, deliver
a standardized risk disclosure document prepared by the Commission, which: (a) contains a description of the nature and level of risk
in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the brokers or dealers
duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements
of Securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny
stocks and significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary
actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such
other information and is in such form as the Commission shall require by rule or regulation. The broker-dealer also must provide to the
customer, prior to effecting any transaction in a penny stock: (a) bid and offer quotations for the penny stock; (b) the compensation
of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other
comparable information relating to the depth and liquidity of the market for such stock; and (d) monthly account statements showing the
market value of each penny stock held in the customers account. In addition, the penny stock rules require that prior to a transaction
in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock
is a suitable investment for the purchaser and receive the purchasers written acknowledgment of the receipt of a risk disclosure
statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitably statement. These
disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock if it becomes subject
to these penny stock rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-indent: 35.65pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Rule 144</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">There were 87,352,364
shares of our common stock issued and outstanding at March 28, 2022, of which 61,208,711 shares are deemed either restricted securities
or control securities within the meaning of Rule 144. Absent registration under the Securities Act, the sale of restricted
or control shares is subject to Rule 144, as promulgated under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">In general, under
Rule 144, subject to the satisfaction of certain other conditions, a person deemed to be one of our affiliates, who has beneficially owned
restricted shares of our common stock for at least one year is permitted to sell in a brokerage transaction, within any three-month period,
a number of shares that does not exceed the greater of 1% of the total number of outstanding shares of the same class, or, if our common
stock is quoted on a stock exchange, the average weekly trading volume during the four calendar weeks preceding the sale, if greater.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">Rule 144 also permits
a person who presently is not and who has not been an affiliate of ours for at least three months immediately preceding the sale and who
has beneficially owned the shares of common stock for at least six months to sell such shares without restriction other than the requirement
that there be current public information as set forth in Rule 144. To the extent that Rule 144 is otherwise available, this provision
is currently applicable to all of the restricted shares. If a non-affiliate has held the shares for more than one year, such person may
make unlimited sales pursuant to Rule 144 without restriction. The possibility that substantial amounts of our common stock may be sold
under Rule 144 into the public market may adversely affect prevailing market prices for the common stock and could impair our ability
to raise capital in the future through the sale of equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">We have not paid
any dividends on our common stock and our Board of Directors (the <b>Board</b>) presently intends to continue a policy of
retaining earnings, if any, for use in our operations. The declaration and payment of dividends in the future, of which there can be no
assurance, will be determined by the Board in light of conditions then existing, including earnings, financial condition, capital requirements
and other factors. The Nevada Revised Statutes prohibit us from declaring dividends if after giving effect to the distribution of the
dividend:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we would not be able to pay our debts as they become due in the usual course of business; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&nbsp;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b></b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">Except as set forth
above, there are no restrictions that currently materially limit our ability to pay dividends or which we reasonably believe are likely
to limit materially the future payment of dividends on common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><span style="text-transform: uppercase"><b><span id="a_009"></span>ITEM
6. SELECTED FINANCIAL DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><span style="text-transform: uppercase"><b><span id="a_010"></span>ITEM
7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Discussion and Analysis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><i>The following
discussion and analysis is based upon our consolidated financial statements, which have been prepared in accordance with&nbsp;</i>accounting&nbsp;<i>principles
generally accepted in the United States of America, and should be read in conjunction with our financial statements and related notes.
The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its
estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates under different assumptions or conditions. In addition, the following discussion
and analysis contains forward-looking statements that involve risks and uncertainties, including, but not limited to, those discussed
in <b>Forward Looking Statements</b>, and elsewhere in this Form 10-K.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development-stage
biotechnology and medical device company focusing on the research, development and commercialization of autologous (using a patient's
own cells) cellular therapies that can be used for medical and aesthetic applications. The Company does not have any commercialized products.
The Company's activities have consisted principally of performing research and development activities, business development efforts, and
raising capital to support such activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, through its wholly
owned subsidiary, RenovaCare Sciences Corp., owns the CellMist System which <span style="color: #212121">is a cell isolation procedure
that enzymatically renders stem cells from the patients own skin or other tissues. The resulting stem cell suspension is administered
topically with our&nbsp;SkinGun spray device as a cell therapy onto wounds including burns to facilitate healing.</span> The CellMist
System also includes our unique, closed, automated cell isolation device (the <b>CID</b>) to harvest stem cells from tissues
which is in prototype development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212121">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt"><span style="background-color: white">Currently,
our proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and
seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed
in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Lichtenstein, and the United
Kingdom.</span> The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United
Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, the Company announced
that the US Food and Drug Administration (FDA) fully approved the Companys Investigational Device Exemption (IDE) application to
conduct a clinical trial, designated CELLMIST 1, designed to evaluate the safety and feasibility of autologous skin and pluripotent stem
cells rendered by its manual CellMist System from donor skin and applied topically with the electronic SkinGun spray device
for treatment of acute burn wounds. The clinical trial protocol is an open-label, single-arm clinical study designated to enroll 14 adult
human burn subjects with partial-thickness, second-degree deep thermal burn wounds covering between 10% and 30% total body surface area.
The Company may engage up to four (4) U.S. burn centers to conduct the clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to year end, the
Board decided to stop enrollment of patients into the clinical trial and take other measures to reduce the Companys overhead in
an effort to conserve financial resources as it continues to defend against the Lawsuits. The Company hopes to restart the clinical trial
at a future date upon the occurrence of a favorable outcome against the Lawsuits and additional financing.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research, development and
commercialization of new technologies generally requires significant financial resources, involves a high degree of risk, and there is
no assurance that development activities will result in a commercially viable product. The Company has not generated any revenue and has
sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues
development of its products and technologies and defends itself against the Lawsuits. The Company will need to raise additional capital
through partnerships or the sale of securities to accomplish its business plan. Failing to secure such additional funding poses a significant
risk. The Company's ability to meet its financial obligations, including to fund the development of its cellular therapies depends on
the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon
which such financing and capital might be available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Components of Our Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date we have not generated
any product revenues and do not expect to generate any revenue for the foreseeable future. Our ability to generate revenue and become
profitable depends upon our ability to obtain marketing approval and successfully commercialization of our CellMist<sup>TM</sup>&nbsp;System.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development (<b>R&amp;D</b>)
expenses consist primarily of costs incurred for the development of our CellMist<sup>TM</sup>&nbsp;System and include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">design, pilot-scale manufacturing and pre-clinical testing of our cell isolation and SkinGun<b><sup>TM </sup></b>spray devices.</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">employee-related expenses associated with our research and development activities, including salaries, benefits, travel and non-cash stock-based compensation expenses.</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">costs associated with quality management systems including device
verification and validation testing, and regulatory operations and regulatory compliance.</p></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">expenses incurred under agreements related to our clinical trial.</span></td></tr>
  </tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">other research and development costs including contract consulting fees and non-cash stock-based compensation to contract research organizations (CROs) and other third parties.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that it
is possible at this time to accurately project total expenses required for us to reach commercialization of our CellMist<sup>TM</sup>&nbsp;System.
In the future, we expect that research and development expenses will increase due to our ongoing product development and approval efforts.
We expense research and development costs as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General and Administrative</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of personnel costs, including non-cash stock-based compensation related to directors and employees, professional
service costs including legal, accounting, and other consulting fees and other general and administrative expenses including investor
relations, insurance, and facilities costs. We expect general and administrative expenses to increase in the future as we hire personnel
and incur additional costs to support the expansion of our research and development activities, our operation as a public company and
to defend against the Lawsuits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><i>Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.05pt 0pt 1.4pt; text-align: justify; text-indent: 34.6pt">Expense associated
with equity-based transactions is calculated and expensed in our financial statements as required pursuant to various accounting rules
and is non-cash in nature. Stock compensation represents the expense associated with the amortization of our stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Income (Expense)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other income consists of interest income earned
on our cash and cash equivalents and the reimbursement of legal fees from our Directors &amp; Officers insurance policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have yet to generate taxable
income. We have historically incurred operating losses resulting in carry forward tax losses totaling approximately $21,945,000 as of
December 31, 2021. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry
forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes until we have taxable income
after the full utilization of our carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax
assets related to these carry forward losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comparison of Years Ended December 31, 2021 and December 31,
2020</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap"><b>Increase / <br>
(Decrease)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; text-align: left"><span style="font-size: 10pt">Manufacturing clinical supplies<sup>(1)</sup></span></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">279,711</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,675,935</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,396,224</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Personnel related<sup>(2)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">496,173</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">276,137</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">220,036</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Stock-based compensation<sup>(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">948,938</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,536,168</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(587,230</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Clinical trial<sup>(4)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,060,573</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">129,650</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">930,923</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Regulatory<sup>(5)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">35,688</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">96,688</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(61,000</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">All other<sup>(5)</sup></span></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">383,812</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">419,347</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(35,535</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">3,204,895</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">4,133,925</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(929,030</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(1)</td><td style="text-align: justify; padding-right: 0.35pt">Manufacturing clinical supplies decreased due to completion of the pilot-scale
manufacturing and validation testing of the components of the CellMist System and the electronic SkinGun spray device to
be used in our clinical trial.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(2)</td><td style="text-align: justify; padding-right: 0.35pt">Personnel related expenses increased due to the allocation of Stem Cell Systems
personnel in support of the development of our CellMist System.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(3)</td><td style="text-align: justify; padding-right: 0.35pt">Stock compensation expense decreased due primarily to the completion of vesting
in 2020 of prior issued stock options in excess of the amounts recognized in the current year upon the continued vesting of other R&amp;D
related stock option grants.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(4)</td><td style="text-align: justify; padding-right: 0.35pt">Clinical trial expenses increased due to the addition of clinical professionals,
clinical site activation costs and costs related to the preparation of our clinical trials which began in the second quarter of 2021.
We expect clinical trial expenses to decrease moving forward due to the suspension of patient enrollment resulting from the need to conserve
funds.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(5)</td><td style="text-align: justify; padding-right: 0.35pt">All other expenses decreased as validation testing for the electronic SkinGun 
concluded and we transitioned to prototype development of the cell isolation device at StemCell Systems.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">&nbsp;</p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap"><b>Increase / <br>
(Decrease)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; text-align: left"><span style="font-size: 10pt">Personnel related <sup>(1)</sup></span></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">809,406</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,066,773</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(257,367</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Stock-based compensation <sup>(2)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,122,101</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,670,084</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(3,792,185</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Professional and consultant fees <sup>(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,277,679</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,202,523</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,075,156</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">All other <sup>(4)</sup></span></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">239,537</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">603,793</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(364,256</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">2,204,521</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">5,543,173</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(3,338,652</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(1)</td><td style="text-align: justify; padding-right: 0.35pt">Personnel related costs decreased due to lower headcount starting mid-year 2021.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(2)</td><td style="text-align: justify; padding-right: 1.05pt">Stock compensation expense decreased due to the forfeiture and cancellation of
2,805,571 stock options as a result of the resignation of the Companys former Chairman, President and Chief Executive Officer,
the Companys former Chief Financial Officer, and two members of the Companys Board of Directors. Compensation expense was
recorded on these options prior to their full vesting. As a result, the Company recognized a $1,314,705 reversal of the prior recognized
compensation expense related to the cancelled options. The G&amp;A expense recognized for options still in their vesting period totaled
$192,604.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(3)</td><td style="text-align: justify; padding-right: 1.05pt">Professional and consultant fees increased primarily due to an $1,180,000 increase
in legal fees related to the Lawsuits, $125,000 increase in fees related to our patents and trademarks, offset by a $229,000 decrease
in accounting and consulting fees. Legal and other costs related specifically to the Lawsuits totaled $1,094,000 and $1,708,000 during
the fourth quarter and year ended 2021, respectively, and are expected to be mostly offset by insurance proceeds paid directly from AIG
pursuant to our D&amp;O Policy. The available insurance to defend the Company and its officers and directors is expected to be depleted
in our first quarter of 2022. On March 18, 2022, our Chairman loaned the Company $800,000 to be used towards the payment of legal fees
related to the Lawsuits. The Company is obligated, pursuant to its bylaws, to indemnify its directors and officers. As a result, all legal
costs related to the Lawsuits are recorded to the books of the Company.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.35pt"></td><td style="width: 18pt">(4)</td><td style="text-align: justify">All other costs decreased primarily due to the absence of the charitable contribution to the Office of
Research at the University of Pittsburgh which the Company recognized $125,000 in 2020 in addition to decreases in investor relations
and insurance offset by an increase in rent.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Liquidity and Capital Resources</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not have
any commercialized products, has not generated any meaningful revenue since inception and has sustained recurring losses and negative
cash flows since inception. The Company has incurred operating losses of $5,409,000 and $9,677,000 during the years ended December 31,
2021 and 2020, respectively. The Company has used cash in operating activities of $4,564,000 and $4,723,000 during the years ended December
31, 2021 and 2020, respectively. The Company expects to incur losses as it continues to fund its legal defense and scaled-back development
of its products and technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">At
December 31, 2021, the Company had current and total liabilities of $1,305,000, including $855,000 of liabilities related to reimbursable
legal fees, $2,800,000&nbsp;of cash on hand, and $1,070,000 available under its </span>D&amp;O Policy <span style="background-color: white">with
AIG to offset legal fees. Subsequent to 2021 and through February 28, 2022, the Company has incurred legal fees related to the Lawsuits
of approximately $350,000 and has effectively depleted the amounts available under its D&amp;O policy. In order to preserve its cash resources,
the Company has taken measures to streamline operations, including ending enrollment of patients into its clinical trial, renegotiate
certain agreements and service arrangements and entered into a loan agreement with our Chairman for $800,000. As a result of the actions
taken, the Company estimates cash on hand will be sufficient for the twelve months following the date these financial statements are issued.
</span>Historically, the Company has been funded through the sale of equity securities and debt financings. The future of the Company
will depend on its ability to successfully raise capital from external sources to fund operations. If the Company is unable to obtain
adequate funds, or if such funds are not available to it on acceptable terms, the Company's ability to continue its business to develop
its cellular therapies will be significantly impaired and it may cause the Company to curtail operations. Although the Company has instituted
cost savings measures, it will continue to assess its ongoing expenses, including, but not limited to its research and development efforts
through its agreement with StemCell Systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-Balance Sheet Arrangements and Contractual Obligations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our ongoing business,
we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities
often referred to as structured finance or special purpose entities (SPEs), which would have been established for the purpose of facilitating
off-balance sheet arrangements or other contractually limited purposes. As of December 31, 2021, we were not involved in any SPE transactions.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A critical accounting policy
is one that is both important to the portrayal of a companys financial condition and results of operations and requires managements
most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are
inherently uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are presented in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).
All applicable U.S. GAAP accounting standards effective as of December&nbsp;31, 2021 have been taken into consideration in preparing the
consolidated financial statements. The preparation of consolidated financial statements requires estimates and assumptions that affect
the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex,
and, consequently, actual results could differ from those estimates. The following accounting policies and estimates have been highlighted
as significant because changes to certain judgments and assumptions inherent in these policies could affect our consolidated financial
statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="width: 0.5in">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; width: 0.5in; text-align: justify"><span style="font-size: 10pt"></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">share-based compensation expenses.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We base our estimates, to
the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and
various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities.
We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates. For a complete
discussion of our significant accounting policies and estimates, see <span style="background-color: white"><i>Item 8. Financial
Statements and Supplementary DataNotes to Consolidated Financial StatementsNote</i></span><i> (2), Significant Accounting
Policies.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b><span id="a_011"></span>ITEM 7A. QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Smaller reporting companies are not required to
provide the information required by this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b><span id="a_012"></span>ITEM 8. FINANCIAL STATEMENTS
AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following audited consolidated financial statements
are filed as part of this annual report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="background-color: #CCEEFF">
    <td style="width: 92%"><a href="#a_027" tabindex="18"><span style="font-size: 10pt">Reports of Independent Registered Public Accounting Firm</span></a></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 6%; text-align: right"><a href="#a_027" tabindex="18"><span style="font-size: 10pt">44</span></a></td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td></tr>
  <tr>
    <td><a href="#a_028" tabindex="18"><span style="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_028" tabindex="18"><span style="font-size: 10pt">45</span></a></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td><a href="#a_029" tabindex="18"><span style="font-size: 10pt">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_029" tabindex="18"><span style="font-size: 10pt">48</span></a></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr>
    <td><a href="#a_030" tabindex="18"><span style="font-size: 10pt">Consolidated Statements of Stockholders Equity for the years ended December 31, 2021 and 2020</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_030" tabindex="18"><span style="font-size: 10pt">49</span></a></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td><a href="#a_031" tabindex="18"><span style="font-size: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_031" tabindex="18"><span style="font-size: 10pt">50</span></a></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr>
    <td><a href="#a_032" tabindex="18"><span style="font-size: 10pt">Notes to the Consolidated Financial Statements</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_032" tabindex="18"><span style="font-size: 10pt">51</span></a></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_027"></span>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 77.65pt; margin-bottom: 0pt"><b>To the Board of Directors
and</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Stockholders of RenovaCare, Inc.
and Subsidiary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">We have audited the accompanying
consolidated balance sheets of RenovaCare, Inc. and Subsidiary (the Company) as of December 31, 2021 and 2020, the related
consolidated statements of operations, stockholders equity, and cash flows for the years ended December 31, 2021 and 2020 and the
related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results
of its operations and its cash flows for the years ended December 31, 2021 and 2020, in conformity with accounting principles generally
accepted in the United States of America.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Basis for Opinion</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">These consolidated financial statements
are the responsibility of the Companys management. Our responsibility is to express an opinion on the Companys consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness
of the Companys internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable
basis for our opinion.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Substantial Doubt About the Companys
Ability to Continue as a Going Concern</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, to the consolidated
financial statements, the Companys recurring losses from operations, negative cash flows from operating activities and pending
litigation raise substantial doubt about its ability to continue as a going concern. Managements evaluation of the events and conditions
and managements plans regarding these matters are also described in Note 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Critical Audit Matters</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The critical audit matters communicated
below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to
be communicated to the board of directors and that (1) relate to accounts or disclosures that are material to the consolidated financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
do not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Uncertainties Regarding the Future
Outcome of Litigation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">As discussed in Note 8, the Company
is currently the subject to various legal proceedings including the Securities and Exchange Commission, as well as Class Action and derivative
complaints. In preparing its consolidated financial statements, the Company is required to assess the probability of loss associated with
each legal proceedings and amount of such loss, if any. The outcome of legal proceedings to which the Company is a party is not within
the complete control of the Company or may not be known for prolonged periods of time. The proceedings involve claims that are subject
to substantial uncertainties and unascertainable damages and could have a material adverse effect on the Companys business, reputation,
financial condition, results of operations and/or stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6pt; margin-bottom: 0pt; text-align: justify">The principal consideration for our determination
that the uncertainties regarding the future outcome of litigation was a critical audit matter is the significant judgment and subjectivity
inherent in predicting future outcomes of litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i>How the Critical Audit Matter Was Addressed
in the Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">We assessed the disclosures made
by reading letters received directly from the Companys external and in-house legal counsel that discussed the Companys legal
matters. We evaluated management's conclusion that no amounts should be accrued for as of December 31, 2021 based on the opinion of external
and in house legal counsel and our assessment of contingencies in accordance with <i>ASC Topic 450 Contingencies</i>. In addition, we
examined legal invoices related to the complaints in order to evaluate the appropriateness of the disclosures in the financial statements.
We considered relevant publicly available information, such as published press releases about the Company and its legal matters and performed
a search for unrecorded liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Going Concern Assessment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i>Critical Audit Matter Description</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">As described further in Note 1 to
the consolidated financial statements, the Company has incurred net losses each year from inception through December 31, 2021, has not
generated revenue since inception and has had a decrease in cash in excess of $4.5 million for each of the years ended December 31, 2021
and 2020. The Company determined these, and other factors which include the pending litigations, raised substantial doubt as to the Company's
ability to continue as a going concern one year from the issuance date of the consolidated financial statements. In making this determination,
management prepared a short-term cash flow projection through December 2023. Management used significant assumptions in preparing the
short-term cash flow projection, which included expected operating costs and other obligations.</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt">&nbsp;</p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The principal considerations for
our determination that the evaluation of management's going concern assessment was a critical audit matter are the significant judgment
and subjectivity inherent in the Company's future cash flow and a high degree of auditor judgment in evaluating management's forecasts
for at least the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i>How the Critical Audit Matter Was Addressed
in the Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6pt; margin-bottom: 0pt; text-align: justify">Our audit procedures related to the evaluation
of management's forecasted future cash flow projections and going concern assessment included the following, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 24pt"></td><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt"></span></td><td style="text-align: justify; padding-right: 6pt">Assessed the overall reasonableness of the Company's future cash flow projections,
including significant assumptions utilized by the Company.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 24pt"></td><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt"></span></td><td style="text-align: justify; padding-right: 5.9pt">Compared January and February 2022 actual operating results to forecasted amounts
as well as the Companys 2021 operating budget to actual results to determine overall accuracy of future operating cash flow projections.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 24pt"></td><td style="width: 18pt"><span style="font-family: Symbol; font-size: 10pt"></span></td><td style="text-align: justify">Evaluated the adequacy of the Company's financial statement disclosures.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">/s/ <span id="xdx_902_edei--AuditorName_c20210101__20211231_ziIG0d3XpAP9"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorName" inside-table="false" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">PKF OConnor Davies, LLP</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We have served as the Companys
auditor since 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 345.05pt; margin-bottom: 0pt"><span id="xdx_902_edei--AuditorLocation_c20210101__20211231_zwwFj0TiRJCc"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorLocation" inside-table="false" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New York, New York</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 345.05pt; margin-bottom: 0pt">March 30, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">PCAOB ID No. <span id="xdx_902_edei--AuditorFirmId_c20210101__20211231_zEsGzVDMXd5"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorFirmId" inside-table="false" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 222.6pt; text-align: center">* * * * *</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="a_028"></span><span style="font-size: 10pt"><b>RENOVACARE, INC AND SUBSIDIARY<br> CONSOLIDATED BALANCE SHEETS<br> AS OF DECEMBER 31, 2021 AND 2020</b></span></p>



<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zC9jIVTdPJIl" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_494_20211231_ztYtXbANRj5l" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_494_20201231_zcINl8f68w3e" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsAbstract_iB_zChfOvMGe388" style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: center">ASSETS</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; text-align: center">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_z9bWlMwphtve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCz0F5_z1nLbkl4deA5" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,849,192</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,412,969</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssets_i02I_maCz0F5_zq3tghszLZgd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">533,445</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">566,275</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i01TI_mtCz0F5_maCzr2a_zCDoEzzdj8k3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total current assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,382,637</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,979,244</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzr2a_zxrV6fpSAzMg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fixed assets, net of accumulated depreciation of $<span id="xdx_90C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20211231_zlFN8IecFlBb" title="Accumulated depreciation"><span><ix:nonfraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,952</ix:nonfraction></span></span> and $<span id="xdx_903_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20201231_z6KH7i2QIfCi" title="Accumulated depreciation"><span><ix:nonfraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,584</ix:nonfraction></span></span>, respectively</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,271</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,640</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--IntangibleAssetsCurrent_i01I_maCzr2a_zKc0HW9m7494" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IntangibleAssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152,854</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IntangibleAssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152,854</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--SecurityDeposit_i01I_maCzr2a_zNLH5rk11Lm6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Security deposit</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,995</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,995</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzr2a_zGdHYua2reQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right of use asset</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,630</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79,462</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAssetsNoncurrent_i01I_maCzr2a_zBVyh0HyIO79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherAssetsNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,747</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherAssetsNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,749</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_iTI_mtCzr2a_zHGeC53GK4xh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.25pt">Total assets</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,652,134</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,395,944</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z99o8QmAM0v9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS' EQUITY</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrentAbstract_i01B_zdniVJ2JwWb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzgOr_zZ18WTJ2END7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,274,748</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,237,437</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzgOr_z3rkYEd0hr2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liability</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,497</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,125</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i01TI_mtCzgOr_maCzimm_z47c9LnEB1Yh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total current liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,305,245</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,288,562</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzimm_zk9KL0FwVJC6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liability</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextref="AsOf2021-12-31" id="fact-identifier-60" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0095" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,607</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtCzimm_maCz9sp_zIZynbwnYfna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,305,245</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,317,169</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_i01I_zxj1afUAbUP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_i01B_zNRvL2npuWnl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders' equity</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--PreferredStockValue_i02I_maCzQP7_zrTNDxfEAWWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preferred stock: $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231_pdd" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pdd" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20211231_pdd" title="Preferred stock, Authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20201231_pdd" title="Preferred stock, Authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares authorized, <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_z8wCHSRjQU1g" title="Preferred stock, shares Issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zC0ouUVL3hIc" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_do_c20201231_zgwraAWOoNp7" title="Preferred stock, shares Issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20201231_zxyhbUwh5Vue" title="Preferred stock, shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> shares issued and outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31" id="fact-identifier-72" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0108"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-12-31" id="fact-identifier-73" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockValue_i02I_maCzQP7_zNh46GEJnAu4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock: $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value; <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common stock, Authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, Authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares authorized, <span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common stock, shares Issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common stock, shares outstanding"><span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common stock, shares Issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,352,364</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> shares issued and outstanding at December 31, 2021 and 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">874</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">874</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i02I_maCzQP7_zTgfYitfZrM7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,585,919</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,846,082</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzQP7_z5g2QG4soyGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Retained deficit</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,239,904</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,768,181</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i01TI_mtCzQP7_maCz9sp_zrA3FsHjHFRa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders' equity</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,346,889</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,078,775</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCz9sp_zNQVj1DJGewk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.25pt">Total liabilities and stockholders' equity</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,652,134</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,395,944</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(The accompanying notes are an integral part of
these consolidated financial statements)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="a_029"></span><span style="font-size: 10pt"><b>RENOVACARE, INC. AND SUBSIDIARY</b></span></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>



<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_zovvXCtUFfs3" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49F_20210101_20211231" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49D_20200101_20201231" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ended <br> December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--Revenues_maCzOy1_zC6W4P5V7qt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenue</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0157"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2021-01-01to2021-12-31" id="fact-identifier-92" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0158"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-01-012020-12-31" id="fact-identifier-93" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maCznGk_zJxiNCySECPk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 70%; text-align: left">Research and development</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,204,895</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,133,925</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_maCznGk_ziKAGCtOBAMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,204,521</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,543,173</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpenses_i01T_mtCznGk_msCzOy1_zTJR5QcWt7Pg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,409,416</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,677,098</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_mtCzOy1_maCzF25_zjQUPwVdju3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,409,416</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,677,098</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zSY7cCWZbkT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestIncomeExpenseNet_i01_maCzRuI_zeTDbL8vzla1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeExpenseNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,417</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeExpenseNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,762</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherIncome_i01_maCzRuI_zWkxiZsU2bTk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherIncome" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">931,276</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182"><span><ix:nonfraction name="us-gaap:OtherIncome" contextref="From2020-01-012020-12-31" id="fact-identifier-105" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzRuI_maCzF25_zPfZvmOp0xJg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">937,693</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,762</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtCzF25_zbRgvKeEjdMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.25pt">Net loss</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,471,723</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,548,336</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_ecustom--BasicAndDilutedLossPerCommonShare_zgX4ljPazEdc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.25pt">Basic and Diluted Loss per Common Share</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="rcar:BasicAndDilutedLossPerCommonShare" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.05</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="rcar:BasicAndDilutedLossPerCommonShare" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.11</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_ecustom--WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_zM0JCVRCQlOf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.25pt">Weighted average number of common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="rcar:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">87,352,364</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="rcar:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">87,352,364</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(The accompanying notes are an integral part of
these consolidated financial statements)&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="a_030"></span><span style="font-size: 10pt"><b>RENOVACARE, INC. AND SUBSIDIARY <br> CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</b></span></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020</b></span></p>



<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_z19xMbk1xK46" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zP61YZecbn28" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zNcOR78cNpZ7" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zbItTOVv4joh" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B7_zknPQ4zA7TMa" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Additional <br>
Paid</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Retained</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Total <br>
Stockholders'</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">-in Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Equity</td></tr>
  <tr id="xdx_43D_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zhGqWHD1cx17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Balance, December 31, 2019</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmnf88bcmFc8" title="Beginning Balance, Shares" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,352,364</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">874</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,378,833</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,219,845</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,159,862</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_ecustom--StockBasedCompensationDueToCommonStockPurchaseOptions_znTZR31VA0xa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation due to common stock purchase options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-119" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,206,252</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-121" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,206,252</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_ecustom--StockBasedCompensationForPrepaidServices_zywIwr3BHOqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation for prepaid services</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0208"><span><ix:nonfraction name="rcar:StockBasedCompensationForPrepaidServices" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-123" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:StockBasedCompensationForPrepaidServices" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">260,997</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210"><span><ix:nonfraction name="rcar:StockBasedCompensationForPrepaidServices" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-125" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:StockBasedCompensationForPrepaidServices" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">260,997</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zuF5jgvdBny" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss for the year ended December 31, 2020</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-127" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-128" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,548,336</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,548,336</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zkddxpJJ9LZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, December 31, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlWABwPDz6Oj" title="Beginning Balance, Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,352,364</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">874</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,846,082</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,768,181</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,078,775</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_ecustom--StockBasedCompensationDueToCommonStockPurchaseOptions_zr5dGOFbzv8f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation due to common stock purchase options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-136" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,054,542</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-138" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:StockBasedCompensationDueToCommonStockPurchaseOptions" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,054,542</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_ecustom--ReversalOfStockbasedCompensationDueToCommonStockPurchaseOptionCancellations_iP3custom--StockBasedCompensationDueToCommonStockPurchaseOptions_zumbbs6hzuM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reversal of stock-based compensation due to common stock purchase option cancellations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230"><span><ix:nonfraction name="rcar:ReversalOfStockbasedCompensationDueToCommonStockPurchaseOptionCancellations" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-140" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="rcar:ReversalOfStockbasedCompensationDueToCommonStockPurchaseOptionCancellations" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,314,705</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232"><span><ix:nonfraction name="rcar:ReversalOfStockbasedCompensationDueToCommonStockPurchaseOptionCancellations" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-142" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="rcar:ReversalOfStockbasedCompensationDueToCommonStockPurchaseOptionCancellations" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,314,705</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zTd1A9V05P0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss for the year ended December 31, 2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-144" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-145" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,471,723</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,471,723</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20210101__20211231_eus-gaap--StockholdersEquity_iE_z5pBZITiIoh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt">Balance, December 31, 2021</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5AsxyUTg9j2" title="Ending Balance, Shares" style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,352,364</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">874</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,585,919</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,239,904</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,346,889</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(The accompanying notes are an integral part of
these consolidated financial statements)&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_031"></span><b>RENOVACARE, INC. AND SUBSIDIARY</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>




<table cellspacing="0" cellpadding="0" id="xdx_30D_112_zTqOjtQnQTKb" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td id="xdx_49E_20210101__20211231_z6MaCa5p66Zk" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td id="xdx_492_20200101__20201231_zB0A2hPxDNz1" style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="7" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Years Ended <br>
December 31,</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="3" style="text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&nbsp;</td>
    <td colspan="3" style="text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z47jjQ1ORMR6" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt"><b>Cash flows from operating activities</b></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_i01_maCzRTp_zxJKFHzmgVf3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 72%"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,471,723</ix:nonfraction></span></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,458,336</ix:nonfraction></span></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_ziEimtDUTUpf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Adjustments to reconcile net loss to net cash flows from operating activities</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--Depreciation_i02_pp0p0_maCzRTp_zurAFg7wIcu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Depreciation expense</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,368</ix:nonfraction></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,633</ix:nonfraction></span></span></td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_i02_maCzRTp_zY61oHig3Gm5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Stock based compensation expense</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">173,163</ix:nonfraction></span></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,206,252</ix:nonfraction></span></span></td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_402_ecustom--NonCashLeaseExpense_i02_maCzRTp_zhbeToix9ww4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Non cash lease expense</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="rcar:NonCashLeaseExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,600</ix:nonfraction></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="rcar:NonCashLeaseExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">270</ix:nonfraction></span></span></td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zrT6rC5olCob" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Changes in operating assets and liabilities:</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msCzRTp_zOLZ7Y8hQjO8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">(Increase) decrease in prepaid expenses and other current assets</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,830</ix:nonfraction></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">340,528</ix:nonfraction></span></span></td>
    <td><span style="font-size: 10pt">)&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maCzRTp_zxmASBnrl0rb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Increase (Decrease) in accounts payable and accrued expenses</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,311</ix:nonfraction></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,068,394</ix:nonfraction></span></span></td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_i02_maCzRTp_zy9ulDdFOZw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Increase in accounts payable - related parties</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0274"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextref="From2021-01-01to2021-12-31" id="fact-identifier-165" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">111,696</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">)&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzRTp_maCz9xd_zcYemvfh5Ru7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Net cash flows used in operating activities</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,563,777</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,723,011</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><b>Cash flows from investing activities</b></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsForDeposits_i01N_di_msNCPBUzQaF_zCuKvpdcz0Y1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Payment for security deposit</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0283"><span><ix:nonfraction name="us-gaap:PaymentsForDeposits" contextref="From2021-01-01to2021-12-31" id="fact-identifier-169" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&nbsp;(<span><ix:nonfraction name="us-gaap:PaymentsForDeposits" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,995</ix:nonfraction></span></span></td>
    <td><span style="font-size: 10pt">)&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzQaF_zlV4lwwPlxLk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Purchase of equipment</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0286"><span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2021-01-01to2021-12-31" id="fact-identifier-171" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,273</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">)&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzQaF_maCz9xd_zUJCoM1KdABe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Net cash flows from investing activities</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0289"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2021-01-01to2021-12-31" id="fact-identifier-173" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,268</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">)&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_mtCz9xd_ztolJOCTwxXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt"><b>Decrease in cash and cash equivalents</b></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,563,777</ix:nonfraction></span></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,772,279</ix:nonfraction></span></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zaZG2oz4D2yf" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><b>Cash and cash equivalents at beginning of year</b></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,412,969</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,185,248</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zVX6BGinuIHj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"><b>Cash and cash equivalents at end of year</b></span></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,849,192</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,412,969</ix:nonfraction></span></span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zCsl7CHV8Cn8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt"><b>Supplemental disclosure of non-cash transactions:</b></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr id="xdx_40D_ecustom--StockBasedCompensationsIssuedForPrepaidServices_i01_zHjRw1A5RSIe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Stock based compensation issued for prepaid services</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0304"><span><ix:nonfraction name="rcar:StockBasedCompensationsIssuedForPrepaidServices" contextref="From2021-01-01to2021-12-31" id="fact-identifier-181" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="rcar:StockBasedCompensationsIssuedForPrepaidServices" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">260,997</ix:nonfraction></span></span></td>
    <td>&nbsp;</td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(The accompanying notes are an integral part of
these consolidated financial statements)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_032"></span><b>RENOVACARE, INC. AND SUBSIDIARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zORDRawK0a23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 1. <span id="xdx_821_zEUdJupmmkp8">Organization and Liquidity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Organization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RenovaCare, Inc., formerly Janus Resources, is
a Nevada corporation. RenovaCare, Inc. was incorporated under the laws of the State of Utah on July 14, 1983 as Far West Gold, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an authorized capital of <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zVb9Lmky12Ki" title="Common stock, Authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zTdpuTJDy1E7" title="Common stock, Authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span>
shares of $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zBrLVRHOvAGb" title="Common stock, par value"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231_zfrrgvgJFgK" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-186" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value common stock, of which <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20211231_zwT97SGzMFO2" title="Common stock, shares Issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zC62I6XPkN6i" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,352,364</ix:nonfraction></span></ix:nonfraction></span></span></span> shares are outstanding as of December 31, 2021, and <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zXaFGmiOs2Ae" title="Preferred stock, Authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zaMFdFfQhVg8" title="Preferred stock, Authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares of
$<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zkH5PNdouIhk" title="Preferred stock, par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zdKZ1kkjK51f" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value preferred stock, of which <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_zj4YjSRkihu3" title="Preferred stock, shares Issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zxyjuiQ1tBFi" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_dn_c20201231_zvHsV0Ly6YYj" title="Preferred stock, shares Issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20201231_z4wGovSaeDMk" title="Preferred stock, shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">none</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> are outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RenovaCare, Inc., through its wholly owned subsidiary,
RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using
a patients own cells) cellular therapies that can be used for medical and aesthetic applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 12, 2013, the Company completed the acquisition
of its flagship technologies (collectively, the <b>CellMist<sup>TM&nbsp;</sup>System</b>). <span style="color: #212121">The
CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patients own skin or other
tissues. The resulting stem cell suspension is administered topically from </span>the Companys novel solution sprayer device (the
<b>SkinGun<sup>TM</sup></b>) <span style="color: #212121">as a cell therapy onto wounds including burns to facilitate healing.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212121">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Currently,
our proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and
seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed
in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Liechtenstein, and the United
Kingdom.</span> The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United
Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212121">On May 6, 2021 the Food and Drug
Administration gave full-approval of the Companys Investigational Device Exemption (IDE) application to proceed with initial clinical
testing of the CellMist<span style="font-family: Times New Roman, Times, Serif"></span> System and SkinGun<span style="font-family: Times New Roman, Times, Serif"></span>
spray device in adult burn patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Improvements in the design and efficiency of the
CellMist System including a closed, automated cell isolation device and the SkinGun spray device are in development with
StemCell Systems (Berlin, Germany), the Companys R&amp;D innovation partner. The Company is adapting its core technologies for
possible use in other clinical indications. The Company is also developing the cell isolation and spray gun devices as stand-alone 510(k)-cleared
products for isolation of cells from other tissues and spraying other solutions of medical importance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any commercialized products.
The Company's activities have consisted principally of performing research and development activities and raising capital to support such
activities. The Company has enlisted the assistance of several Contract Manufacturing Organizations (CMO) to manufacture clinical supplies
including components of the CellMist System and the electronic SkinGun spray devices in compliance with FDAs guidance
for current Good Manufacturing Practices (cGMP) and Contract Research Organizations (CRO) to test and validate the Companys products
and processes and to conduct clinical trials that evaluate initially the safety and feasibility of an autologous skin cell therapy using
the Companys products to facilitate burn wound healing. These development activities are subject to significant risks and uncertainties,
including possible failure of preclinical and clinical testing. The Company has not generated any revenue and has sustained recurring
losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its
products and technologies and will need to raise additional capital through partnerships or the sale of its securities to accomplish its
business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant
risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future
financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 53; Value: 1 -->
    <div id="xdx_23A_zcLGtNRkzBEd" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_233_z41YMMicqfSi" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td id="xdx_234_z53vlxwAP0R1" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_233_zHWKD73WAOZg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><p id="xdx_23F_zjD85KXTujee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not generated any revenue since
inception and has sustained recurring losses and negative cash flows from operations since inception. We expect to incur losses as we
continue our research and development activities. The Company's activities are subject to significant risks and uncertainties due to the
stage of the development of the Company's cellular therapies. <span style="background-color: white">At December 31, 2021, the Company
had approximately $<span id="xdx_901_eus-gaap--Cash_iI_c20211231_zUkhsrRaJAG1" title="Cash on hand"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,800,000</ix:nonfraction></span></span>&nbsp;in cash on hand and an accumulated deficit of $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_zbpg5jWvTkN" title="Retained deficit"><span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="false" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,239,904</ix:nonfraction></span></span>. </span>The Company has historically funded
its operations through the issuance of convertible notes, the sale of common stock and issuance of warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether there are any conditions
and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year
beyond the filing of this Annual Report on Form 10-K. Based on such evaluation and the Companys current plans, which are subject
to change, management believes that the Companys existing cash as of December 31, 2021 is sufficient to satisfy its operating cash
needs for the year after the filing of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is responsible to bear the costs to
defend itself and its directors and officers, pursuant to the indemnification clause in the Companys bylaws, against the Lawsuits.
Subsequent to December 31, 2021, the Company depleted the funds available under its D&amp;O Policy. The legal costs to defend the Company
against the Lawsuits are expected to be material. The Companys legal counsel provided a non-binding estimate of the legal costs
to defend the Company of approximately $3,000,000 over the next 16  20 months. To assist the Company in paying the costs to defend
against the Lawsuits, the Companys Chairman loaned the Company $<span id="xdx_900_eus-gaap--LoansPayable_iI_c20220318__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNoteMember_zL0cgzolYVmh" title="Loan"><span><ix:nonfraction name="us-gaap:LoansPayable" contextref="AsOf2022-03-18_us-gaap_SubsequentEventMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">800,000</ix:nonfraction></span></span> on March 18, 2022 pursuant to a convertible note, see <i>Note
11  Subsequent Events</i>, for additional information. Due to the nature of the Lawsuits, and the early stage of the proceedings,
the estimated amounts disclosed above is only an estimate. The estimate above does not include the potential costs to the Company in the
event that it is not successful in its defense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has experienced and continues to experience
negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The future of the
Company will depend on its ability to successfully raise capital from external sources. As noted above, management believes that the Companys
existing cash as of December 31, 2021 are sufficient to satisfy its operating cash needs for the year after the filing of this Annual
Report on Form 10-K. However, if the Company is unable to maintain sufficient financial resources, its business, financial condition and
results of operations will be materially and adversely affected. This could affect future development and business activities and potential
future product development and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed
financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the
holdings of the Companys existing stockholders. Debt financing may involve agreements that include covenants limiting or restricting
the Companys ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends,
and may be secured by all or a portion of the Companys assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_zPUFgEstuMkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 2. <span id="xdx_826_zNeBSYicutt8">Significant Accounting Policies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zKq6voK3TpXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_ziNXEv6YPZri">Principles of Consolidation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) and include
the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences Corp. All intercompany transactions and balances have
been eliminated. RenovaCare Sciences Corp. was incorporated under the laws of the State of <span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zk2KedleGIfe" title="State Country Name"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="false" id="fact-identifier-203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nevada</ix:nonnumeric></span></span> on <span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20210101__20211231_zFu8QIV9XOZf" title="Date of Incorporation"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation" inside-table="false" id="fact-identifier-204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">June 12, 2013</ix:nonnumeric></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_847_eus-gaap--UseOfEstimates_zO0DAymiWjwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_867_zPlGPCcYnKNb">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ
from these estimates. Management utilizes various other estimates, including but not limited to, determining the estimated lives of long-lived
assets, determining the potential impairment of intangibles, the fair value of warrants issued, the fair value of stock options and other
legal claims and contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<ix:exclude><!-- Field: Page; Sequence: 54; Value: 1 -->
    <div id="xdx_23A_zJJRsx1DrtUh" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td id="xdx_238_zNJy1awLyTg3" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23E_zrZQqchZjhJ1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zoGTL63CLso2" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_z4ncYcayPAE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b>&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLNjxaYmQba4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_zwdRPTVbmVO8">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid instruments
purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally
insured limits. The Company did <span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20211231_zPx3ENAM6NR5" title="Cash and cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20201231_zq8uGwWOy4e3" title="Cash and cash equivalents"><span><ix:nonfraction name="us-gaap:CashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span>t have any cash equivalents as of December 31, 2021 and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" inside-table="false" id="fact-identifier-209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zNj4wNh0u2me" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zB3QZSTKCCs5">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for fair value measurements
for financial assets and financial liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements. The authoritative
guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure
for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined
as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes
a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1: Quoted prices (unadjusted)
in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2: Inputs other than quoted prices
included within Level 1 that are observable for the asset or liability, either directly or indirectly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3: Unobservable inputs
for the asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021 and 2020, the Company
did not have any assets or liabilities that were measured at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Companys financial statements include
cash, other current assets and accounts payable and accrued expenses which are short term in nature and, accordingly, approximate fair
value. It is the Companys policy to measure non-financial assets and liabilities at fair value on a nonrecurring basis. The instruments
are not measured at fair value on an ongoing basis but are subject to fair value adjustments in certain circumstances (such as evidence
of impairment), which if material, are disclosed in the accompanying notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" inside-table="false" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zulxDHSeek72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_z12IVhmM15Nk">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
in accordance with Accounting Standards Codification (ASC) 718, Stock Based Compensation.&nbsp; ASC 718 requires all stock-based
payments to directors, employees and consultants, including grants of stock options, to be recognized in the consolidated statements of
operations based on their fair values. The Company uses the Black-Scholes option pricing model (the <b>Black-Scholes Model</b>)
to determine the weighted-average fair value of options granted and recognizes the compensation expense of stock-based awards on a straight-line
basis over the vesting period of the award. If a stock-based award contains performance-based conditions, at the point that it becomes
probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to
the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement
of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The determination of the fair value of stock-based
payment awards utilizing the Black-Scholes option pricing model requires the use of the following assumptions: expected volatility of
our common stock, which is based on our own calculated historical rate; expected life of the option award, which we elected to calculate
using the simplified method; expected dividend yield, which is 0%, as we have not paid and do not have any plans to pay dividends on our
common stock; and the risk-free interest rate, which is based on the U.S. Treasury rate in effect at the time of grant with maturities
equal to the stock option awards expected life. The Company evaluates the assumptions used to value the awards at each grant date
and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has
been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required
to accelerate, increase or cancel any remaining unearned stock-based compensation expense. Forfeitures are accounted for as they occur.
See NOTE 6. Equity for additional information on the Companys stock-based compensation plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div id="xdx_23F_zem7x69Hl6ld" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td id="xdx_236_zlmZGqeY81ij" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_237_ztrGsVxxo6D9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zxBeQijVFIab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zaDhLnt7Bd5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zruwTsO8iwNg">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes their leases with a term
of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either
operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in front-loaded
expense. The Companys lease consists of an operating lease for office space. The Company does not recognize a lease liability or
right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense
on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term
of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zRCr3qn5ULYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_869_zAsFYk3YVQi">Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment is carried at cost, less accumulated
depreciation and amortization. Major improvements are capitalized, while repair and maintenance are expensed when incurred. Renewals and
betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost
and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation is computed on a straight-line basis
over estimated useful lives of the related assets. The estimated useful lives of depreciable assets are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="rcar:SummaryOfEstimatedUsefulLivesOfDepreciableAssetsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellspacing="0" cellpadding="0" id="xdx_89A_ecustom--SummaryOfEstimatedUsefulLivesOfDepreciableAssetsTableTextBlock_zbg6b1xdoEpf" summary="xdx: Disclosure - Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="background-color: White">
    <td style="vertical-align: top"><span id="xdx_8B0_zryFa8wM9vrk" style="display: none">Schedule of estimated useful lives of depreciable assets</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 54%">&nbsp;</td>
    <td style="width: 46%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Estimated</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Useful Lives</b></p></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Office equipment</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zIs7q0pxu1Vf" title="Estimated Useful Lives"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonnumeric></span></span> - <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zMXZVFBVjugj" title="Estimated Useful Lives"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span> years</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Furniture &amp; equipment</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zGC416Inpl6h" title="Estimated Useful Lives"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span> - <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zB3L3TDWYIM" title="Estimated Useful Lives"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonnumeric></span></span> years</span></td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8A7_zJ6WY6TQatW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="rcar:PatentAndTrademarkCostsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_84A_ecustom--PatentAndTrademarkCostsPolicyTextBlock_zcjb0GQTtZo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86C_zT79SdnewPxh">Patent and Trademark Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Costs related to filing and pursuing patent applications
are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zx3g9nXeOr08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_zPMnPePZChw2">Research and Development Expenses</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses research and development
expenses to operations as incurred. Research and development expenses consist of (i) regulatory compliance, (ii) pilot-scale manufacturing
of the Companys cell isolations and SkinGun<span style="background-color: white"></span> spray, (iii) employee-related expenses
including salaries, benefits, travel and stock-based compensation, (iv) clinical trials and (v) other research and development costs including
consulting fees and stock-based compensation to contract research organizations (CROs) other third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for nonrefundable advance
payments for goods and services that will be used in future research and development as expenses when the services have been performed
or when the goods have been received rather than when the payment is made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zykXobQzXPtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86E_zXqy4L4ALxMk">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Companys intangible asset consists
primarily of the CellMist<sup>TM</sup>&nbsp;System technology that the Company acquired in 2013 and is recorded at cost. At the time of
acquisition, the technology had not reached technological feasibility. The amount capitalized is accounted for as an indefinite-lived
intangible asset, subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made
as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are
expected to be generated and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently
if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing
the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances
indicate that the intangible asset is not impaired, additional impairment tests are not necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div id="xdx_232_zY3lS6GaUSDf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td id="xdx_23F_zRxqbk29e0Ji" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_231_zdgHd633coWl" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><p id="xdx_23A_zHoWbvp7zVce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the following qualitative
factors that could affect any change in the fair value of the intangible asset: analysis of the technology's current phase, additional
testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes
in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a
qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely
than not that the intangible asset related to the CellMist<sup>TM&nbsp;</sup>System is not impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zcxMltzUyOIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_zB8yylh26NUd">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax
consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company
reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken
in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zMAqf8Co4ww2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_863_zwqqrt04yjsh">Segment Reporting</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Companys business is considered to
be operating in one segment based upon the Companys organizational structure, the way in which the operations are managed and evaluated,
the availability of separate financial results and materiality considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zAripkFzN3lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zKNPpcrojtA">Net Loss Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The computation of basic earnings per share (<b>EPS</b>)
is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable
at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding
plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using
the treasury stock method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance
of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced
a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and
warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the
period exceeds the exercise price of the options or warrants (they are in the money).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following is the computation of basic and diluted
net loss per share for the years ended December 31, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z24v4eRanyn2" summary="xdx: Disclosure - Significant Accounting Policies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BE_zfBndyrvSuV5" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_496_20210101__20211231_zE1hhqN2veMe" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_490_20200101__20201231_ztTVJ1PN06K9" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ended <br> December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and Diluted EPS Computation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td>Numerator:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Loss available to common stockholders</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,471,723</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,548,336</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td>Denominator:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_ecustom--WeightedAverageNumberOfCommonSharesOutstanding_zXQOpN3lmlo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="rcar:WeightedAverageNumberOfCommonSharesOutstanding" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">87,352,364</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="rcar:WeightedAverageNumberOfCommonSharesOutstanding" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">87,352,364</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_ecustom--BasicAndDilutedEps_zedA1q98rSH2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.25pt">Basic and diluted EPS</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="rcar:BasicAndDilutedEps" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.05</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="rcar:BasicAndDilutedEps" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.11</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr>
  </tbody></table>


</ix:nonnumeric></span><p id="xdx_8A6_zuzJS31WJyl9" style="margin: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div id="xdx_235_zPtKwDapwJx2" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td id="xdx_237_zz4Ac3EtjJ7h" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_239_zAOlpR8els6k" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin: 0"></p>

<ix:exclude><p id="xdx_234_zb3TfhKjXK3a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:</span></p>



<p style="margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zzfFSe4eWx22" summary="xdx: Disclosure - Significant Accounting Policies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B1_z2twLLsqe5K3" style="display: none">Schedule of anti dilutive shares</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Stock options</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" title="Total shares not included in the computation of diluted losses per share" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_StockCompensationPlanMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,139,999</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" title="Total shares not included in the computation of diluted losses per share" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_StockCompensationPlanMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,895,570</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" title="Total shares not included in the computation of diluted losses per share" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,712,496</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" title="Total shares not included in the computation of diluted losses per share" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,296,912</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.25pt">Total shares not included in the computation of diluted losses per share</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_pdd" title="Total shares not included in the computation of diluted losses per share" style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,852,495</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_pdd" title="Total shares not included in the computation of diluted losses per share" style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,192,482</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AC_zrWCuTBXrMDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="rcar:RelatedPartyTransactionsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_84D_ecustom--RelatedPartyTransactionsPolicyTextBlock_zYQfc9rOsx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86B_zBdPCfSzqiU5">Related Party Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A related party is generally defined as (i) any
person who holds 10% or more of the Company's securities and their immediate families; (ii) the Company's management; (iii) someone who
directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence
the financial and operating decisions of the Company. A transaction is a related party transaction when there is a transfer of resources
or obligations between related parties. See Note 9. Related Party Transactions for further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" inside-table="false" id="fact-identifier-239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z172nY965hsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zzIuq9w2Ormj">Concentration of Credit Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash. The Company maintains deposits in an accredited financial institution
in excess of federally insured limits. The Company deposits its cash in a financial institution that it believes has high credit quality
and has not experienced any losses on such account and does not believe it is exposed to any unusual credit risk beyond the normal credit
risk associated with commercial banking relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zzAkiM3bzS19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zDCTE9o0zpe3">Accounting Pronouncements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate all Accounting Standards Updates (ASUs)
issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures
were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>New Accounting Pronouncements Not Yet Adopted</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Accounting Pronouncements Recently Adopted</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued&nbsp;ASU 2019-12,&nbsp;Income
Taxes  Simplifying the Accounting for Income Taxes.&nbsp;The guidance removes certain exceptions for recognizing deferred taxes
for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds
guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a
consolidated group, among others. This guidance is effective&nbsp;for interim and annual reporting periods beginning&nbsp;after December
15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements
have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either
prospectively or retrospectively. The Company adopted ASU 2019-12 effective January 1, 2021 with no impact on its Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_z36GOkMSmzQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 3. <span id="xdx_825_zVNPEHzTO17d">Assets  Intellectual Property</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 12, 2013, the Company, together with its
wholly owned subsidiary, RenovaCare Sciences, entered into an Asset Purchase Agreement with Dr. Jrg Gerlach, MD, PhD, pursuant to
which RenovaCare Sciences purchased all of Dr. Gerlachs rights, title and interest in the CellMist<sup>TM</sup>&nbsp;System. Acquisition
related costs amounted to $<span id="xdx_909_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20130701__20130731__us-gaap--PlanNameAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrGerlachMember_pp0p0" title="Acquisition related costs"><span><ix:nonfraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextref="From2013-07-012013-07-31_custom_AssetPurchaseAgreementMember_custom_DrGerlachMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,852</ix:nonfraction></span></span> and were capitalized together with the cash payment upon the closing of the transaction in July 2013
of $<span id="xdx_90A_eus-gaap--MineReclamationAndClosingLiabilityNoncurrent_c20130731__us-gaap--PlanNameAxis__custom--AssetPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrGerlachMember_pp0p0" title="Closing cash payment"><span><ix:nonfraction name="us-gaap:MineReclamationAndClosingLiabilityNoncurrent" contextref="AsOf2013-07-31_custom_AssetPurchaseAgreementMember_custom_DrGerlachMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,002</ix:nonfraction></span></span>. Intangible assets amounted to $<span id="xdx_902_eus-gaap--IntangibleAssetsCurrent_c20211231_pp0p0" title="Intangible Assets"><span id="xdx_901_eus-gaap--IntangibleAssetsCurrent_c20201231_pp0p0" title="Intangible Assets"><span><ix:nonfraction name="us-gaap:IntangibleAssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:IntangibleAssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152,854</ix:nonfraction></span></ix:nonfraction></span></span></span> as of December 31, 2021 and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<ix:exclude><p id="xdx_23B_zH6s9FqzY8qb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 58; Value: 1 -->
    <div id="xdx_232_zW33OEU2V5Xb" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td id="xdx_233_za099Gob4Hgk" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_239_zhrkFGEEjHLc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zVzx0Q6s7mf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="rcar:PrepaidExpensesAndOtherCurrentAssetsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_800_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zB8Qt6TufX3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 4. <span id="xdx_82C_zYo7qidG09Vc">Prepaid Expenses and Other Current Assets</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid expenses and other current assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zjaNacdVgnxf" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B9_zxdeTmFmsoUc" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_495_20211231" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_494_20201231" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECz55L_zOFTfxWBPgQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Prepaid insurance</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450"><span><ix:nonfraction name="us-gaap:PrepaidInsurance" contextref="AsOf2021-12-31" id="fact-identifier-248" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidInsurance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,180</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_ecustom--PrepaidStockOptionsForServices_iI_pp0p0_maPECz55L_z6PsDYjMwMT4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid stock options for services</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:PrepaidStockOptionsForServices" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">87,001</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:PrepaidStockOptionsForServices" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">86,999</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_ecustom--PrepaidProfessionalFees_iI_pp0p0_maPECz55L_zDSt3SMAdDa9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid professional fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:PrepaidProfessionalFees" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,930</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:PrepaidProfessionalFees" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">65,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidResearchAndDevelopmentExpense_iI_pp0p0_maPECz55L_zEq9YHq44s4h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid research and development expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:PrepaidResearchAndDevelopmentExpense" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">289,746</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:PrepaidResearchAndDevelopmentExpense" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">289,746</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECz55L_zOSYfLQB49C3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherPrepaidExpenseCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,964</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherPrepaidExpenseCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,350</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_ecustom--RefundsDue_iI_pp0p0_d0_maPECz55L_zj0TlIStcZzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Refunds due</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="rcar:RefundsDue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">41,804</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="rcar:RefundsDue" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtPECz55L_zyoZjKLEMWo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.25pt">Total prepaid expenses</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">533,445</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">566,275</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zvvSpLXNE7Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 5. <span id="xdx_82C_zWZikYiAhKHg">Accounts Payable and Accrued Liabilities</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts payable and accrued expenses consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zjGRCVDCuZ2l" summary="xdx: Disclosure - Accounts Payable and Accrued Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B0_z9eTJrqUO566" style="display: none">Schedule of accounts payable and accrued expenses</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_493_20211231_zcCZLJLpsZhe" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_495_20201231_zmdiXJpYRCUi" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_zcnYSFSdMYY8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Legal fees</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedProfessionalFeesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">869,950</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedProfessionalFeesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">192,053</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_ecustom--AccruedOfficerCompensation_iI_z9Weyb7msZ31" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Officer compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:AccruedOfficerCompensation" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">55,040</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:AccruedOfficerCompensation" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">313,396</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedConsultants_iI_zq4tAI95ZQF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Consultants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:AccruedConsultants" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">117,943</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:AccruedConsultants" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">99,096</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_ecustom--AccruedTradePayables_iI_zouynMQExoSa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Trade payables</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="rcar:AccruedTradePayables" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">231,815</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="rcar:AccruedTradePayables" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">632,892</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_zuhZXBdEq3Ne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,274,748</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,237,437</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Of the legal fees of $<span id="xdx_905_eus-gaap--LegalFees_c20210101__20211231_zcyGhnQdIND6" title="Legal fees"><span><ix:nonfraction name="us-gaap:LegalFees" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">869,950</ix:nonfraction></span></span> as of December 31, 2021, approximately
$855,000 are expected to be reimbursed by our directors and officers insurance policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zdo7yPjHmSE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 6. <span id="xdx_820_z0RKVzaem8u4">Equity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2013 Long-Term Incentive Plan </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 20, 2013, the Companys Board of
Directors adopted the 2013 Long-Term Incentive Plan (the <b>2013 Plan</b>) and on November 15, 2013, a stockholder owning
a majority of the Companys issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan,
an aggregate of <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20211231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--TwoThousandThirteenPlanMember_pdd" title="Common shares reserved for issuance"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2021-12-31_custom_TwoThousandThirteenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,000,000</ix:nonfraction></span></span> shares of the Companys common stock have been reserved for issuance to the Companys officers,
directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees
under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options;
options granted to others under the 2013 Plan are limited to non-qualified stock options. As of December 31, 2021, there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231_zev2Hp2yqK71" title="Number of shares available for future grants"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,618,266</ix:nonfraction></span></span>
shares available for future grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90F_ecustom--StockOptionsGrantDescription_c20210101__20211231__us-gaap--PlanNameAxis__custom--Plan2013Member_z8NpVe7fNMQb" title="Stock options grant description"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_Plan2013Member" name="rcar:StockOptionsGrantDescription" inside-table="false" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">The 2013 Plan is administered by the Board or
a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers,
employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and
conditions of each option that is granted to them; however, no person may be granted options to purchase more than 2,000,000 shares in
any one fiscal year under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares
with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed
$100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise price per share of common stock for
options granted under the 2013 Plan is the fair market value of the Company's common stock on the date of grant, using the closing price
of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder
of ten percent or more of the Company's common stock, for whom the exercise price per share will <span id="xdx_904_ecustom--ExcecisePricePerShareLimit_c20210101__20211231__us-gaap--PlanNameAxis__custom--Plan2013Member" title="Excecise price per share limit"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_Plan2013Member" name="rcar:ExcecisePricePerShareLimit" inside-table="false" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">not be less than 110% of the fair market
value.</ix:nonnumeric></span></span> No option can be granted under the 2013 Plan after June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div id="xdx_23A_zAnXYjVSR89h" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td id="xdx_230_zdMQiUurxsZa" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23E_z3ASlbJoNP7e" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zreO988T5Hcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b>&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021, the Company had <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zlN8iCZcG1b7" title="Common stock, Authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zZ1vQpemSj78" title="Common stock, Authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span>
authorized shares of common stock with a par value of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zdjpUhFnJtV6" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231_zWMWPOD7S7Ea" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00001</ix:nonfraction></span></ix:nonfraction></span></span></span> per share and <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20211231_zUI1X7Iw8Idb" title="Common stock, shares Issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zR8jV7gXYDni" title="Common stock, shares outstanding"><span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20201231_zjKdiuRg1y8a" title="Common stock, shares Issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zsWcDr1gCwyk" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,352,364</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> shares of common stock outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 and 2020,
the Company did <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_do_c20210101__20211231_z3ndCqGfVlc7" title="Number of new shares issued"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_do_c20200101__20201231_zDSXtBTFuSL1" title="Number of new shares issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-01to2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-01-012020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span>t issue any new shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has issued warrants to purchase common
stock at various exercise prices in connection with loan agreements and private placements. The following table summarizes information
about warrants outstanding at December 31, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>


<p style="margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="rcar:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock_zCPUhGvAgH31" summary="xdx: Disclosure - Equity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BA_zhz4AURGt3oj" style="display: none">Schedule of warrants outstanding</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap">&nbsp;</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares of Common Stock Issuable for <br>
Warrants Outstanding as of</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="padding-bottom: 1pt; white-space: nowrap; text-align: center"><b>Weighted</b></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; white-space: nowrap; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap">&nbsp;</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="padding-bottom: 1pt; white-space: nowrap; text-align: center"><b>Average</b></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; white-space: nowrap; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">Description</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 27%; text-align: left">Series E</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2021-12-31_custom_SeriesEMember" id="fact-identifier-291" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2020-12-31_custom_SeriesEMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">584,416</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" title="Weighted Average Exercise Price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_custom_SeriesEMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2020-12-31_custom_SeriesEMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.54</ix:nonfraction></span></ix:nonfraction></span></span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 27%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_zOwTHk7tTtbb" title="Expiration"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SeriesEMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">September 8, 2021</ix:nonnumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series F</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2021-12-31_custom_SeriesFMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,246</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2020-12-31_custom_SeriesFMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,246</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Weighted Average Exercise Price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_custom_SeriesFMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2020-12-31_custom_SeriesFMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.45</ix:nonfraction></span></ix:nonfraction></span></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MinimumMember_zxrQQ2f2n9Pk" title="Expiration"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SeriesFMember_srt_MinimumMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" inside-table="true" id="fact-identifier-300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">February 23, 2022</ix:nonnumeric></span></span> &amp; <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MaximumMember_z5c6bbCz5ydh" title="Expiration"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SeriesFMember_srt_MaximumMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" inside-table="true" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March 9, 2022</ix:nonnumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series G</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2021-12-31_custom_SeriesGMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">460,250</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2020-12-31_custom_SeriesGMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">460,250</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Weighted Average Exercise Price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_custom_SeriesGMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2020-12-31_custom_SeriesGMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.68</ix:nonfraction></span></ix:nonfraction></span></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_z2mKhnDdwT7c" title="Expiration"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SeriesGMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" inside-table="true" id="fact-identifier-306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">July 21, 2022</ix:nonnumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series H</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2021-12-31_custom_SeriesHMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">910,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2020-12-31_custom_SeriesHMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">910,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Weighted Average Exercise Price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_custom_SeriesHMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2020-12-31_custom_SeriesHMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.75</ix:nonfraction></span></ix:nonfraction></span></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_z7na5FGtQRA8" title="Expiration"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SeriesHMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" inside-table="true" id="fact-identifier-311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">October 16, 2022</ix:nonnumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Series I</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2021-12-31_custom_SeriesIMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,335,000</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2020-12-31_custom_SeriesIMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,335,000</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Weighted Average Exercise Price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_custom_SeriesIMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2020-12-31_custom_SeriesIMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.00</ix:nonfraction></span></ix:nonfraction></span></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_zzcQqlgthbh2" title="Expiration"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SeriesIMember" format="ixt:datemonthdayyearen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" inside-table="true" id="fact-identifier-316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">November 26, 2025</ix:nonnumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,712,496</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" title="Shares of Common Stock Issuable from Warrants Outstanding" style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,296,912</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A4_zwySdB6D5zW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, all the
Series E Warrants expired unexercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock option activity
for the years ended December 31, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zNDO6AEBTpu6" summary="xdx: Disclosure - Equity (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B2_zuTXO9H8e7E1" style="display: none">Schedule of stock option activity</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Number of <br>
Options</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted <br>
Average <br>
Exercise <br>
Price ($)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted <br>
Average <br>
Remaining <br>
Contractual <br>
Term (years)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Aggregate <br>
Intrinsic <br>
Value ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Outstanding at December 31, 2019</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zvwTXiUCPBz9" title="Options outstanding - beginning balance" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,317,500</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zgfFWILtVnK2" title="Options outstanding - beginning balance" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.41</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">&nbsp;</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">&nbsp;</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_pdd" title="Options granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,615,570</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" title="Options granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.31</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zYaVTmoA6QL3" title="Options forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,500</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" title="Options forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.20</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at December 31, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zDi2bmZZgUxf" title="Options outstanding - beginning balance" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,895,570</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zNixXTum600j" title="Options outstanding - beginning balance" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.45</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_pdd" title="Options granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_pdd" title="Options granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.72</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_z1pTzFDVOLHb" title="Options forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,805,571</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_pdd" title="Options forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.74</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2021</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zsMM0UoPrZH6" title="Options oustanding - ending balance" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,139,999</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zkCV51WiMHsj" title="Options outstanding - ending balance" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.17</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zvAC0JbvAY0g" title="Weighted average remaining contracted term"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.54</ix:nonnumeric></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231_zcQp1xbNJPBh" title="Aggregate intrinsic value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0613"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2021-12-31" id="fact-identifier-335" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and exercisable at December 31, 2021</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231_pdd" title="Options Vested and Exercisable" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,639,999</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231_pdd" title="Options Vested and Exercisable" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.99</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zl9fnPFs9gBh" title="Options Vested and Exercisable"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.48</ix:nonnumeric></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231_pp0p0" title="Options Vested and Exercisable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextref="AsOf2021-12-31" id="fact-identifier-339" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A5_z8CLD838zAQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation methodology used to determine the
fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including
volatility of the stock price, the risk-free interest rate, and the expected term of the stock options. The ranges of assumptions used
in the Black-Scholes Model during the years ended December 31, 2021 and 2020 is set forth in the table below:</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellspacing="0" cellpadding="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJSvmszDpOAh" summary="xdx: Disclosure - Equity (Details 2)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="background-color: White">
    <td style="vertical-align: bottom"><span id="xdx_8B5_z4LvNrrAU4Qj" style="display: none">Schedule of assumption of stock option activity</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="5" style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Years Ended December 31,</b></span></td></tr>
  <tr>
    <td style="padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt; vertical-align: top; text-align: center">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 69%"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="vertical-align: top; text-align: center; width: 15%"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231_zQ2oZV1u5Ym8" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.73</ix:nonfraction></span></span>%</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center; width: 5%"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zQK5XhA0eod7" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-01-012020-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.21</ix:nonfraction></span></span>%</span></td>
    <td style="text-align: center; width: 5%"> -</td>
    <td style="text-align: center; width: 5%"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zDYrZ2yEYRXj" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-01-012020-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.67</ix:nonfraction></span></span>%</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Expected term in years</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_znPlmn7Sa1N2" title="Expected life in years"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.38</ix:nonnumeric></span></span></span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&nbsp;<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zt7kFeyzs2Z1" title="Expected life in years"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.25</ix:nonnumeric></span></span> </span></td>
    <td style="text-align: center"></td>
    <td style="text-align: center"> <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zZHlZ8HUGJ99" title="Expected life in years"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.00</ix:nonnumeric></span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Weighted Avg. Expected Volatility</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231_zIohyMGfLKO5" title="Weighted Avg. Expected Volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">102.07</ix:nonfraction></span></span></span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">&nbsp;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zpK9JjPC74F1" title="Weighted Avg. Expected Volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-01-012020-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97.20</ix:nonfraction></span></span>%</span></td>
    <td style="text-align: center"> </td>
    <td style="text-align: center"> <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zImqeQYPw2Ve" title="Weighted Avg. Expected Volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-01-012020-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110.71</ix:nonfraction></span></span>%</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Expected dividend yield</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20211231_zCXVdDRIrBOl" title="Expected dividend yield"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span>%</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20201231_zPFGH75VPCve" title="Expected dividend yield"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span>%</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8A5_za3t7mhPU2Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div id="xdx_239_ziXKuFtCpx26" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td id="xdx_237_z0uXM6FI0XBc" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23B_z8DLktKRlN6i" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><p id="xdx_23E_z0eRd8yLwnkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. <span style="color: #252525">Estimated
volatility is a measure of the amount by which the stock price is expected to fluctuate each year during the term of an award. Our calculation
of estimated volatility is based on historical stock prices over a period equal to the term of the awards. The average expected life is
based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact
that we have never paid cash dividends and have no current intention to pay cash dividends. Future stock-based compensation may significantly
differ based on changes in the fair value of our Common Stock and our estimates of expected volatility and the other relevant assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the share-based
compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in
the Companys Statements of Operations for the years ended December 31, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_899_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zna9ggbOeJmi" summary="xdx: Disclosure - Equity (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B5_zp8yFjZxCb3e" style="display: none">Schedule of consolidated statement of operations</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Research and development</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Total" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" contextref="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">948,938</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Total" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" contextref="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,536,168</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" contextref="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,122,101</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" contextref="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,670,084</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20211231_pp0p0" title="Total" style="border-bottom: Black 2.25pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">173,163</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200101__20201231_pp0p0" title="Total" style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,206,252</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AA_zkgnYKsOHgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2021, the Company had $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20211231_pp0p0" title="Unrecognized compensation cost"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,382,997</ix:nonfraction></span></span> unrecognized compensation
cost related to unvested stock options to be amortized through 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Year Ended December 31, 2021</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 26, 2021, in connection with an Executive
Services Consulting Agreement of the same date, the Company granted Justin Frere, the Companys former Chief Financial Officer,
an option to purchase up to <span id="xdx_90C_ecustom--NumberOfSharesPurchase_iI_c20210726__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JustinFrereMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zmE3hD0RGbSj" title="Number of shares purchase"><span><ix:nonfraction name="rcar:NumberOfSharesPurchase" contextref="AsOf2021-07-26_custom_ConsultingAgreementMember_custom_JustinFrereMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,000</ix:nonfraction></span></span> shares of the Companys common stock at an exercise price of $<span id="xdx_90D_eus-gaap--StockOptionExercisePriceDecrease_c20210701__20210726__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JustinFrereMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTufFxOPD025" title="Common stock exercise price"><span><ix:nonfraction name="us-gaap:StockOptionExercisePriceDecrease" contextref="From2021-07-012021-07-26_custom_ConsultingAgreementMember_custom_JustinFrereMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.72</ix:nonfraction></span></span> and with a term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20210726__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JustinFrereMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zq8dwiTey6Pb" title="Option term"><span><ix:nonnumeric contextref="From2021-07-012021-07-26_custom_ConsultingAgreementMember_custom_JustinFrereMember_us-gaap_CommonStockMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="false" id="fact-identifier-362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonnumeric></span></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the first half of 2021, certain individuals
resigned from the Company resulting in the forfeiture and cancellation of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zVHHiQjqNgIg" title="Number of option forfeiture and cancellation"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,805,571</ix:nonfraction></span></span> options. Compensation expense was recorded on some
of these options prior to their full vesting. As a result, during the year ended December 31, 2021, the Company recognized $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_zCDEPSKCeAB7" title="Share based compensation expense"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,314,705</ix:nonfraction></span></span>
of reversals of the prior recognized compensation expense related to the cancelled options. During the year ended December 31, 2021, the
expense recognized on options still in their vesting period totaled $<span id="xdx_907_ecustom--RecognizedExpenses_c20210101__20211231_z4YwI00rNxkh" title="Recognized expenses"><span><ix:nonfraction name="rcar:RecognizedExpenses" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,141,542</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80E_eus-gaap--LeasesOfLesseeDisclosureTextBlock_ztGftJsAUCEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 7. <span id="xdx_824_zM0CuV6GqkT3">Leases</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the Company entered into a two-year
lease for office premises located at 4 Becker Farm Road, Suite 105, Roseland, New Jersey. Monthly base rent in year one of the lease is
$<span id="xdx_900_ecustom--BaseRentForFirstYear_c20210101__20211231_pp0p0" title="Base rent for First year"><span><ix:nonfraction name="rcar:BaseRentForFirstYear" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,356</ix:nonfraction></span></span>; and $<span id="xdx_908_ecustom--BaseRentForSecondYear_c20210101__20211231_pp0p0" title="Base rent for Second year"><span><ix:nonfraction name="rcar:BaseRentForSecondYear" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,459</ix:nonfraction></span></span> in year <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20211231_zg1vT2NTMES4" title="Lease term"><span><ix:nonnumeric contextref="AsOf2021-12-31" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" inside-table="false" id="fact-identifier-369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonnumeric></span></span> of the lease. The term (and payment of the monthly rent) commenced upon completion of the landlords
work on August 1, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Companys existing Lease is not subject
to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of&nbsp;December 31, 2021,&nbsp;the Company
has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional
obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company does not have any finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div id="xdx_238_zqFv5TfS6hui" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td id="xdx_23A_ze8J4kUlOpUe" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23B_zAa7UgVAlLtg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><p id="xdx_235_zQMhpYz5jb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental lease information:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z3RJI4ovloSb" summary="xdx: Disclosure - Leases (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8B3_zV11BHhzY4yg" style="display: none">Schedule of supplemental lease information</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49A_20211231_ztQmEW8hn8xh" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49C_20201231_zwsWYUyuQ152" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">As of December 31, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Operating lease right-of-use asset</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,630</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79,462</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current maturities of operating lease</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,497</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,125</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zSQib8jFLOZf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Non-current operating lease</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextref="AsOf2021-12-31" id="fact-identifier-375" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0693" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,607</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zvm14CIUoFE9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.25pt">Total operating lease liabilities</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiability" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,497</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiability" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79,732</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Cash paid for amount included in the measurement of lease liabilities for operating lease</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeasePaymentsUse_c20210101__20211231_pp0p0" title="Cash paid for amount included in the measurement of lease liabilities for operating lease" style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasePaymentsUse" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,789</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePaymentsUse_pp0p0_c20200101__20201231_z3ttHuGe6T7j" title="Cash paid for amount included in the measurement of lease liabilities for operating lease" style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasePaymentsUse" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,134</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Weighted Average remaining lease term (in years):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zJeF46ANvEKl" title="Remaining term (years)"><span><ix:nonnumeric contextref="AsOf2021-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" inside-table="true" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.58</ix:nonnumeric></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zHM5KjcQ2Vbj" title="Remaining term (years)"><span><ix:nonnumeric contextref="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.6</ix:nonnumeric></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Discount rate:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_z9bTwyeCmDpf" title="Discount rate"><span><ix:nonfraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20201231_zgt0a0eYqSG8" title="Discount rate"><span><ix:nonfraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Right-of-use asset obtained in exchange for lease obligation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20200101__20201231_zEOG7MGPzNqc" title="Right-of-use asset obtained in exchange for lease obligation" style="text-align: right"><span><ix:nonfraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98,402</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AB_zFL6d80zpQSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases office space under a non-cancellable
operating lease expiring in 2022. Future lease payments included in the measurement of lease liabilities on the balance sheet at December
31, 2021 for future periods are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z8FPeDYLF4aj" summary="xdx: Disclosure - Leases (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B5_zUugG0DqKyVi" style="display: none">Schedule of future lease payments</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49B_20211231_zSQanEXVSY91" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0_maOLFMPz2Fc_zEIATEKQRBIf" style="vertical-align: bottom; background-color: white">
    <td style="width: 85%; text-align: left; padding-bottom: 1pt">2022</td><td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,213</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_pp0p0_mtOLFMPz2Fc_zM2pF00kxoBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,213</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_ecustom--ImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="rcar:ImputedInterest" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">716</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiability" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,497</ix:nonfraction></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A2_zQa97CEqQBzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zEVgB4t41P1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 8. <span id="xdx_82F_zsziSm1vsJ9j">Commitments and Contingencies</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>R&amp;D Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Companys anticipated
regulatory filings, the Company has engaged StemCell Systems GmbH (<b>StemCell Systems</b>) to provide it with prototypes
and related documents under various agreements. On July 1, 2020, the Company and StemCell Systems entered into a Strategic R&amp;D Agreement
(the <b>Strategic Agreement</b>) having an initial term of three years with successive one-year extensions unless earlier
terminated. The Strategic Agreement includes a $<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentTransfersAndChanges_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--CharitableGiftAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfPittsburghMember_zNjOYLjCGXp5" title="Donation"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" contextref="From2021-01-012021-12-31_custom_CharitableGiftAgreementMember_custom_UniversityOfPittsburghMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,000</ix:nonfraction></span></span> monthly fee to be paid to StemCell Systems along with any additional expenses incurred.
The Company, StemCell Systems and certain affiliates of StemCell Systems entered into a Rights of First Refusal and Corporate Opportunities
Agreement (the <b>ROFR Agreement</b>). Pursuant to the ROFR Agreement, (i) in the event a StemCell Systems stockholder receives
an offer from a third party to acquire the StemCell Systems stockholders ownership interest, the Company shall have ten business days
to purchase such ownership, and (ii) if during the terms of the Strategic Agreement, any StemCell Systems inventions, with respect to
skin, burns and wounds, designs, inventions and among other things, whether or not patentable, copyrightable or otherwise legally protectable
are discovered by StemCell Systems, the Company shall have the first option to negotiate mutually agreeable terms for the Companys
acquisition or licensing of the StemCell Systems inventions. Pursuant to these engagements the Company incurred expenses of approximately
$<span id="xdx_90B_eus-gaap--CostsAndExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StemCellSystemsMember_pp0p0" title="Incurred expenses"><span><ix:nonfraction name="us-gaap:CostsAndExpenses" contextref="From2021-01-012021-12-31_custom_StemCellSystemsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">523,840</ix:nonfraction></span></span> and $<span id="xdx_909_eus-gaap--CostsAndExpenses_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StemCellSystemsMember_pp0p0" title="Incurred expenses"><span><ix:nonfraction name="us-gaap:CostsAndExpenses" contextref="From2020-01-012020-12-31_custom_StemCellSystemsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">480,000</ix:nonfraction></span></span> during the years ended December 31, 2021 and 2020, respectively. Pursuant to the Strategic Agreement, as of December,
31, 2021, should the Company terminate the Strategic Agreement, the Company would be obligated to pay approximately $468,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><b><i>SEC Civil Complaint </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify">On May 28, 2021 the SEC filed a civil
complaint (the <b>SEC Complaint</b>), in the United States District Court for the Southern District of New York, naming
the Company and Harmel S. Rayat, the Companys current President, Chief Executive Officer, Chief Financial Officer and Sole Director
as defendants as defendants (the <b>Defendants</b>). The SEC Complaint alleges among other things that Mr. Rayat and the
Company with violated the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and
also alleges that Mr. Rayat with aided and abetted the Company's violations of those provisions. The SEC Complaint also alleges that the
Company with violated the reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks, among
other relief, permanent injunctions and civil penalties against the Defendants, and officer-and-director and penny stock bars against
Mr. Rayat. On August 31, 2021 the Defendants filed an answer to the Complaint. On September 21, 2021, the SEC filed a motion to strike
Defendants equitable affirmative defenses which motion was granted by the court on October 18, 2021. The Company continues to defend itself
and the named individuals against the allegations set forth in the SEC Complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div id="xdx_23A_zFEDadnqycVf" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td id="xdx_234_zfNE4j7bIGl3" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_235_zKyo6maY4Cw3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify"></p>

<ix:exclude><p id="xdx_238_zdoniyuvsR9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Class Action Complaints</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, Gabrielle A. Boller filed a
class action lawsuit in the U.S. District Court for the District of New Jersey (the <b>Boller Lawsuit</b>), against the
Company and certain past and current officers and members of the Companys board of directors (collectively, the <b>Boller
Defendants</b>). The Boller Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying
the allegations in the SEC Complaint, the Boller Defendants engaged in fraudulent conduct and made false and misleading statements of
material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination
that the Boller Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs
and expenses incurred in the Boller Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes the plaintiffs claims
in the Boller Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Boller
Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among
other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss
that may result from these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2021, Michael Solakian, filed a class
action lawsuit in the U.S. District Court for the District of New Jersey (the <b>Solakian Lawsuit</b>), against the Company
and certain past and current officers and members of the Companys board of directors (collectively, the <b>Solakian Defendants</b>).
The Solakian Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying the allegations in the
SEC Complaint, the Solakian Defendants engaged in fraudulent conduct and made false and misleading statements of material fact or omitted
to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination that the Solakian Lawsuit
is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs and expenses incurred
in the Solakian Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes the plaintiffs claims
in the Solakian Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Solakian
Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among
other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss
that may result from these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><b><i>Shareholder Derivative Complaints</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2021, Melvin Emberland (Emberland),
derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the <b>Emberland Lawsuit</b>) in the United
States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the
<b>Emberland Defendants</b>). In the complaint, Emberlands allegations, relating to the facts and circumstances underlying
the allegations in the SEC Complaint include, but are not limited to (i) breach of fiduciary duties by the individual Emberland Defendants,
(ii) unjust enrichment and (iii) violation of Section 10(b) and 21D of the Securities Exchange Act of 1934. Emberland did not quantify
any alleged damages in his complaint but, in addition to attorneys fees and costs, Emberland seeks (i) a declaration that the Emberland
Defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company, (ii) a determination awarding to
the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation
obtained by the Emberland Defendants, (iii) a directive to the Company and the Emberland Defendants to take all necessary actions to reform
and improve the Companys corporate governance and internal procedures to comply with applicable laws, and (iv) Plaintiff is seeking,
among other things, restitution from the individual Emberland Defendants and disgorgement of profits, benefits and other compensation
obtained by such Emberland Defendants, costs and disbursements of the action including reasonable attorneys fees, accountants
and expert fees and expenses, an order directing the taking of certain corporate actions relating to its board of directors and corporate
governance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div id="xdx_236_zb6gkJpMieQ" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td id="xdx_237_zm8DHLGdagZi" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_z0reYGI4dttd" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><p id="xdx_230_zpiTRaFi8nP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes Emberlands claims
and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Emberland Defendants. Given
the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class
certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from
these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2022, Zoser Vargas (<b>Vargas</b>),
derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the <b>Vargas Lawsuit</b>) in the United
States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the
<b>Vargas Defendants</b>). In the complaint Vargas allegations relating to the facts and circumstances underlying
the allegations in the SEC Complaint include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii)
violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys
fees and costs, Meyer seeks, in addition to other things, (i) against the Vargas Defendants and in favor of the Company the amount of
damages sustained by the Company as a result of the Vargas Defendants breaches of fiduciary duties, waste of corporate assets and
unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal procedures
to comply with applicable law and (iii) awarding to the Company restitution from the Vargas Defendants, and each of them, and ordering
disgorgement of all profits, benefits and other compensation obtained by the Vargas Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes Vargas claims and
intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Vargas Defendants. Given the uncertainty
of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification
and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, Aviva Meyer (<b>Meyer</b>),
derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the <b>Meyer Lawsuit</b>) in the United
States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the
<b>Meyer Defendants</b>). In the complaint Meyers allegations relating to the facts and circumstances underlying
the allegations in the SEC Complaint include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii)
violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys
fees and costs, Meyer seeks, in addition to other things, (i) against the <b>Vargas</b> Defendants and in favor of the Company the amount
of damages sustained by the Company as a result of the <b>Vargas</b> Defendants breaches of fiduciary duties, waste of corporate
assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal
procedures to comply with applicable law and (iii) awarding to the Company restitution from the Meyer Defendants, and each of them, and
ordering disgorgement of all profits, benefits and other compensation obtained by the Meyer Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes Meyers claims and
intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Meyer Defendants Given the uncertainty
of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification
and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify">The Company believes that the claims
asserted in the SEC Complaint, the Boller Lawsuit, the Solakian Lawsuit, the Emberland Lawsuit, the Vargas Lawsuit, and the Meyer Lawsuit
(collectively, the <b>Lawsuits</b>) are without merit and intends to defend itself vigorously. As of the date of this Annual
Report, the Company has effectively depleted the funds available under its D&amp;O Policy and is responsible for costs related to its
defense. See Note 1. Organization and Liquidity above for specific estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zhNjW8YOcID7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 9. <span id="xdx_82C_zNZQ10KtFDd6">Related Party Transactions</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, Talia
Jevan Properties, Inc. made payments totaling $<span id="xdx_909_eus-gaap--RelatedPartyCosts_pp0p0_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StephenYanKlessonMember_zfgoGzVgrcp" title="Related Party expenses"><span><ix:nonfraction name="us-gaap:RelatedPartyCosts" contextref="From2020-01-012020-12-31_custom_StephenYanKlessonMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,811</ix:nonfraction></span></span> to Stephen Yan-Klassen, former CFO who resigned in 2020, for his salary on behalf
of the Company. Talia Jevan Properties, Inc. is a related party of Harmel S. Rayat, Chairman of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div id="xdx_23A_zRTj1vbWZs6g" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td id="xdx_23F_zLsd4RX7OQfl" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zXU5xuG9JZdl" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zQ5Q5za8wkjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kalen Capital Corporation (KCC), a corporation wholly
owned by Mr. Rayat, on April 1, 2020, provided a short-term advance of $<span id="xdx_90F_eus-gaap--OtherShortTermBorrowings_c20200402__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalCorpMember_pp0p0" title="Short-term advance"><span><ix:nonfraction name="us-gaap:OtherShortTermBorrowings" contextref="AsOf2020-04-02_custom_KalenCapitalCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span> to the Company. The advance was repaid by the Company in
July 2020. The Company paid KCC $<span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20201001__20201031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalCorpMember_pp0p0" title="Payment to related party"><span><ix:nonfraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextref="From2020-10-012020-10-31_custom_KalenCapitalCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,156</ix:nonfraction></span></span> for reimbursable expenses in October 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2013, the Company entered into a
consulting agreement, as amended on May 1, 2016, with Jatinder Bhogal, an individual owning in excess of 5% of the Companys issued
and outstanding shares of common stock, to provide consulting services to the Company through his wholly owned company, Vector Asset Management,
Inc. (<b>VAMI</b>). Pursuant to the consulting agreement, VAMI assisted the Company with identifying subject matter experts
in the medical device and biotechnology industries and assisted the Company with its ongoing research and development. Pursuant to an
amendment dated May 1, 2016, the VAMI monthly consulting fee was increased from $5,000 to $6,800. On June 22, 2018, the Company and VAM
entered into an Executive Consulting Agreement (the <b>ECA</b>) pursuant to which Mr. Bhogal served as the Companys
Chief Operating Officer. The ECA superseded the prior consulting agreement. Pursuant to the ECA, VAMI received compensation of $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20180601__20180622__us-gaap--RelatedPartyTransactionAxis__custom--VectorAssetManagementIncMember_pp0p0" title="Compensation"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2018-06-012018-06-22_custom_VectorAssetManagementIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">120,000</ix:nonfraction></span></span>
per year. On July 1, 2020 the <span id="xdx_909_ecustom--PaymentOfCompensationDescription_c20180601__20180622__us-gaap--RelatedPartyTransactionAxis__custom--VectorAssetManagementIncMember" title="Payment Of Compensation Description"><span><ix:nonnumeric contextref="From2018-06-012018-06-22_custom_VectorAssetManagementIncMember" name="rcar:PaymentOfCompensationDescription" inside-table="false" id="fact-identifier-400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter
until May 31, 2021 at which time the ECA as amended expired.</ix:nonnumeric></span> </span>For consulting services provided by VAMI, during the years ended December
31, 2021 and 2020, the Company recognized expenses of $<span id="xdx_907_eus-gaap--CostsAndExpensesRelatedParty_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--VectorAssetManagementIncMember_pp0p0" title="Costs and Expenses, Related Party"><span><ix:nonfraction name="us-gaap:CostsAndExpensesRelatedParty" contextref="From2021-01-012021-12-31_custom_VectorAssetManagementIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000</ix:nonfraction></span> </span>and $<span id="xdx_905_eus-gaap--CostsAndExpensesRelatedParty_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--VectorAssetManagementIncMember_pp0p0" title="Costs and Expenses, Related Party"><span><ix:nonfraction name="us-gaap:CostsAndExpensesRelatedParty" contextref="From2020-01-012020-12-31_custom_VectorAssetManagementIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84,000</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_z6dOO15flfo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b><span style="text-decoration: underline">Note 10. <span id="xdx_82C_z99NcMwe7hN7">Income Taxes</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Income taxes
are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the Company's financial statements or tax returns. A valuation allowance
is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized.&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">There is
no current or deferred tax expense for 2021 and 2020, due to the Companys loss position. Realization of the future tax benefits
related to the deferred tax assets is dependent on many factors, including the Companys ability to generate taxable income within
the net operating loss carryforward period. Management has considered these factors in reaching its conclusion as to the valuation allowance
for financial reporting purposes and has recorded a full valuation allowance against the deferred tax asset. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The income
tax effect of temporary differences comprising the deferred tax assets and deferred tax liabilities is a result of the following at December
31:</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zysx4ysLNjig" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8BE_zT0RuyePl6Lb" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_499_20211231_z2kMsMrrdRvl" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_491_20201231_zEdv7MYd42i" style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets (liability):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzzoF_z3YPYr3gb5E4" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: justify">Net operating loss carryforwards</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,645,000</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,677,000</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetPropertyPlantAndEquipment_i01I_pp0p0_maDTAGzzoF_zrzIsXW9DDyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fixed asset</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="rcar:DeferredTaxAssetPropertyPlantAndEquipment" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="rcar:DeferredTaxAssetPropertyPlantAndEquipment" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0p0_maDTAGzzoF_zkpcR5o4Cwo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Intangible asset</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pp0p0_maDTAGzzoF_zDome9BGw4bj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Charitable contributions</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_pp0p0_maDTAGzzoF_zFrWEIoV2vtg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Stock-based compensation</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">772,000</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">696,000</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01I_pp0p0_mtDTAGzzoF_maDTANzS5R_zIMeLWiOwUj3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); text-align: justify">Deferred tax assets gross</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,446,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,411,000</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzS5R_zq9WSqAnQTm7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,446,000</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,411,000</ix:nonfraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01I_pp0p0_mtDTANzS5R_zaJTTlAaYJL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.25pt">Net deferred tax assets</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-12-31" id="fact-identifier-419" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0778" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2020-12-31" id="fact-identifier-420" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0779" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A8_zjDia3WzPQTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2021 increase in the valuation allowance was
$<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_pp0p0" title="Increase in the valuation allowance"><span><ix:nonfraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,035,000</ix:nonfraction></span></span> compared to an increase of $<span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_pp0p0" title="Increase in the valuation allowance"><span><ix:nonfraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,339,000</ix:nonfraction></span></span> in 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has available net operating loss carryforwards of approximately $</span><span id="xdx_905_eus-gaap--OperatingLossCarryforwards_c20211231_pp0p0" title="Net operating loss and contribution carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,945,000</ix:nonfraction></span></span> <span style="background-color: white">for tax purposes
to offset future taxable income which $9,613,000 was incurred prior to <span id="xdx_906_ecustom--CapitalLossCarryforwardExpirationPeriod_c20210101__20211231" title="Capital loss carryforward expiration period"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="rcar:CapitalLossCarryforwardExpirationPeriod" inside-table="false" id="fact-identifier-424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2018 and expires through the year 2037</ix:nonnumeric></span></span> while $</span><span id="xdx_90F_ecustom--NetOperatingLossAndContributionCarryforwardsExpiry_c20210101__20211231" title="Net operating loss and contribution carryforwards expiry"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="rcar:NetOperatingLossAndContributionCarryforwardsExpiry" inside-table="false" id="fact-identifier-425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12,331,000 incurred subsequent do not expire.</ix:nonnumeric></span></span> <span id="xdx_902_eus-gaap--TaxCreditCarryforwardDescription_c20210101__20211231" title="Tax Reform description"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="us-gaap:TaxCreditCarryforwardDescription" inside-table="false" id="fact-identifier-426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Pursuant to the Tax Reform Act of 1986, annual utilization of
the Companys net operating loss and contribution carryforwards may be limited if a cumulative change in ownership of more than
50% is deemed to occur within any three-year period. The tax years 2018 through 2021 remain open to examination by federal agencies and
other jurisdictions in which it operates.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div id="xdx_235_zw9tsqiFj6x7" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_239_zCx4arMTKHaf" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td id="xdx_230_z2TcIx2vy26e" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23E_zmKGbovFKH18" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zkeDYSa9qAjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">A reconciliation
between the statutory federal income tax rate and the effective rate of income tax expense for the years ended December 31 follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zwlozaVe4JU6" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8B9_zu9icmIXw6Mb" style="display: none">Schedule of statutory federal income tax expense</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Statutory federal income tax rate</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210101__20211231_z0mtZH3Obnfj" title="Statutory federal income tax rate"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">%</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20200101__20201231_zoVGrDZCC8d3" title="Statutory federal income tax rate"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21</ix:nonfraction></span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences and other</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_c20210101__20211231_zbwMbqNuRt3h" title="Permanent differences and other"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.38</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_c20200101__20201231_zpBuIhmrsaP" title="Permanent differences and other">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.91</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">NOL expirations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_905_ecustom--NolExpirations_dp_c20210101__20211231_zz8ks0sfsC1j" title="NOL expirations">(<span><ix:nonfraction name="rcar:NolExpirations" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.83</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_909_ecustom--NolExpirations_dp_c20200101__20201231_zXZvaBldWrGh" title="NOL expirations">(<span><ix:nonfraction name="rcar:NolExpirations" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.10</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">True-up</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--Trueup_dp_c20210101__20211231_zpZpJ3KjW73f" title="True-up"><span><ix:nonfraction name="rcar:Trueup" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.60</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--Trueup_dp_c20200101__20201231_zhoEP1qwH00a" title="True-up"><span><ix:nonfraction name="rcar:Trueup" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.03</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20210101__20211231_zOz1jd579Y9k" title="Valuation allowance">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23.15</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)%</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20200101__20201231_zR0VR9ylpf2a" title="Valuation allowance">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14.02</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20210101__20211231_z769VbBsG3je" title="Income tax provision (benefit)"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20200101__20201231_zQdZ9L9hJXdc" title="Income tax provision (benefit)"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-439" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A8_zws4wIpsPU02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zAbVylC7UbQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 11. <span id="xdx_824_z2FNPuMQl31a">Subsequent Events</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has reviewed material events subsequent
of the period ended December 31, 2021 and prior to the filing of financial statements in accordance with FASB ASC 855 Subsequent
Events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2022, the Company paid its legal
counsel, Spears &amp; Imes, a $<span id="xdx_909_eus-gaap--LegalFees_c20220201__20220215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpearsAndImesMember_zyxTGtKgQDUg" title="Legal Fees"><span><ix:nonfraction name="us-gaap:LegalFees" contextref="From2022-02-012022-02-15_us-gaap_SubsequentEventMember_custom_SpearsAndImesMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span></span> retainer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Companys President and Chief Executive Officer and Director,
Dr. Kaiyo Nedd and its Chief Financial Officer, Mr. Justin Frere resigned all their respective positions in the Company effective March
24, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: -0.35pt">On March 18,
2022, the Company issued an Unsecured Convertible Promissory Note (the <b>Note</b>) to KCC. Pursuant to the terms of the
Note, KCC agreed to loan the Company $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20220318__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalCorpMember_zommFztBpdbi" title="Loan"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2022-03-18_us-gaap_SubsequentEventMember_custom_KalenCapitalCorpMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">800,000</ix:nonfraction></span></span> at an annual interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220301__20220318__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalCorpMember_znRl37qJ9uIf" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2022-03-012022-03-18_us-gaap_SubsequentEventMember_custom_KalenCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span></span>% per year, compounded daily. The Note, including any interest
due thereon, may be prepaid at any time without penalty. The Note, and any balance thereunder, automatically converts into securities
of the Company upon receipt of an equity financing from third-party(s) of not less than ten million dollars ($10,000,000) at a conversion
price equal to 80% of the price paid in such a financing. Also, after June 23, 2023, KCC may convert all or any portion of the balance
into shares of common stock at a conversion price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220318__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRRxPVpIIXOa" title="Conversion price"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2022-03-18_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.45</ix:nonfraction></span></span> per share, representing a fifty 50% percent premium to the closing price of
the Companys common stock on March 17, 2022.</p>

</ix:nonnumeric></span><p id="xdx_81C_z1bdroqVeqRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt"><span style="text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt"><span style="text-transform: uppercase; background-color: white"><b><span id="a_013"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt"><span style="text-transform: uppercase; background-color: white"><b><span id="a_014"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Evaluation of Disclosure Controls
and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, under the
direction of our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures
(as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Exchange Act, as amended, as of December 31, 2021. The term disclosure
controls and procedures, as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Exchange Act, means controls and
other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECs
rules&nbsp;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that
information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated
to the Companys management, including its principal executive and principal financial officers, or persons performing similar functions,
as appropriate to allow timely decisions regarding required disclosure. The Companys disclosure controls and procedures are also
designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our evaluation, our
Interim Chief Executive Officer and Interim Chief Financial Officer have concluded that our disclosure controls and procedures were effective
as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Managements Report on Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the responsibility of
the management of RenovaCare to establish and maintain effective internal control over financial reporting (as defined in Rule&nbsp;13a-15(f)&nbsp;under
the Exchange Act). Internal control over financial reporting is designed to provide reasonable assurance to RenovaCares management
and board of directors regarding the preparation of reliable financial statements for external purposes in accordance with generally accepted
accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RenovaCares internal
control over financial reporting includes those policies and procedures that: (i)&nbsp;pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of RenovaCare; (ii)&nbsp;provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of RenovaCare are being made only in accordance with authorizations of management
and directors of RenovaCare; and (iii)&nbsp;provide reasonable assurance regarding the prevention or timely detection of unauthorized
acquisition, use or disposition of RenovaCares assets that could have a material effect on the financial statements of RenovaCare.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective
can provide only reasonable assurance with respect to financial statement preparation and presentation. Management has performed an assessment
of the effectiveness of RenovaCares internal control over financial reporting as of December 31, 2021, based upon criteria set
forth in Internal Control&nbsp;- Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013
COSO Framework).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on this assessment,
management has concluded that our internal control over financial reporting were effective as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in Internal Control Over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of our fiscal year ended
December 31, 2021 and based on the COSO criteria, management identified control deficiencies that constituted material weaknesses. A material
weakness, as defined by COSO, is a deficiency, or combination of deficiencies, in internal control over financial reporting, such
that there is more than a reasonable possibility that a material misstatement of the Companys annual or interim financial statements
will not be prevented or detected on a timely basis. Management identified the following material weaknesses in our internal control over
financial reporting as of December 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr>
    <td style="width: 0.5in; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; width: 0.5in; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Inadequate segregation of duties;</span></td></tr>
  <tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
  <tr>
    <td style="text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Ineffective monitoring controls related to the financial close and reporting process, including managements risk assessment process and its identification, evaluation, and timely remediation of control deficiencies.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company began implementing
new and more robust internal controls during 2021 to remediate the material weaknesses in our internal controls over financial reporting
identified above. The Companys internal control implementation and remediation efforts included the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in"><span style="font-family: Symbol"></span></td><td style="text-align: justify">Since July 2021, we have been performing more extensive and frequent reviews of critical estimates, journal
entries, complex calculations, the financial close and financial reporting processes on a regular basis;</td></tr></tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in"><span style="font-family: Symbol"></span></td><td style="text-align: justify">We have implemented formal policies and procedures over various operating activities designed to address
the underlying causes associated with the aforementioned material weaknesses; and</td></tr></tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in"><span style="font-family: Symbol"></span></td><td style="text-align: justify">Regular informal and formal meetings of Board members who also have been incorporated into the review
process of all financial statement filings.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to monitor our
control environment and will implement additional controls and processes utilizing internal resources, and outside resources (when deemed
necessary) to strengthen our controls over the financial reporting and disclosure process as applicable in order to meet the needs of
our organization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form&nbsp;10-K
does not include an attestation report by PKF OConnor Davies LLP ("PKF"), our independent registered public accounting
firm, regarding internal control over financial reporting. As a smaller reporting company, our internal control over financial reporting
was not subject to audit by our independent registered public accounting firm pursuant to rules&nbsp;of the Securities and Exchange Commission
that permit us to provide only managements report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_015"></span>Item 9B. Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.35pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.35pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_016"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt"><span style="text-transform: uppercase"><b><span id="a_017"></span>ITEM 10. DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors and Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table and text
set forth the names and ages of all of the persons serving as our principal executive officer, principal financial officer, directors
and executive officers, as of the date of this report. All of the directors will serve until the next annual meeting of stockholders and
until their successors are elected and qualified, or until their earlier death, retirement, resignation or removal. Executive officers,
subject in each case to the terms and conditions of their respective employment or consulting agreements, serve at the discretion of the
Board, and are appointed to serve by the Board.&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: bottom">
    <td style="border: Black 1pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="border: Black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border: Black 1pt solid; width: 5%; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="border: Black 1pt solid; white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="border: Black 1pt solid; width: 49%; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td>
    <td style="border: Black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border: Black 1pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Director / Officer Since</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border: Black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Harmel S. Rayat</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></td>
    <td style="border: Black 1pt solid">&nbsp;</td>
    <td style="border: Black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">60</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p></td>
    <td style="border: Black 1pt solid; white-space: nowrap">&nbsp;</td>
    <td style="border: Black 1pt solid"><span style="font-size: 10pt">Director and Chairman of the Board, Interim President, Chief Executive Officer, Interim Chief Financial Officer and Secretary</span></td>
    <td style="border: Black 1pt solid">&nbsp;</td>
    <td style="border: Black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 16, 2021</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border: Black 1pt solid"><span style="font-size: 10pt">Dr. Robin A. Robinson</span></td>
    <td style="border: Black 1pt solid">&nbsp;</td>
    <td style="border: Black 1pt solid; text-align: center"><span style="font-size: 10pt">66</span></td>
    <td style="border: Black 1pt solid; white-space: nowrap">&nbsp;</td>
    <td style="border: Black 1pt solid"><span style="font-size: 10pt">Chief Scientific Officer</span></td>
    <td style="border: Black 1pt solid">&nbsp;</td>
    <td style="border: Black 1pt solid"><span style="font-size: 10pt">May 26, 2020</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Harmel S. Rayat. </b>Mr.
Rayat was appointed to the Board of Directors on March 16, 2021 and was appointed Chairman of the Board on March 26, 2021. Mr Rayat previously
served the Company in a number of capacities, including, at various times, as its President and Chief Executive Officer, Chairman and
as a member of the Companys Board of Directors. Mr. Rayat has been a long-time majority stockholder and financial supporter of
RenovaCare. Through his family office, Kalen Capital Corporation, he has invested over $20 million RenovaCare since 2013. Mr Rayats
support was key to advancing the SkinGun<sup>TM </sup>spray device and CellMist System<sup>TM </sup>from an unpatented technology with
little published data to a technology platform with eight patent families, numerous peer reviewed articles and FDA approval of its Investigational
Device Exemption application to conduct a clinical trial to evaluate safety and feasibility. Beginning his career in the financial industry
as a messenger and mail-room clerk in a stock brokerage in 1981, Mr. Rayat has since invested in a wide range of businesses and sectors,
ranging from auto wreckers and alternative energy to raw land and artificial livers. In recent years, and in addition to commercial real
estate in Canada and the United States, Mr. Rayat has narrowed his focus to impact investing, despite the high risks associated with early
stage, pre-revenue, and pre-clinical companies. His goal is to help inventors, entrepreneurs, and scientists to create and commercialize
products and technologies that will have a beneficial impact on society at large.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dr. Robin A. Robinson</b>.
From 2008 to 2016, Dr. Robinson was the founding Director of the Biomedical Advanced Research and Development Authority at the U.S. Department
of Health and Human Services (HHS). From May 2016 to the present, Dr. Robinson has provided consultation services to multiple multi-national
and U.S.-based vaccine, pharmaceutical, venture capital, and scientific consulting companies. Dr Robinson is on the board of multiple
vaccine and antiviral drug companies. He has served as head of HHS pandemic influenza program from 2004-2008 and as Director of Vaccines
at Novavax, Inc from 1995  2004.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between or among the directors, executive officers (or persons nominated or charged by our company to become directors or executive officers)
non-executive officers, significant employees and consultants.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consideration of Director Nominees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Qualifications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt">We believe that
our Board, to the extent that our limited resources permit, should encompass a diverse range of talent, skill and expertise sufficient
to provide sound and prudent guidance with respect to our operations and interests. Each director also is expected to: exhibit high standards
of integrity, commitment and independence of thought and judgment; use his or her skills and experiences to provide independent oversight
to our business; participate in a constructive and collegial manner; be willing to devote sufficient time to carrying out their duties
and responsibilities effectively; devote the time and effort necessary to learn our business; and, represent the long-term interests of
all stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">The Board has determined
that the Board as a whole must have the right diversity, mix of characteristics and skills for the optimal functioning of the Board in
its oversight of our affairs. The Board believes it should be generally comprised of persons with skills in areas such as: medicine (including
dermatology; wound treatment); medical device technologies; finance; banking; strategic planning; human resources and diversity; leadership
of business organizations; and legal matters. The Board may also consider in its assessment of the Boards diversity, in its broadest
sense, reflecting, but not limited to, age, geography, gender and ethnicity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">In addition to
the targeted skill areas, the Board looks for a strong record of achievement in key knowledge areas that it believes are critical for
directors to add value to the Board, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: right"></td>
    <td style="width: 0.5in"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Strategy</b>knowledge of our business model, the formulation of corporate strategies, knowledge of key competitors and markets;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.6pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: right"></td>
    <td style="width: 0.5in"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Leadership</b>skills in coaching and working with senior executives and the ability to assist the Chief Executive Officer;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: right"></td>
    <td style="width: 0.5in"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Organizational Issues</b>understanding of strategy implementation, change management processes, group effectiveness and organizational design;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.6pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: right"></td>
    <td style="width: 0.5in"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Relationships</b>understanding how to interact with investors, accountants, attorneys, management companies, analysts, and communities in which we operate;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.6pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: right"></td>
    <td style="width: 0.5in"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Functional</b>understanding of finance matters, financial statements and auditing procedures, technical expertise, legal issues, information technology and marketing; and</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.6pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: right"></td>
    <td style="width: 0.5in"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Ethics</b>the ability to identify and raise key ethical issues concerning our activities and those of senior management as they affect the business community and society.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board of Directors Meetings, Committees of the Board of Directors,
and Annual Meeting Attendance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have any
standing committees of the Board. The full Board is responsible for performing the functions of: (i) the Audit Committee, (ii) the Compensation
Committee and (iii) the Nominating Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide that the
number of Directors shall be fixed from time to time by the Board, but in no event shall be less than the minimum required by law. The
Board should be sufficiently large to maintain our required expertise but not too large so as not to function efficiently. Director nominees
are recommended, reviewed and approved by the entire Board. The Board believes that this process is appropriate due to the relatively
small number of directors on the Board and the opportunity to benefit from a variety of opinions and perspectives in determining director
nominees by involving the full Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Board is solely
responsible for the selection and nomination of directors, the Board may consider nominees recommended by stockholders as it deems appropriate.
The Board evaluates each potential nominee in the same manner regardless of the source of the potential nominee's recommendation. Although
we do not have a policy regarding diversity, the Board does take into consideration the value of diversity among Board members in background,
experience, education and perspective in considering potential nominees for recommendation to the Board for selection. Stockholders who
wish to recommend a nominee should send nominations to our President and Chief Executive Officer, 9375 E Shea Blvd., Suite 107-A, Scottsdale,
AZ 85260, and include all information relating to such person that is required to be disclosed in solicitations of proxies for the election
of directors. The recommendation must be accompanied by a written consent of the individual to stand for election if nominated by the
Board and to serve if elected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors and Officers Liability Insurance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not currently maintain directors and
officers liability insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None of or directors or officers is involved in
any legal proceedings as described in Regulation S-K (229.401(f)).&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compliance with Section 16(a) of the Exchange Act</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we do not have a class
of equity securities registered pursuant to section 12 of the Exchange Act we are not required to make the disclosures required by Item
405 of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Code of
Ethics that applies to all our officers, directors and employees, including our Chief Executive Officer and Chief Financial Officer, which
complies with the requirements of the Sarbanes-Oxley Act of 2002 and applicable FINRA listing standards. Accordingly, the Code of Ethics
is designed to deter wrongdoing, and to promote, among other things, honest and ethical conduct, full, timely, accurate and clear public
disclosures, compliance with all applicable laws, rules and regulations, the prompt internal reporting of violations of the Code of Ethics,
and accountability. Our Code of Ethics is available on our website at http://www.renovacareinc.com. To access our Code of Ethics, click
on Investors, and then click on Corporate Governance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our Code of Ethics
may be obtained at no charge by sending a written request to our President and Chief Executive Officer, 9375 E Shea Blvd., Suite 107-A,
Scottsdale, AZ 85260.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted Corporate
Governance Principles applicable to our Board. Our Corporate Governance Principles are available on our website at http://www.renovacareinc.com.
To access our Corporate Governance Principles, click on Investors, and then click on Corporate Governance.<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Leadership Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have three
executive officers and two directors. Our Board has reviewed our current Board leadership structure in light of the composition of the
Board, our size, the nature of our business, the regulatory framework under which we operate, our stockholder base, our peer group and
other relevant factors, and has determined that this structure is currently the most appropriate Board leadership structure for our company.
Nevertheless, the Board intends to carefully evaluate from time to time to determine what the Board believes is best for us and our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<b>Board Role in Risk Oversight</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Risk is inherent in every
business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including strategic risks,
enterprise risks, financial risks, and regulatory risks. While our management is responsible for day-to-day management of various risks
we face, the Board, as a whole, is responsible for evaluating our exposure to risk and to satisfy itself that the risk management processes
designed and implemented by management are adequate and functioning as designed. The Board reviews and discusses policies with respect
to risk assessment and risk management. The Board also has oversight responsibility with respect to the integrity of our financial reporting
process and systems of internal control regarding finance and accounting, as well as its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our securities are not listed
on a U.S. securities exchange and, therefore, are not subject to the corporate governance requirements of any such exchange, including
those related to the independence of directors. Upon our listing on any national securities exchange or any inter-dealer quotation system,
we will elect such independent directors as is necessary under the rules of any such securities exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><span style="text-transform: uppercase"><b><span id="a_018"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are eligible, and have
chosen, to comply with the executive and director compensation disclosure rules applicable to a smaller reporting company,
as defined in applicable Securities and Exchange Commission rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information concerning the compensation paid for 2021 and 2020 to our named executive officers as of December 31, 2021, who consisted
of our Chief Executive Officer and our next two highly compensated executive officers during 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border: black 1pt solid; width: 20%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name and principal</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>position</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Salary/</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>consulting fee</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Bonus</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Stock</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>awards</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Option</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>awards</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)(1)</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 13%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>All other</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>compensation</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)(2)</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Kaiyo Nedd</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Former President and CEO <sup>(3)</sup></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">122,500</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">122,500</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Justin Frere, CPA</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Former CFO and Secretary <sup>(3)</sup></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">90,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">66,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">156,000</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Alan L. Rubino Former President and CEO</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">410,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">205,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,495,576</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">30,968</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">2,141,544</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td rowspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jatinder Bhogal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Former COO</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><b>-</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><b>-</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><b>-</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,000</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">84,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><b>-</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><b>-</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">930,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><b>-</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">1,014,000</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td rowspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robin Robinson</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Scientific Officer</p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">220,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">220,000</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">178,333</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">39,310</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-&nbsp;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">214,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">-&nbsp;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right">&nbsp;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">431,643</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Reflects the aggregate grant date fair value
of common stock option awards determined in accordance with Financial Accounting Standards Board Accounting Codification Topic 718, Compensation-
Stock Compensation. The amounts shown in this column are not necessarily indicative of the actual value that will be realized by the named
officers with respect to such awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) In 2020, Mr. Rubino received other compensation
in the form of Health and Welfare related insurance premiums of $18,968 and an auto allowance in the amount of $12,000. In 2019, Mr. Rubino
received other compensation in the amount of $1,500 in the form of an auto allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Effective March 24, 2022, Dr. Nedd and Mr.
Frere resigned all their respective positions with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at December 31, 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding equity awards that have been awarded to each of the Named Executives and which remained outstanding as of December
31, 2021. All of the outstanding options were granted pursuant to our 2013 Long-Term Incentive Plan (the 2013 Plan) described
below and which was approved by our stockholders on November 15, 2013. No options were issued outside of the 2013 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top; background-color: #CCEEFF">
    <td colspan="5" style="border: black 1pt solid"><span style="font-size: 10pt"><b>Option Awards</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top; width: 20%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Name</b></p></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 25%"><span style="font-size: 10pt"><b>Number of securities underlying unexercised options exercisable</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%"><span style="font-size: 10pt"><b>Number of securities underlying unexercised options unexercisable</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 15%"><span style="font-size: 10pt"><b>Option Exercise Price ($)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 25%"><span style="font-size: 10pt"><b>Option Expiration Date</b></span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Justin Frere</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">25,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">1.72</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">July 26, 2031</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Justin Frere</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">25,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">1.72</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">July 26, 2031</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Jatinder Bhogal</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">1,000,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">1.40</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">May 22, 2026</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Robin Robinson</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">200,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">1.65</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">June 1, 2026</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Freres option awards vest and are exercisable as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in">&nbsp;</td>
    <td style="width: 0.5in"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td><span style="font-size: 10pt">25,000 vest, and are exercisable commencing on, July 26, 2021 at price of $1.72 per share (the closing price of the Companys common stock as quoted on the OTC Pink-Current on July 26, 2021 (the date of grant);</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in">&nbsp;</td>
    <td style="width: 0.5in"><span style="font-family: Symbol; font-size: 10pt"></span></td>
    <td><span style="font-size: 10pt">25,000 vest, and are exercisable commencing on, January 26, 2022 at price of $1.75 per share</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Long-Term Incentive Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">On June 20, 2013,
our Board adopted our 2013 Plan and on November 15, 2013, a stockholder owning a majority of our issued and outstanding stock approved
adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of our common stock are reserved
for issuance to our officers, directors, employees and consultants in order to attract and hire key technical personnel and management.
Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or
non-qualified stock options; options granted to others under the Incentive Plan are limited to non-qualified stock options. As of December
31, 2021, there were 16,618,266 shares available for grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">The 2013 Plan is
administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority
to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting
rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Companys
fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the
time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee
during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after
the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">The exercise price
per share of common stock for options granted under the 2013 Plan will be the fair market value of the Companys common stock on
the date of grant, using the closing price of the Companys common stock on the last trading day prior to the date of grant, except
for incentive stock options granted to a holder of ten percent or more of the Companys common stock, for whom the exercise price
per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0.7pt; text-align: justify; text-indent: 35.3pt">There are
no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers, except that
our directors and executive officers may receive stock options at the discretion of our Board. We do not have any material bonus or profit-sharing
plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options
may be granted at the discretion of our Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment and Consulting Contracts</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered into
the following employment and consulting agreements all of which reflect at will engagement of the named individuals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration: underline">Dr. Robin Robinson</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 26, 2020, the Company
entered into an employment agreement with Dr. Robinson (the <b>Robinson Employment Agreement</b>) pursuant to which Dr.
Robinson was appointed the Companys Vice President  Chief Scientific Officer. Dr. Robinson receives a base salary of $220,000
and is eligible to receive an annual target bonus equal up to 30% of his base salary, based on the achievement of Company performance
goals established by the Board or its Compensation Committee, if any. The Company also agreed to grant Dr. Robinson a total of 200,000
options with an exercise price of $1.65 per share and which became fully vested on June 1, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Robinson Employment Agreement
has a two (2) year term. However, the Robinson Employment Agreement, subject to its terms, may be terminated by the Company at any time
for or without cause, and by Mr. Robinson for good reason or no reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon termination of the Robinson
Employment Agreement by the Company for cause or Dr. Robinson for no reason, Dr. Robinson shall be entitled to receive: (i)&nbsp;his Base
Salary payable through the date of such termination; (ii)&nbsp;reimbursement for reasonable business expenses necessarily incurred by
him in the ordinary course of his duties and in accordance with the Companys policies; (iii)&nbsp;a prorated portion of the annual
bonus the Executive would have received but for his termination prior to the bonus payment date, which prorated portion shall be paid
on the bonus payment date; (iv)&nbsp;a prorated portion of benefits under any Company compensative or incentive plan that he would have
received but for his termination; and (v)&nbsp;provided his spouse timely elects to continue family health insurance benefits under the
federal law known as COBRA, the Company shall pay the cost of such health insurance coverage at the same rate the Company contributed
for family health insurance coverage prior to his termination of employment with the Company until the earlier of twelve (12)&nbsp;months
or the loss of COBRA entitlement (collectively (the <b>Accrued Benefits</b>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon termination of the Robinson
Employment Agreement by the Company without cause or Dr. Robinson for good reason, Dr. Robinson shall be entitled to receive, in addition
to the Accrued Benefits, and subject to delivery of a general release acceptable to the Company, his base salary in effect at termination,
for six (6)&nbsp;months, payable in accordance with the normal payroll practices of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that, following
a Change of Control (as defined below), Dr. Robinsons employment is terminated without cause later of (x) the first anniversary
of the Effective Date or (y) within six months of the Change of Control, then Dr. Robinson shall be entitled to receive (i)&nbsp;the Accrued
Rights; (ii)&nbsp;prorated bonus payment; (iii) prorated plan benefit; and (iv) subject to delivering to the Company the general release,&nbsp;his
Base Salary in effect at termination, for six (6)&nbsp;months, payable in accordance with the normal payroll practices of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As defined in the Robinson
Employment Agreement, <b>Change of Control</b> means (i)&nbsp;the acquisition by any individual, entity or group (within
the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the <b>Exchange Act</b>)),
other than any individual, entity or group which, as of the date of this Agreement, beneficially owns more than ten percent (10%)&nbsp;of
the then outstanding shares of common stock of the Company (the <b>Common Stock</b>), of beneficial ownership (within the
meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%)&nbsp;or more of the then outstanding Common Stock; <b><i><span style="text-decoration: underline">provided</span></i>,
<i><span style="text-decoration: underline">however</span></i></b>, that any acquisition by the Company or its subsidiaries, or any employee benefit plan (or related trust) of
the Company or its subsidiaries of fifty percent (50%)&nbsp;or more of outstanding Common Stock shall not constitute a Change of Control,
and <b><i><span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">further</span></i></b>, that any acquisition by an entity with respect to which, following such acquisition,
more than fifty percent (50%)&nbsp;of the then outstanding equity interests of such entity, is then beneficially owned, directly or indirectly,
by all or substantially all of the individuals and entities who were the beneficial owners of the outstanding Common Stock immediately
prior to such acquisition of the outstanding Common Stock, shall not constitute a Change in Control; or (ii)&nbsp;the consummation of
(A)&nbsp;a reorganization, merger or consolidation (any of the foregoing, a <b>Merger</b>), in each case, with respect to
which all or substantially all of the individuals and entities who were the beneficial owners of the outstanding Common Stock immediately
prior to such Merger do not, following such Merger, beneficially own, directly or indirectly, more than fifty percent (50%) of the then
outstanding shares of common stock of the corporation resulting from Merger, or (iii)&nbsp;the sale or other disposition of all or substantially
all of the assets of the Company, excluding (a)&nbsp;a sale or other disposition of assets to a subsidiary of the Company; and (b)&nbsp;a
sale or other disposition of assets to any individual, entity or group which, as of the date of this Agreement, beneficially owns more
than ten percent (10%)&nbsp;of the then outstanding Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span style="text-decoration: underline">Justin Frere</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 26, 2021, the Company
entered into an executive services consulting agreement with Mr. Frere (the <b>Frere ECA</b>) pursuant to which Mr. Frere
is to provide services generally associated with the office of the Chief Financial Officer, will receive a monthly fee of $10,000, a grant
of 50,000 options with an exercise price of $1.72 per share which vest as to 25,000 on the date of grant and 25,000 on January 26, 2022,
and have an indefinite term cancelable five (5) days after written notice by either party. Mr. Frere resigned all positions with the Company
effective March 24, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Change of Control Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no understandings
or agreements known by management at this time which would result in a change in control. In the event of the termination of employment
of the Named Executive Officers all unvested options expire as of the date of such termination; and, any and all vested and unexercised
stock options shall expire and no longer be exercisable after a specified time following the date of the termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board determines the non-employee
directors compensation for serving on the Board and its committees. In establishing director compensation, the Board is guided
by the following goals:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify">&nbsp;</td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt"><b></b></span></td>
    <td style="width: 93%; text-align: justify"><span style="font-size: 10pt">compensation should consist of a combination of cash and equity awards that are designed to fairly pay the directors for work required for a company of our size and scope;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">compensation should align the directors interests with the long-term interests of stockholders; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">compensation should assist with attracting and retaining qualified directors.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We reimburse our directors
for reasonable travel and other out-of-pocket expenses incurred in connection with attendance at meetings of our Board. We do not pay
director compensation to directors who are also employees. All non-employee directors are paid a directors fee. Our Board may award
special remuneration to any director undertaking any special services on our behalf other than services ordinarily required of a director.
Directors are entitled to participate in, and have been issued options under, our 2013 Long-Term Stock Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table reports
all compensation we paid to non-employee directors during the last two fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border: black 1pt solid; width: 26%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 8%">&nbsp;</td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fees earned or</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: center"><b>paid in cash&nbsp;<sup>(1)&nbsp;</sup>($)</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%; text-align: center"><span style="font-size: 10pt"><b>Option awards Aggregate Grant Date Fair Value ($)<sup>(2)</sup></b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 16%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>All Other</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Compensation ($)</b></p></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 16%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 2%">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td rowspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Harmel S. Rayat<sup>(3)</sup></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Dr. Kaiyo Nedd <sup>(4)</sup></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2021</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Lydia Evans<sup>(5)</sup></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">8,333</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">41,800</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">8,333</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Kenneth Kirkland<sup>(6)</sup></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2020</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">13,000</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify"><sup>(1)&nbsp;</sup>The amounts in
this column represent payments of directors fees.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(2)&nbsp;</sup>The amounts in this column
represent the total fair value assigned to options granted in 2020 to Dr. Evans.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(3)</sup>Mr. Rayat receives $1.00 per year
as compensation for his service to the Company. Mr. Rayat resigned as a director and Chairman of the Board effective October 1, 2020.
Mr. Rayat was reappointed to the Board as a director on March 16, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(4)&nbsp;</sup>Dr. Nedd served on the Board
of Directors from March 16, 2021 to March 24, 2022.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(5)&nbsp;</sup>Dr. Evans served on the Board
of Directors from August 1, 2020 until March 16, 2021.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<sup>(6) </sup>Kenneth Kirkland served on
the Board of Directors from August 2013 until March 16, 2021.</p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<span style="text-transform: uppercase"><b><span id="a_019"></span>ITEM 12. SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information as of the date of this report with respect to the beneficial ownership of the Companys common stock by its
executive officers, directors, all persons known by the Company to be the beneficial owners of more than 5% of its outstanding shares
and by all officers and directors as a group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="background-color: white">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 48%"><span style="font-size: 10pt"><b>Name and Address of Beneficial Owner&nbsp;</b><sup>(1)</sup></span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Number of shares Beneficially Owned&nbsp;</b><sup>(2)</sup></span></td>
    <td style="vertical-align: bottom; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 25%; text-align: center"><span style="font-size: 10pt"><b>% of Class Owned&nbsp;</b><sup>(2)</sup></span></td></tr>
  <tr style="background-color: white">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Directors and Officers</span></b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt">Harmel S. Rayat, Chairman <sup>(3)</sup></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">70,517,037</span></td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">71.88</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt">Dr. Robin Robinson, Chief Scientific Officer<sup>(5)</sup></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">200,000</span></td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">All Directors and Officers as a Group </span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">70,717,037</span></td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">71.94%</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt"><b><span style="text-decoration: underline">5% Shareholders</span></b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kalen Capital Corporation&nbsp;<sup>(3)</sup></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Kalen Capital Building</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">688 West Hastings St.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suite 700</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vancouver, BC V6B 1P1</p></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">70,517,037&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt">71.88&nbsp;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Jatinder S. Bhogal<sup>(4)</sup></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6,029,425</span></td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6.82</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* less than 1%</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(1) </sup>Beneficial ownership is determined
in accordance with SEC rules and generally includes voting or investment power with respect to securities. Each of the beneficial owners
listed above has direct ownership of and sole voting power and investment power with respect to the shares of our common stock and except
as indicated the address of each beneficial owner is 9375 E Shea Blvd Suite 107-A, Scottsdale, AZ 85260.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(2) </sup>Calculated pursuant to Rule 13d-3(d)
of the Exchange Act. Beneficial ownership is calculated based on 87,352,364 shares of common stock issued and outstanding on a fully diluted
basis as of March 28, 2022. Under Rule 13d-3(d) of the Exchange Act, shares not outstanding which are subject to options, warrants, rights
or conversion privileges exercisable within 60 days are deemed outstanding for the purpose of calculating the number and percentage owned
by such person, but are not deemed outstanding for the purpose of calculating the percentage owned by each other person listed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(3) </sup>Harmel Rayat, directly and indirectly
through various entities owned by him, beneficially owns an aggregate of 70,517,037 shares of the Companys common stock, consisting
of the following: (i) Kalen Capital Corporation 100,000 shares; (ii) 1420525 Alberta Ltd., 3,000,000 shares; (iii) Kalen Capital Corporation,
13,033,406 shares; (iv) Kalen Capital Holdings LLC, 40,838,631 shares (v) 2,800,000 owned by Mr. Rayat directly; (vi) 410,000 shares issuable
upon exercise of Series G Warrant at an exercise price of $2.68 per share through July 21, 2022; and (viii) 10,335,000 a Series I Warrant
to purchase up to shares of common stock at an exercise price of $2.00 per share through November 26, 2025. The Series G Warrants may
be exercised on a cashless basis. For tax purposes, a portion of the equity securities of owned by KCC have been assigned to Kalen Capital
Holdings, LLC, its wholly owned subsidiary. Mr. Rayat disclaims beneficial ownership of 57,888 owned by his wife, Tajinder Chohan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(4) </sup>Includes (a) 2,529,425 shares of
common stock held by Boston Financial Group, Ltd., (b) 2,500,000 shares of common stock held by 1420527 Alberta Ltd., Mr. Bhogal is the
sole principal of each entity and in such capacity, Mr. Bhogal may be deemed to have beneficial ownership of these shares, and (c) vested
options to purchase 1,000,000 shares of common stock. Does not include 30,800 shares of stock owned by Mr. Bhogals wife, of which
he disclaims beneficial ownership. Mr. Bhogal is the President and sole shareholder of Vector Asset Management, Inc., which has provided
us with consulting services in the past.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>(5) </sup>Represents vested options to purchase
shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt"><span style="text-transform: uppercase"><b><span id="a_020"></span>ITEM 13. CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proposed business raises
potential conflicts of interests between certain of our officers and directors and us. Certain of our directors may become directors of
other biotechnology companies and, to the extent that such other companies may participate in ventures in which we may participate, our
directors may have a conflict of interest in negotiating and concluding terms regarding the extent of such participation. In the event
that such a conflict of interest arises at a meeting of our directors, a director who has such a conflict will abstain from voting for
or against the approval of such participation or such terms. In appropriate cases, we will establish a special committee of independent
directors to review a matter in which several directors, or management, may have a conflict.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In determining whether we
will acquire a new technology or participate in a research and development program, the directors will primarily consider the potential
benefits to us, the degree of risk to which we may be exposed and its financial position at that time. Other than as indicated, we have
no other procedures or mechanisms to deal with conflicts of interest. We are not aware of the existence of any conflict of interest as
described herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Review, Approval or Ratification of Transactions
with Related Persons</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Code of Corporate
Governance and Ethics and our policy and procedures pertaining to related-party transactions, our executive officers, directors, employees,
and principal stockholders, including their immediate family members and affiliates, are prohibited from entering into a related party
transaction with us without the prior consent of our Board which reviews and approves any related-party transactions. In the event of
a potential conflict of interest, the Board will generally evaluate the transaction in terms of the following standards: (i) the benefits
to us; (ii) the impact on a director's independence in the event the related person is a director, an immediate family member of a director
or an entity in which a director is a partner, shareholder or executive officer; (iii) the availability of other sources for comparable
products or services; (iv) the terms and conditions of the transaction; and (v) the terms available to unrelated parties or the employees
generally. The Board will then document its findings and conclusion in written minutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Code of Corporate Governance
and Ethics and our policy and procedures pertaining to related-party transactions require actual or potential conflict of interest to
be reported to the Board. Our employees are expected to disclose personal interests that may conflict with ours and they may not engage
in personal activities that conflict with their responsibilities and obligations to us. Periodically, we inquire as to whether or not
any of our directors have entered into any transactions, arrangements or relationships that constitute related party transactions. If
any actual or potential conflict of interest is reported, our entire Board and outside legal counsel review the transaction and relationship
disclosed and the Board makes a formal determination regarding each director's independence. If the transaction is deemed to present a
conflict of interest, the Board will determine the appropriate action to be taken.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transactions with Related Persons</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are related
party transactions for the fiscal years ended December 31, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, Talia Jevan Properties, Inc. made payments totaling $10,811 to Stephen Yan-Klassen, former CFO who resigned in 2020, for his
salary on behalf of the Company. Talia Jevan Properties, Inc. is a related party of Harmel S. Rayat, Chairman of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Kalen Capital Corporation, a corporation wholly
owned by Mr. Rayat, on April 1, 2020, provided a short-term advance of $50,000 to the Company. The advance was repaid by the Company in
July 2020. The Company paid KCC $65,156 for reimbursable expenses in October 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 1, 2013, the Company
entered into a consulting agreement, as amended on May 1, 2016, with Jatinder Bhogal, an individual owning in excess of 5% of the Companys
issued and outstanding shares of common stock, to provide consulting services to the Company through his wholly owned company, Vector
Asset Management, Inc. Pursuant to the consulting agreement, VAMI assisted the Company with identifying subject matter experts in the
medical device and biotechnology industries and assisted the Company with its ongoing research and development. Pursuant to an amendment
dated May 1, 2016, the VAMI monthly consulting fee was increased from $5,000 to $6,800. On June 22, 2018, the Company and VAM entered
into an Executive Consulting Agreement pursuant to which Mr. Bhogal served as the Companys Chief Operating Officer. The ECA superseded
the prior consulting agreement. Pursuant to the ECA, VAMI received compensation of $120,000 per year. On July 1, 2020 the Company amended
the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the ECA
as amended expired. For consulting services provided by VAMI, during the years ended December 31, 2021 and 2020, the Company recognized
expenses of $1,000 and $84,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><span style="text-transform: uppercase"><b><span id="a_021"></span>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>INDEPENDENT PUBLIC ACCOUNTANTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has appointed PKF
OConnor Davies as the Companys independent registered public accounting firm on October 1, 2020 for the fiscal year ended
December 31, 2021 and 2020. Marcum LLP served as the Companys registered public accountant from October 2018 until October 1, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board, in its discretion,
may direct the appointment of different public accountants at any time during the year, if the Board believes that a change would be in
the best interests of the stockholders. The Board has considered the audit fees, audit-related fees, tax fees and other fees paid to out
independent registered public accounting firm, as disclosed below, and has determined that the payment of such fees is compatible with
maintaining the independence of the accountants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have an
audit committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>PRINCIPAL ACCOUNTING FEES
AND SERVICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
aggregate fees for professional services rendered by our independent registered public accounting firms during the years ended December
31, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center">Year Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Audit fees</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">43,375</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-related fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,150</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,500</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All other fees</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.25pt">Total fees</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">53,150</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">51,875</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Audit fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Audit fees consist of fees
billed or to be billed by PKF for professional services rendered for the audit of our financial statements in our Annual Report on Form
10-K; for the review of the financial statements included in our quarterly reports on Form 10-Q since the period ended September 30, 2020;
and fees billed by Marcum LLP for the review of the financial statements included in our quarterly reports on Form 10-Q for the periods
ended March 31, 2020 and June 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Tax Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax fees consist of the aggregate
fees billed by PKF for professional services rendered for tax compliance, tax advice and tax planning.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>All Other Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no fees billed
to us for products and services other than reported under Audit Fees, Audit-Related Fees and Tax Fees for the years ended December 31,
2021 and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_022"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b><span id="a_023"></span>ITEM 15. EXHIBITS, FINANCIAL
STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following documents are filed as a part of
this Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following financial statements, notes related
thereto and reports of independent auditors are included in Part II, Item 8 of this Form 10-K:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 2%"><span style="font-size: 10pt"><b></b></span></td>
    <td style="width: 93%"><span style="font-size: 10pt">Reports of Independent Registered Public Accounting Firms</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td><span style="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td><span style="font-size: 10pt">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td><span style="font-size: 10pt">Consolidated Statements of Stockholders Equity for the years ended December 31, 2021 and 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td><span style="font-size: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt"><b></b></span></td>
    <td><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial statement schedules are omitted because
they are not required or are not applicable, or the required information is provided in the consolidated financial statements or notes
described in Item 15(a)(1) above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Exhibits listed in the Exhibit Index, which
appears immediately following the signature page, are incorporated herein by reference, and are filed as part of this Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_024"></span>ITEM 16. FORM 10K SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not Applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_025"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of Section 13 or 15(d)
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>RENOVACARE, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 24%">&nbsp;</td>
    <td style="width: 6%">&nbsp;</td>
    <td style="width: 70%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: March 30, 2022</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="background-color: White; white-space: nowrap"><span style="font-size: 10pt"><i><span style="text-decoration: underline">/s/ Harmel S. Rayat</span></i></span></td></tr>
  <tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Name:</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt">Harmel S. Rayat</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Interim President &amp; Chief Executive Officer, and Interim Chief Financial Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer and Principal Financial Officer)</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in capacities and on
the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 28%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; width: 2%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; width: 43%"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; width: 2%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; width: 25%"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><i>/s/ Harmel S. Rayat</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Harmel S. Rayat</p></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">Chairman of the Board</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-size: 10pt">March 30, 2022</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit Index</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Exhibit #</b></span></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 88%"><span style="font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/0001023856-99-000018.txt" tabindex="18"><span style="font-size: 10pt">Articles of Incorporation, as amended, of the Company, incorporated by reference and included in the Companys Registration Statement on Form 10-SB 12g filed on May 11, 1999, SEC file number 000-30156-99616992.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000114036111002171/ex3_1.htm" tabindex="18"><span style="font-size: 10pt">Articles of Incorporation, as amended, of the Company incorporated by reference and included in the Companys Form 8-K filed on January 10, 2011, SEC file number 000-30156-11520181.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.3</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793214000112/rcar_ex31.htm" tabindex="18"><span style="font-size: 10pt">Articles of Incorporation, as amended, of the Company incorporated by reference and included in the Companys Form 8-K filed on January 10, 2014, SEC file number 000-30156-14521612.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.4</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/0001023856-99-000018.txt" tabindex="18"><span style="font-size: 10pt">By-laws of the Company incorporated by reference and included in the Companys Registration Statement on Form 10-SB 12g filed on May 11, 1999, SEC file number 000-30156-99616992.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213003268/janus_ex41.htm" tabindex="18"><span style="font-size: 10pt">Form of Series A Common Stock Purchase Warrant dated July 12, 2013, incorporated by reference and included in the Companys Form 8-K filed on July 18, 2013, as amended on November 21, 2013 and December 27, 2013, SEC file number 000-30156-131300357.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.2</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213005947/jani_ex41.htm" tabindex="18"><span style="font-size: 10pt">Form of Stock Purchase Warrant, incorporated by reference and included in the Companys Form 8-K filed on December 5, 2013, SEC file number 000-30156-131259657.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.3</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213005947/jani_ex42.htm" tabindex="18"><span style="font-size: 10pt">Registration Rights Agreement dated November 29, 2013, between Kalen Capital Corporation and the Company, incorporated by reference and included in the Companys Form 8-K filed on December 5, 2013, SEC file number 000-30156-131259657.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.4</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793215003786/rcar_ex41.htm" tabindex="18"><span style="font-size: 10pt">Form of Series D Common Stock Purchase Warrant, incorporated by reference and included in the Companys Form 8-K filed on June 10, 2015, SEC file number 000-30156-15981571.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.5</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793216012529/rcar_ex41.htm" tabindex="18"><span style="font-size: 10pt">Convertible Promissory Note dated September 9, 2016, between Kalen Capital Corporation and the Company; incorporated by reference and included in the Companys Form 8-K filed on September 16, 2016, SEC file number 000-30156-161888353</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.6</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793216012529/rcar_ex42.htm" tabindex="18"><span style="font-size: 10pt">Series E Stock Purchase Warrant dated September 9, 2016; incorporated by reference and included in the Companys Form 8-K filed on September 16, 2016, SEC file number 000-30156-161888353</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.7</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217000999/rcar_ex41.htm" tabindex="18"><span style="font-size: 10pt">Form of Convertible Promissory Note dated February 23, 2017; incorporated by reference and included in the Companys Form 8-K filed on March 1, 2017, SEC file number 000-30156-17654590</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.8</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217000999/rcar_ex42.htm" tabindex="18"><span style="font-size: 10pt">Form of Series F Stock Purchase Warrant dated February 23, 2017; incorporated by reference and included in the Companys Form 8-K filed on March 1, 2017, SEC file number 000-30156-17654590</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.9</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217001139/rcar_ex41.htm" tabindex="18"><span style="font-size: 10pt">Convertible Promissory Note dated March 9, 2017; incorporated by reference and included in the Companys Form 8-K filed on March 14, 2017, SEC file number 000-30156-17686968</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.10</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217003496/rcar_ex41.htm" tabindex="18"><span style="font-size: 10pt">Form of Series G Stock Purchase Warrant dated July 21, 2017; incorporated by reference and included in the Companys Form 8-K filed on July 24, 2017, SEC file number 000-30156-17978114</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.11</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217005123/rcar_ex41.htm" tabindex="18"><span style="font-size: 10pt">Form of Series H Stock Purchase Warrant dated October 16, 2017; incorporated by reference and included in the Companys Form 8-K filed on October 18, 2017, SEC file number 000-30156-171141509</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.12</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/0001016708/000147793217003496/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Form of Subscription Agreement dated July 21, 2017; incorporated by reference and included in the Companys Form 8-K filed on July 24, 2017, SEC file number 000-30156-17978114</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.13</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217005123/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Form of Securities Purchase Agreement dated October 16, 2017; incorporated by reference and included in the Companys Form 8-K filed on October 18, 2017, SEC file number 000-30156-171141509</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213002999/jani_ex103.htm" tabindex="18"><span style="font-size: 10pt">Employment Agreement dated June 20, 2013, between Rhonda B. Rosen and the Company, incorporated by reference and included in the Company's Form 8-K filed on June 26, 2013, SEC file number 000-30156-131259657</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213003268/janus_ex101.htm" tabindex="18"><span style="font-size: 10pt">Asset Purchase Agreement dated as of June 21, 2013, between Jrg Gerlach, MD, PhD and the Company, incorporated by reference and included in the Company's Form 8-K filed on July 18, 2013, as amended on November 21, 2013 and December 27, 2013, SEC file number 000-30156-131300357</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.3</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213002999/jani_ex104.htm" tabindex="18"><span style="font-size: 10pt">Form of Stock Option Agreement, incorporated by reference and included in the Companys Form 8-K filed on June 26, 2013, SEC file number 000-30156-131259657.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.4</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213003740/jani_ex106.htm" tabindex="18"><span style="font-size: 10pt">Finder's Agreement dated August 13, 2013, between Vector Asset Management, Inc. and the Company, incorporated by reference and included in the Company's Form 10-Q filed on August 14, 2013, SEC file number 000-30156-13109753</span></a></td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top; background-color: white">
    <td style="width: 10%"><span style="font-size: 10pt">10.5</span></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 88%"><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213005519/jani_ex101.htm" tabindex="18"><span style="font-size: 10pt">At-Will Executive Services Agreement dated October 1, 2013, between Rhonda B. Rosen and the Company, incorporated by reference and included in the Company's Form 10-Q filed on November 14, 2013, SEC file number 000- 30156-13129717</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.6</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213005947/jani_ex101.htm" tabindex="18"><span style="font-size: 10pt">Subscription Agreement for 3,500,000 units dated November 29, 2013, between Kalen Capital Corporation and the Company, incorporated by reference and included in the Company's Form 8-K filed on December 5, 2013, SEC file number 000-30156-131259657</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.7</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213005947/jani_ex103.htm" tabindex="18"><span style="font-size: 10pt">At-Will Consulting Agreement effective as of December 1, 2013, between Thomas Bold and the Company, incorporated by reference and included in the Company's Form 8-K filed on December 5, 2013, SEC file number 000-30156- 131259657</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.8</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793214000056/jani_ex21.htm" tabindex="18"><span style="font-size: 10pt">Stock Purchase Agreement dated December 31, 2013, between Duke Mountain Resources, Inc., Fostung Resources Ltd. and the Company, incorporated by reference and included in the Company's Form 8-K filed on January 7, 2014, SEC file number 000-30156-14513586</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.9</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793214001588/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">At-Will Consulting Agreement effective as of April 1, 2014, between Patsy Trisler and the Company, incorporated by reference and included in the Company's Form 8-K filed on April 7, 2014, SEC file number 000-30156- 14838542</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.10</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793214001588/rcer_ex102.htm" tabindex="18"><span style="font-size: 10pt">Stock Option Agreement dated April 1, 2014, between Patsy Trisler and the Company, incorporated by reference and included in the Company's Form 8-K filed on April 7, 2014, SEC file number 000-30156-14838542</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/0001016708/000147793214004693/rcar_8k.htm" tabindex="18"><span style="font-size: 10pt">Stock Option Agreements dated August 14, 2014, between Kenneth Kirkland, Joseph Sierchio, Rhonda B. Rosen and the Company, incorporated by reference and included in the Company's Form 8-K filed on August 20, 2014, SEC file number 000-30156-141054256</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.12</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793214005015/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Post-Closing Amendment to Asset Purchase Agreement between Jrg Gerlach, MD, PhD and the Company, incorporated by reference and included in the Company's Form 8-K filed on September 15, 2014, SEC file number 000- 30156-141102510</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.13</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793215002898/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Option Agreement dated May 1, 2015 between Jrg Gerlach, MD, PhD and the Company, incorporated by reference and included in the Companys Form 8-K filed on May 5, 2015; SEC file number 000-30156-158333270.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.14</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793215003786/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Form of Subscription Agreement, incorporated by reference and included in the Companys Form 8-K filed on June 10, 2015, SEC file number 000-30156-15923671.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.15</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793216012529/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Loan Agreement between Kalen Capital Corporation and the Company; incorporated by reference and included in the Companys Form 8-K filed on September 16, 2016, SEC file number 000-30156-161888353</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.16</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217000999/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Form of Loan Agreement dated February 23, 2017; incorporated by reference and included in the Companys Form 8-K filed on March 1, 2017, SEC file number 000-30156-17654590</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.17</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217001139/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Loan Agreement dated March 9, 2017; incorporated by reference and included in the Companys Form 8-K filed on March 14, 2017, SEC file number 000-30156-17686968</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.18</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217001139/rcar_ex102.htm" tabindex="18"><span style="font-size: 10pt">Amendment to Loan Agreement between Joseph Sierchio and the Company dated March 9, 2017; incorporated by reference and included in the Companys Form 8-K filed on March 14, 2017, SEC file number 000-30156-17686968</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.19</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217001139/rcar_ex103.htm" tabindex="18"><span style="font-size: 10pt">Amendment to Loan Agreement between Kalen Capital Corporation and the Company dated March 9, 2017; incorporated by reference and included in the Companys Form 8-K filed on March 14, 2017, SEC file number 000-30156-17686968</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.20</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217003496/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Form of Subscription Agreement dated July 21, 2017; incorporated by reference and included in the Companys Form 8-K filed on July 24, 2017, SEC file number 000-30156-17978114</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.21</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793217005123/rcar_ex101.htm" tabindex="18"><span style="font-size: 10pt">Form of Securities Purchase Agreement dated October 16, 2017; incorporated by reference and included in the Companys Form 8-K filed on October 18, 2017, SEC file number 000-30156-171141509</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.22</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000147793218001262/rcar_ex1022.htm" tabindex="18"><span style="font-size: 10pt">January 29, 2018 Amendment to Convertible Promissory Note dated February 23, 2017; incorporated by reference and included in the Companys Form 10-K filed on March 31, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.23</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000147793218001262/rcar_ex1023.htm" tabindex="18"><span style="font-size: 10pt">January 29, 2018 Amendment to Convertible Promissory Note dated September 9, 2016; incorporated by reference and included in the Companys Form 10-K filed on March 31, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.24</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000147793218001262/rcar_ex1024.htm" tabindex="18"><span style="font-size: 10pt">Corporate Research Agreement dated August 1, 2017; incorporated by reference and included in the Companys Form 10-K filed on March 31, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.25</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000147793218001262/rcar_ex1025.htm" tabindex="18"><span style="font-size: 10pt">Amendment to Consulting Agreement dated May 1, 2016 between Vector Asset Management, Inc. and the Company; incorporated by reference and included in the Companys Form 10-K filed on March 31, 2021.</span></a></td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><span style="font-size: 10pt">10.26</span></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 88%"><a href="https://www.sec.gov/Archives/edgar/data/0001016708/000117184321005317/exh_101.htm" tabindex="18"><span style="font-size: 10pt">Executive Services Consulting Agreement dated July 26, 2021 between Justin Frere and the Company; incorporated by reference and included in the Companys Form 8-K filed on July 30, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.27</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/0001016708/000117184321005317/exh_102.htm" tabindex="18"><span style="font-size: 10pt">Stock Option Agreement dated July 26, 2021, between Justin Frere and the Company, incorporated by reference and included in the Companys Form 8-K filed on July 30, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.28</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793218001262/rcar_ex1026.htm" tabindex="18"><span style="font-size: 10pt">January 29, 2018 First Amendment to Loan Agreement dated February 23, 2017&nbsp;&nbsp;</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.29</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793218001262/rcar_ex1027.htm" tabindex="18"><span style="font-size: 10pt">January 29, 2018 First Amendment to Loan Agreement dated September 9, 2016&nbsp;&nbsp;</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.30</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/0001016708/000147793218003189/rcar_8k.htm" tabindex="18"><span style="font-size: 10pt">Executive Consulting Agreement dated June 22, 2018, incorporated by reference and included in the Companys Form 8-K filed on June 25, 2018, SEC file number 000-30156-18916934</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.31</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/0001016708/000117184321002160/f8k_033021.htm" tabindex="18"><span style="font-size: 10pt">Separation and Release of Claims Agreement dated March 26, 2021, incorporated by reference and included in the Companys Form 8-K filed on March 30, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.32</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/0001016708/000117184322000761/exh_101.htm" tabindex="18"><span style="font-size: 10pt">Research and Collaboration Agreement dated January 28, 2022 entered into between HistoCell S.L. and&nbsp;the Company; incorporated by reference and included in the Companys Form 8-K filed on February 3, 2022.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.33</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000117184322002098/exh_101.htm" tabindex="18"><span style="font-size: 10pt">Unsecured Convertible Promissory Note between Kalen Capital Corporation and the Company dated March 18, 2022; incorporated by reference and included in the Companys Form 8-K filed on March 24, 2022.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">14.1</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000114036109009589/ex14_1.htm" tabindex="18"><span style="font-size: 10pt">Code of Ethics, incorporated by reference and included in the Companys Form 10-K file on April 15, 2009, SEC file number 000-30156-09750383.</span></a></td></tr>
  <tr style="background-color: White">
    <td><span style="font-size: 10pt">23.1</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000117184322002186/exh_231.htm" tabindex="18"><span style="font-size: 10pt">Consent of PKF OConnor Davies, LLP*</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">31.1</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000117184322002186/exh_311.htm" tabindex="18"><span style="font-size: 10pt">Certification of the Interim Chief Executive Officer and Interim Chief Financial Officer pursuant to Rule 13a-14(a).*</span></a></td></tr>
  <tr style="background-color: White">
    <td><span style="font-size: 10pt">32.1</span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1016708/000117184322002186/exh_321.htm" tabindex="18"><span style="font-size: 10pt">Certification by the Interim Chief Executive Officer and Interim Chief Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">99.1</span></td>
    <td>&nbsp;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1016708/000147793213002999/jani_ex101.htm" tabindex="18"><span style="font-size: 10pt">2013 Long-Term Incentive Plan, incorporated by reference and included in the Companys Form 8-K filed on June 26, 2013, SEC file number 000-30156-13933444.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.INS</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Inline XBRL Instance Document**</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">101.SCH</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension - Schema Document**</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.CAL</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension - Calculation Linkbase Document**</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">101.DEF</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension - Definition Linkbase Document**</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.LAB</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension - Label Linkbase Document**</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">101.PRE</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension - Presentation Linkbase Document**</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>104</td>
    <td>&nbsp;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
</td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Portions of this exhibit have been omitted pursuant to a request
for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended, and the omitted material have been separately
filed with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Indicates a management contract or compensatory plan or arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt">** Furnished herewith. XBRL (eXtensible Business Reporting Language)
information is furnished and not filed or a part of a registration statement <span style="background-color: white">or prospectus</span>
for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.</p>

<p style="margin: 0pt">&nbsp;</p>

<p style="margin: 0pt">&nbsp;</p>

<p style="margin: 0pt">&nbsp;</p>

<p style="margin: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt">&nbsp;</p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->

</body>
</html>